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ABSTRACT
Current evidence suggests that endogenous opioids are released in response to 
various stressors and that these opioids interact with cells of the immune system, and 
modulate immune function. However, data substantiating this are conflicting. Therefore, 
this study endeavored to clarify the role of beta-endorphin (BE) in exercise and immune 
function.
Beta-endorphin exhibited a diurnal rhythm in the horse with peak plasma levels 
occurring at 0900 hours. Analgesia, tachycardia and mydriasis were also observed at this 
time, mimicking the effects of morphine in the horse. Therefore, subsequent experiments 
were performed at 0900 hours during times of increased basal opioid activity.
Beta-endorphin levels were increased in response to maximal exercise in the horse. 
The BE response to exercise was attenuated by physical conditioning and was correlated 
with exercise intensity. Analgesia was noted in unfit horses but not in fit horses after a 
standardized exercise bout, suggesting that unfit horses experience greater stress when 
exercised. Naloxone administration resulted in prolonged increases in BE levels following 
exercise in fit and unfit horses. Naloxone administration also reversed the analgesia noted 
in fit horses following a more intense exercise bout, but caused hyperalgesia in unfit 
horses. These results suggest that BE release is controlled through autoreceptors at the 
hypothalamic or pituitary level and that chronic exercise causes a downregulation of 
opioid receptors.
Specific, saturable receptors for beta-endorphin were identified on equine
lymphocytes which appeared to be a mu/delta receptor complex, with a K,, of 17 pM and 
Bm„  of 0.538 fmoles/106 cells. Acute exercise resulted in an increased affinity and 
decreased number of receptors, while chronic exercise resulted in a decreased affinity of 
the receptor for the ligand. Beta-endorphin suppressed the proliferative response of 
equine lymphocytes to mitogens through interaction with opioid receptors. Naloxone also 
suppressed the proliferative response, presumably through opioid receptors.
In conclusion, BE modulates equine immune function through interaction with 
opioid receptors on equine lymphocytes. Beta-endorphin is also a possible mediator of 
the effects of acute and chronic exercise on equine immune function, as demonstrated by 
up- and downregulation of opioid receptors on equine lymphocytes.
CHAPTER ONE 
INTRODUCTION
Endogenous opioids are a group of peptide neurohormones or neurotransmitters 
distributed throughout the central nervous system, pituitary gland and other peripheral 
tissues including the adrenals. The actions of endogenous opioids, such as beta- 
endorphin, have been associated primarily with the central nervous system and pain 
modulation. However, endogenous opioids may also be involved in reproduction, 
cardiovascular control, endotoxic shock, thermoregulation and, as shown most recently, 
regulation of immune function. The physiologic effects of the endogenous opioids are 
mediated through interactions with highly specific membrane receptors. These receptors 
are thought to be the same receptors that mediate the effects of morphine and other opiate 
substances [Akil, et al., 1984].
Stress has been defined as "the result produced when an organism is acted upon 
by physical or psychological forces that disrupt equilibrium or produce strain" [Thomas,
1985]. This term is commonly used to describe biological responses to novel or 
threatening situations. Stress is capable of influencing immune function and tumor 
growth. Usually, stress has been associated with depression of the immune system, 
although, depending on the timing and duration of the stressful stimuli, enhancement of 
immune function may be seen [Monjan and Collector, 1977; Riley, 1981]. The 
endogenous opioids are now thought to be one of the potential mediators of stress-induced 
immunomodulation. Early studies defined the role of the hypothalamic-pituitary-adrenal
1
2axis, particularly the corticosteroids, in immune function in response to stress. Recent 
studies have demonstrated that beta-endorphin is co-released from the pituitary with 
adrenocorticotropin (ACTH) in response to various forms of stress, such as exercise and 
surgery [Cohen, et al., 1986; Guillemin, et al., 1977].
The role of stress in immune function appears to require an interaction between 
the brain and the immune system. Current research suggests that bidirectional 
communication exists between the immune and the central nervous systems [Morley, et 
al., 1987]. Receptors for opioid peptides have been identified on human and murine 
leukocytes. A number of in vitro studies have demonstrated the ability of opioids to 
influence immune function, such as lymphocyte proliferative responses, natural killer cell 
activity and granulocyte activity. Recent research has also demonstrated the production 
of beta-endorphin and ACTH by cells of the immune system, along with the expression 
of the endorphin and enkephalin opioid genes [Sibinga and Goldstein, 1988].
Although it appears that endogenous opioids are released in response to various 
forms of stress and in turn interact with cells of the immune system thereby modulating 
immune function, data substantiating this are conflicting. Opioid binding studies are 
inconclusive, with evidence of both opioid and non-opioid receptors on immune cells. 
Few investigators have reported binding constants, receptor numbers or competitive 
receptor binding data. The ability of opioid peptides to influence leukocyte function 
varies with the opioid peptide, leukocyte cell type, and species. Here again, evidence of 
both opioid and non-opioid effects on leukocyte function have been reported [Sibinga and 
Goldstein, 1988].
3Exercise, as a form of exertional stress, has commonly been used as a method of 
testing physiological responses and adaptations. It can be easily quantified and repeated. 
Exercise has been used in both humans and animals to evaluate the release of endogenous 
opioids. A number of studies in humans have demonstrated increased circulating beta- 
endorphin levels following maximal exercise bouts [Farrell and Gustafson, 1986]. Li and 
Chen [1987] have also demonstrated this phenomenon in thoroughbred horses.
Exercise is particularly stressful in an unfit or unconditioned animal. Through 
athletic conditioning, the stressfulness of intense exercise can be modified in both human 
and equine athletes. Stress, and its effect on immune function, are important in the 
overall physical condition of any animal. Therefore, exertional stress, such as exercise, 
may modulate immune function and influence susceptibility to disease.
The purpose of this study was to clarify the role of peripherally circulating beta- 
endorphin in immune function as it relates to exercise. Thoroughbred horses can be used 
as a model of human athletes because they exercise and compete in a similar manner. 
The role of beta-endorphin in immune function and exercise was assessed by evaluating 
beta-endorphin levels in response to both acute and chronic exercise, characterizing beta- 
endorphin receptors on equine lymphocytes, and evaluating lymphocyte proliferative 
responses in the presence of beta-endorphin. Beta-endorphin levels and beta-endorphin 
receptor binding were evaluated in populations of sedentary, conditioned (or fit) horses, 
and in fit horses following exercise. By measuring these parameters, the effects of both 
acute and chronic fluctuations in circulating beta-endorphin levels on equine lymphocyte 
receptor binding were evaluated. Collectively, these studies contributed to the elucidation
of the role that beta-endorphin plays in modulating immune function at the cellular level 
and how exercise and conditioning alter the ability of beta-endorphin to modulate immune 
function.
The overall objective of this project was to clarify the role of peripherally 
circulating beta-endorphin in immune function as it relates to exercise in the horse. The 
specific objectives of this project were:
1. Determination of optimal sampling times:
Diurnal variation in plasma beta-endorphin levels and nociceptive thresholds have 
been reported in rats and mice. Plasma beta-endorphin levels also demonstrate a diurnal 
rhythm in humans with peak levels occurring at 0800 hours [Petraglia, et al., 1983]. This 
diurnal rhythm influences the quantitative response to stress, suggesting that the opioid 
system has tonic activity, that is, greater response when the system is already active 
[Wesche and Frederickson, 1979]. Therefore, plasma beta-endorphin levels and 
nociceptive thresholds were measured over 24 hours to establish a diurnal rhythm and 
optimum experimental sampling times for this study.
2. Determination of beta-endorphin levels after maximal exercise in sedentary and fit 
horses:
To determine how maximal exercise influences circulating beta-endorphin levels 
in sedentary and fit horses, beta-endorphin levels were assessed after a maximal exercise 
session in sedentary horses and again after a nine week period of physical conditioning
or training. Naloxone pretreatment before exercise was used to evaluate opioid receptor 
involvement in the animal’s response to maximal exercise. Pain threshold measurements, 
heart rate and lactate levels were used to assess the degree of exertional stress produced 
by each exercise session. Fitness and exercise intensity were determined by heart rate, 
respiratory rate and lactate levels.
3. Development of a radioligand binding assay for beta-endorphin receptors on equine 
lymphocytes:
A radioligand binding assay was developed which allowed for identification and 
characterization of beta-endorphin receptors on equine lymphocytes.
4. Determination of the binding parameters of beta-endorphin receptors in a population 
of normal sedentary horses and in fit horses before and after a maximal exercise session:
Binding parameters in normal sedentary horses were determined using the 
radioligand binding assay previously developed. The same assay was used to assess the 
binding parameters in fit horses prior to and immediately following a maximal exercise 
session. The binding parameters of the fit horses at rest were then compared to those of 
the sedentary horses. These measurements provided a means for assessing the effects of 
acute and chronic exercise on equine lymphocyte beta-endorphin receptor regulation.
5. Assessment of beta-endorphin modulation of lymphocyte function:
Beta-endorphin modulation of lymphocyte function was determined by measuring
6the proliferative response of equine lymphocytes to various mitogens in the presence of 
beta-endorphin. Here again, the effects of naloxone were used to evaluate the 
involvement of opioid receptors.
6. Correlation of the binding study results with beta-endorphin levels and lymphocyte 
function analysis:
The results of the binding studies were correlated with beta-endorphin levels in 
sedentary and fit horses before and after maximal exercise. These results were then 
analyzed in relation to the lymphocyte blastogenesis assay results in order to determine 
the role beta-endorphin receptors play in exercise, physical conditioning and immune 
function.
CHAPTER TWO 
LITERATURE REVIEW
Beta-endorphin is an endogenous opioid peptide which is commonly associated 
with the central nervous system and pain modulation. Since this peptide is not thought 
to cross the blood brain barrier, its function in the peripheral circulation is a matter of 
speculation [Banks and Kastin, 1987]. Beta-endorphin is co-released along with ACTH 
into the bloodstream in response to a variety of stressful stimuli [Guillemin, etal. 1977]. 
Stress is capable of altering immune function. Exercise, as a form of exertional stress, 
has also been demonstrated to influence immune function [Keast, et al., 1988]. Beta- 
endorphin has been shown to bind to cells of the immune system and influence the 
function of these cells. It is thought, therefore, that beta-endorphin may be a potential 
modulator of stress-induced immunomodulation [Sibinga and Goldstein, 1988]. This 
review will examine current research dealing with beta-endorphin and its role in immune 
function and exercise.
A, PHYSIOLOGY OF BETA-ENDORPHIN
1. Distribution, Release and Catabolism
Beta-endorphin, a peptide containing thirty-one amino acids, is derived from the 
precursor molecule proopiomelanocortin (POMC) along with adrenocorticotropin (ACTH), 
beta-lipotropin and alpha-melanocyte stimulating hormone (alpha-MSH) (Figure 1). Beta- 
endorphin is the sole product of the precursor proopiomelanocortin that possesses activity
7
8PROOPIOMELANOCORTIN
N-Terminal ACTH B-LPH
/  \
N-Terminal ACTH v-LPH B-Endorphin
N-Terminal ACTH v-LPH B-Endorphin
Figure 1. Generation of beta-endorphin from the precursor molecule proopiomelanocortin 
(POMC). (3-lipotropin = (3-LPH, y-lipotropin = y-LPH, adienocorticotropin = ACTH, a- 
melanocyte-stimulating hormone = cc-MSH, y-melanocyte-stimulating hormone = y-MSH, 
corticotropin-like intermediate peptide = CLIP. (Adapted from Frederickson and Geary, 
1982).
at the opioid receptor. The major site of production of beta-endorphin is in the 
intermediate and anterior lobes of the pituitary, with greater amounts being produced by 
the intermediate lobe in most species [Frederickson and Geary, 1982]. Beta-endorphin 
appears to have a more restricted distribution in the intermediate lobe of the horse than 
in rats and dogs. Equine beta-endorphin positive cells are located in the intermediate lobe 
adjacent to the lobus nervosus and are fewer in number than noted in other species, 
suggesting that one of the functions of beta-endorphin in the horse is regulation of 
oxytocin release [Amann, et al., 1987]. In the mammalian central nervous system, beta- 
endorphin is found in the cell bodies and neurons of the arcuate nucleus of the 
hypothalamus. Fibers from the hypothalamus containing beta-endorphin innervate the 
median eminence and the dorsal midline thalamus. Additional fibers containing beta- 
endorphin also innervate the amygdala, preoptic area, ventromedial nuclei, paraventricular 
nucleus, periaqueductal gray, reticular formation and stria terminalis [Frederickson and 
Geary, 1982].
Proopiomelanocortin cells in the anterior and intermediate lobes of the pituitary 
appear to process the precursor POMC differently. In the anterior lobe, the processing 
results primarily in beta-lipotropin (70%) with unmodified beta-endorphin comprising 
about thirty percent of the material released. The intermediate lobe stores little or no 
beta-lipotropin and therefore primarily produces beta-endorphin (97%). The form of beta- 
endorphin released from the intermediate lobe is not beta-endorphin(l-31) but N-acetyl- 
beta-endorphin(l-27), a modified form which has no activity at the opioid receptor 
[Frederickson and Geary, 1982; Akil, et al., 1984],
10
Circulating levels of beta-endorphin result from release of beta-endorphin by the 
pituitary, while cerebrospinal (CSF) levels derive from the periventricular system in the 
brain. A number of factors can cause changes in beta-endorphin levels in plasma and 
CSF, such as exercise, surgery and stimulation of the periaqueductal gray (Table 1) 
[Frederickson, 1984]. The release of beta-endorphin from the anterior lobe of the 
pituitary is coupled with that of ACTH. These two peptides are released from the anterior 
pituitary in response to the hypothalamic peptide, corticotropin-releasing factor (CRF) 
[Rivier, et al., 1982], Although it has been reported that the anterior lobe primarily 
produces beta-lipotropin, Young, et al. [1986] demonstrated preferential release of beta- 
endorphin from the anterior lobe when stimulated by CRF. These investigators reported 
that equimolar amounts of beta-endorphin and beta-lipotropin were released from an 
unstimulated anterior lobe, while stimulation by CRF produced two-fold more beta- 
endorphin than beta-lipotropin. The CRF neurons also appear to interact with gamma- 
aminobutyric acid (GABA) neurons since GABA receptor agonists exert inhibitory effects 
on beta-endorphin and beta-lipotropin release from the anterior lobe of the pituitary 
[P’etraglia, et al., 1986]. Adrenal steroids regulate the release of ACTH and beta- 
endorphin through negative feedback by inhibiting stimulated but not basal release 
[Frederickson and Geary, 1982]. Beta-endorphin release from the intermediate lobe of 
the pituitary appears to be regulated differently from that of the anterior lobe. Dopamine 
and dopaminergic agents inhibit release, but CRF, adrenal steroids and GABA-ergic 
mechanisms have little or no effect [Frederickson and Geary, 1982; Petraglia, et al.,
1986].
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TABLE 1. Factors That Influence Beta-endorphin Levels in CSF or Plasma
Increase Decrease
Human CSF Stimulation of PAG for 
pain relief 
Electroacupuncture for 
pain relief 
Heroin addiction
Cushing’s disease
Human plasma Surgical stress 
Exercise stress 
Heroin addiction 
Labor/delivery 
Adisson’s disease 
Cushing’s disease 
Morphine
Dexamethasone
Rodent plasma Noxious stress Chronic morphine
Morphine Hypophysectomy
Naloxone
Vasopressin
Adrenalectomy
Insulin
Dexamethasone
‘Adapted from Frederickson [1984].
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Stress appears to alter the pattern of release of both beta-endorphin and ACTH. 
Acute stress results in decreased responsiveness to CRF, while chronically stressed rats 
demonstrate increased ability to release ACTH and beta-endorphin in response to CRF 
[Young and Akil, 1985a]. In fact, chronically stressed rats show increased amounts of 
ACTH and beta-endorphin stored in the anterior pituitary [Young and Akil, 1985b]. 
Stress also appears to cause preferential release of beta-endorphin over beta-lipotropin 
from the anterior pituitary [Young, et al., 1986]. Pretranslational and posttranslational 
mechanisms for regulating release of beta-endorphin and ACTH are altered by stress. 
Shiomi, et al. [1986] have demonstrated acceleration of the rate of translation of POMC 
after acute stress and an increase in the transcription of POMC messenger RNA after 
chronic stress. Hollt, et al. [1986] also noted increased levels of POMC messenger RNA 
after chronic intermittent foot-shock in rats. Stress also modifies the release of beta- 
endorphin from the intermediate lobe of the pituitary. Chronic stress induces increased 
synthesis and release of the opioid-inactive N-acetylated beta-endorphin(l-31) [Akil, et 
al., 1985].
The biological activity of beta-endorphin is dependent upon its structure. 
Acetylation or removal of the N-terminal tyrosine results in loss of activity at opioid 
receptors. If beta-endorphin is shortened at the C-terminal, as with alpha-endorphin or 
gamma-endorphin, there is also loss of activity. An enzyme has been identified which 
is specific for the leu77-phe78 site. The action of this enzyme results in the formation of 
gamma-endorphin from beta-endorphin. Another aminopeptidase has been purified from 
rat brain and has been shown to release tyrosine from alpha, gamma and beta-endorphin
13
[Frederickson and Geary, 1982]. The regulation of the catabolism of beta-endorphin is 
poorly understood and requires further investigation.
2. Structure and Receptor Function
Beta-endorphin is a thirty-one amino acid peptide which is derived from the 
precursor molecule proopiomelanocortin (POMC). This peptide differs slightly between 
species with the main differences occurring at the carboxy terminus. Equine beta- 
endorphin differs from human by three amino acids (Figure 2) [Li, et al., 1981]. The 
sequence of amino acids is important in determining the receptor specificity of the 
particular opioid peptide. All opioid peptides share the same amino acid sequence of Tyr- 
Gly-Gly-Phe-Met(or Leu) at the N-terminus [Akil, et al., 1984]. Binding to opioid 
receptors is traditionally thought to occur through the N-terminal region of the molecule. 
The C-terminal sequence is thought to convey potency and provide stability against 
exopeptidase attack while the N-terminal sequence is necessary for opioid activity 
[Deakin, et al., 1980; Evans, et al., 1986].
The sites of action for the opioid peptides are the "opiate" receptors. The 
existence of multiple forms of opioid receptors was first proposed by Martin, et al. 
[1976]. The basic types are designated as the mu or morphine receptor, the kappa or 
ketocyclazocine receptor, the sigma or SKF-10047 receptor and the delta or enkephalin 
receptor [Akil, et al., 1984]. Thus, the enkephalins, whose structure contains the first four 
amino acids in beta-endorphin, prefer the delta receptor while beta-endorphin binds 
equally well at the mu or delta receptor (Table 2) [Sforzo, 1989]. It has been postulated
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1 5 10
Human: H-Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser- 
Camel, Bovine: H-Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser- 
Equine: H-Tvr-Glv-Glv-Phe-Met-Ser-Ser-Glu-Lys-Ser-
15 20
Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn- 
Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn- 
Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-
25 31
Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu-OH 
Ala-Ile-IIe-Lvs-Asn-AIa-His-Lvs-Lvs-Glv-Gln-OH 
Ala-De-Ile-Lvs-Asn-Ala-His-Lvs-Lvs-Glv-Gln-OH
Figure 2: Comparative amino acid sequences of human, camel, bovine, and equine beta- 
endorphin. (Adapted from Li, et al., 1981)
TABLE 2. Opioid Ligand Interactions With Opioid 
Receptor Subtypes
Ligand Delta Mu Kappa
Agonists
Met-enkephalin High Low Low
Beta-endorphin High High Low
Dynorphin Low Low High
Moiphine Low High Low
Antagonists
Naloxone Low High Low
Adapted from Sforzo [1989].
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that the N-terminal tetrapeptide sequence, Tyr-Gly-Gly-Phe, is the sequence responsible 
for triggering the receptor response while the C-terminal sequence is responsible for 
receptor subtype specificity in addition to possibly conveying potency [Schwyzer, 1986]. 
The different forms of opioid receptors are each associated with specific physiologic 
actions. The physiologic actions associated with mu, kappa and sigma receptors were 
demonstrated by Iwamoto and Martin [1981] in the chronic spinal dog. Later, with the 
discovery of the enkephalins, a distinct receptor, the delta receptor, was proposed. 
Further investigation revealed that specific physiological actions of morphine could be 
attributed to subclasses of the mu receptor or the delta receptor (Table 3) [Goodman and 
Pasternak, 1984].
Gero [1986] has proposed that opioid receptors are flexible and that agonists 
distort the receptor thus activating it. Drugs such as antagonists attach without distortion, 
and therefore have no effect. Other studies suggest that the opioid receptors are in fact 
one receptor which is "interconvertible" or that they exist in close proximity on the cell 
surface membrane in a manner which allows interaction [Morley, 1983; Lee and Smith,
1980]. It has also been proposed that the opioid receptor is composed of both protein and 
lipid. The protein contains the binding site for the enkephalins while the lipid contains 
the site for the alkaloids, such as morphine. Beta-endorphin is proposed to interact with 
both sites [Lee and Smith, 1980]. Bowen, et al. [1981] have postulated that the mu and 
delta forms of the opioid receptor "interconvert" when the mu receptor couples to 
adenylate cyclase, while Schwyzer [1986] has suggested that the opioid peptide receptor 
sites are regulated by peptide membrane interactions. He proposed that the delta site is
TABLE 3. Actions At Opiate Receptors
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Mu, Mu2 Delta Kappa Sigma
Supraspinal
analgesia
Bradycardia Analgesia Miosis Mydriasis
Prolactin release Respiratory
depression
Respiratory
depression
Analgesia Tachy­
cardia
Catalepsy Decreased
gastro-
motility
Modulation of 
dopamine 
turnover
Hypothermia Reversal of 
endotoxic shock
Miosis
‘Adapted from Goodman and Pasternak [1984].
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exposed to the aqueous compartment surrounding the target cell and is in a cationic 
vicinity while the mu site is exposed to the anionic fixed-charge aqueous compartment 
of the membrane and that the kappa site is buried in the hydrophobic membrane 
compartment. Recently, evidence for a mu/delta opioid receptor complex with interacting 
mu and delta binding sites in rat striatal membranes has been demonstrated [Schoffelmeer, 
et al., 1990],
Using antibodies directed against the opioid receptor, several investigators have 
begun to identify opioid receptors by isolating subunits of the receptor. Maneckjee, et 
al. [1988] have identified a subunit of the opioid receptor with a M, of 94,000 daltons 
which they propose to be an opioid recognition unit. Analysis of opioid receptors on 
neuroblastoma X glioma cells has shown that the receptor is a complex with a M,. of
210.000 daltons containing four polypeptide chains with M, of 68,000,58,000,45,000 and
30.000 daltons. A leukocyte opioid receptor which is virtually identical to that on 
neuroendocrine cells has also been demonstrated [Carr and Blalock, 1989]. Affinity 
cross-linking experiments in bovine brain membranes result in labeling of a 65,000 dalton 
and a 53,000 dalton protein in which labeling was reduced by a mu agonist and a delta 
agonist, respectively, suggesting that the mu and delta sites are separate proteins 
possessing different molecular weights. In contrast, affinity cross-linking of the mu/delta 
complex in rat striatal membranes exhibited labeling of a single 80,000 dalton 
glycoprotein in which labeling was only partially (50%) reduced by selective mu and 
delta agonists [Schoffelmeer, et al., 1990]. It therefore appears that the mu and delta 
binding sites may exist independently or in a physically associated manner. Whether or
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not they derive from the same gene and result from different posttranslational 
modifications has yet to be determined.
Finally, endogenous opioids appear to modulate cell activity through inhibition of 
adenylate cyclase activity thereby inhibiting cyclic AMP accumulation [Klee and 
Nirenberg, 1976]. The endogenous opioids appear to convert adenylate cyclase to a form 
with altered activity and thereby alter the relative amounts of low and high activity forms 
of the enzyme [Sharma, et al., 1977]. Zukin and Tempel [1986] have suggested that 
upregulation of the opioid receptor is accompanied by an increased coupling to the 
inhibitory guanyl nucleotide binding protein and that downregulation of the receptor 
involves dissociation from the nucleotide binding protein. Therefore, opioid peptides 
modulate signal transduction mechanisms by altering adenylate cyclase and guanyl 
nucleotide binding protein activity, thus controlling second messenger systems. This 
research appears to indicate a generally inhibitory role for the endogenous opioids.
3. Diurnal Variation
Plasma levels of beta-endorphin demonstrate a diurnal rhythm which coincides 
with that of plasma ACTH, beta-lipotropin, and cortisol, with the highest levels occurring 
at 0800 hours in normal humans [Petraglia, et al., 1983; Gil-Ad, et al., 1986; Farsang, et 
al., 1983]. Beta-endorphin levels in human and monkey cerebrospinal fluid (CSF) also 
vary diumally with the highest levels occurring between 0600 and 0800 hours [Barreca, 
et al., 1986; Naber, et al., 1981]. A diurnal rhythm of proopiomelanocortin (POMC) 
messenger RNA has been demonstrated in the intermediate pituitary lobe of rats. The
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variation of POMC messenger RNA parallels that of beta-endorphin and these events are 
preceded by similar changes in the POMC gene transcription [Millington, et al., 1986]. 
Wesche and Frederickson [1979] suggested that the endogenous opioid system exhibits 
tonic activity. They demonstrated higher levels of endogenous opioid peptides in mice 
after a noxious stimulus in the afternoon as opposed to the morning. Here again, 
increased activity was observed at a time when the endogenous opioid system was the 
most active. These findings are in conflict with those of Kant, et al. [1986], who were 
unable to demonstrate increased release of beta-endorphin in response to stress during the 
dark phase in rats.
A diurnal rhythm in endogenous opioids suggests that they may play a role in the 
diurnal fluctuation of nociceptive responses. Rats and mice both demonstrate decreased 
sensitivity to pain at night [Wright, 1981; Frederickson, et al., 1977]. This coincides with 
the diurnal rhythm of endogenous opioids since both the rat and mouse are nocturnal 
animals with higher opioid levels occurring at night [Tang, et al., 1984]. Henry [1981] 
demonstrated increased activity of dorsal horn units in the spinal cat following naloxone 
administration during the day and early evening. Administration of naloxone at night did 
not produce the excitation seen during the day in cats which were conditioned to a regular 
day/night routine. This investigator suggested that the increase in activity observed was 
due to competition with endogenous opioids by naloxone, proposing therefore that higher 
opioid levels in the day led to an increased observable effect. Evaluation of nociceptive 
thresholds in man has produced conflicting results. The time of day at which the pain 
threshold was the highest varied from 0300 hours to 1800 hours [Morawetz, et al., 1984],
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Morawetz, et al. [1984] suggested that the technique used to measure pain thresholds may 
influence the results leading to erroneous assumptions of a diurnal rhythm. Only one 
human study attempted to correlate beta-endorphin levels with variations in pain threshold 
and they were unable to demonstrate a significant correlation [Sandrini, et al., 1986].
In summary, beta-endorphin is a thirty-one amino acid peptide which is released 
from the anterior and intermediate lobes of the pituitary in response to stress. Stress 
alters the pattern of releasability by causing preferential release of beta-endorphin from 
the anterior lobe of the pituitary. Chronic stress also causes increased storage of beta- 
endorphin in the pituitary of rats. Beta-endorphin binds equally well to the mu and delta 
opioid receptors and appears to exert its action through inhibition of adenylate cyclase 
activity. Identification of opioid receptors has demonstrated very similar characteristics 
between opioid receptors in both the central nervous system and the immune system. 
Beta-endorphin levels exhibit a diurnal rhythm both in plasma and cerebrospinal fluid. 
Although the evidence is conflicting, the diurnal variation of beta-endorphin may follow 
that of pain threshold. Beta-endorphin release seems to exhibit tonic rather than phasic 
activity and therefore increased release of beta-endorphin in response to stress or other 
stimuli may occur at times when basal activity is highest.
B. BETA-ENDORPHIN AND EXERCISE
1. Exercise-induced Changes in Beta-endorphin Levels
Increasing interest in the role of endogenous opioids in exercise and training has
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led to an explosion of research into this area. Early studies demonstrated increased 
plasma beta-endorphin levels following "strenuous" exercise in humans [Colt, et al.,
1981]. These studies did not quantify exercise intensity and therefore were unable to 
demonstrate any relationship between exercise intensity and the levels of beta-endorphin 
released. Most investigators used radioimmunoassay procedures to measure beta- 
endorphin levels. Unfortunately, beta-endorphin exhibits close structural similarity to 
beta-lipotropin and therefore could not always be differentiated from beta-lipotropin by 
available radioimmunoassay procedures. Thus, many investigators were and are 
measuring beta-endorphin-like immunoreactivity rather than actual beta-endorphin levels. 
The different methods used to measure beta-endorphin levels have led to reports of beta- 
endorphin levels varying from 10 pg/ml to 1.6 ng/ml [Farrell, 1985]. Therefore, while 
many of these studies may correctly indicate a change in beta-endorphin levels, the exact 
magnitude of change may not be accurate [Sforzo, 1989].
Current studies suggest that beta-endorphin levels increase significantly after 
moderately high intensity exercise (i.e. 80% V O ^ )  or maximal exercise intensity (i.e. 
graded exercise test to exhaustion) [Gambert, et al., 1981; Goldfarb, et al., 1987]. 
Submaximal exercise intensity (i.e. 60% V 0 2max or lower) does not alter beta-endorphin 
levels significantly [Rahkila, et al., 1987; Langenfeld, et al., 1987]. The exercise stress 
threshold required to stimulate release of beta-endorphin has been reported to occur 
between 50 and 75% V 02max or at exercise intensities greater than 80% VC^a* [Donevan 
and Andrew, 1987; Rahkila, et a l,  1988]. There also appears to be no difference in beta- 
endorphin release between trained men and women [Rahkila, et al., 1987]. Therefore, it
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appears that high exercise intensity is required to significantly elevate beta-endorphin 
levels and is able to do so in as little as thirty to sixty seconds with peak levels two to 
ten fold greater than baseline. Beta-endorphin levels continue to increase for five to 
fifteen minutes post exercise and return to baseline within an hour of cessation of 
exercise. There is also considerable interindividual and intraindividual variation in the 
beta-endorphin response to exercise. The endorphin response to exercise does not appear 
to be linear but perhaps is best described as a curvilinear response which closely 
resembles the exercise-induced blood lactate accumulation curve [Sforzo, 1989].
Recent research suggests that exercise training results in augmented beta-endorphin 
release in response to high intensity exercise. Originally, Carr, et al. [1981] demonstrated 
increased plasma levels of beta-endorphin in response to exercise in trained individuals. 
This work was supported by Farrell, et al. [1987] and Mougin, et al. [1987] who both 
demonstrated greater peak beta-endorphin levels following supramaximal exercise in 
trained athletes versus untrained subjects. The question arises as to whether the absolute 
exercise intensity alone, which is attainable only by trained athletes, is responsible for the 
increased levels of beta-endorphin noted in these experiments. Interestingly, Howlett, et 
al. [1984] showed no change in levels of beta-endorphin released in trained individuals 
following exercise tests at 80% V O ^  as compared to untrained individuals, although 
Bullen, et al. [1984] demonstrated incremental increases in the peak response to an 
exercise test at 85% as training progressed. Metzger and Stein [1984] also were
unable to demonstrate any change in the releasability of beta-endorphin following exercise 
in trained rats. However, these investigators did demonstrate lower basal levels of beta-
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endorphin in the trained animals.
Despite the fact that numerous studies have been performed in order to elucidate 
the role of peripheral opioids in exercise, only a few studies have examined central opioid 
function as it pertains to exercise. Decreased levels of hypothalamic beta-endorphin have 
been reported following a 20-30 minute swim in cold water in rats [Wardlaw and Frantz, 
1980]. However, Metzger and Stein [1984] were unable to detect any difference in brain 
levels of beta-endorphin after sprint running in rats. Another study performed in rats was 
unable to demonstrate any change in brain beta-endorphin levels following exercise in 
trained versus untrained animals, although this study did demonstrate increased levels of 
beta-endorphin in the nucleus accumbens following exercise to fatigue in all animals 
[Blake, et al., 1984]. Houghten, et al. [1986] examined brain receptor binding after 
exercise in rats and found no change in the dissociation constant but decreased receptor 
number. Sforzo, et al. [1986] found enhanced binding of an opioid antagonist in five 
regions of the brain after 2 hours of warm water swimming in rats but Wagner [1986] 
was unable to reproduce these results in humans. In humans, treadmill exercise resulted 
in decreased binding of radiolabeled carfentanil, a potent mu ligand. Although these 
studies report altered brain opioid activity following exercise there are no uniform results 
or experimental design, therefore making it difficult to draw conclusions about the 
significance of these findings.
The correlation between beta-endorphin levels in the bloodstream and the CSF 
provokes much controversy. While some investigators maintain that beta-endorphin does 
not cross the blood-brain barrier and therefore peripheral levels are not necessarily
25
correlated with central levels, others suggest that opioid peptides have sufficient 
permeability to exert central effects [Rossier, et al., 1977; Rapoport, et al., 1980]. One 
interesting study attempted to correlate peripheral with CSF levels of beta-endorphin in 
the dog following both high and low intensity exercise. The peripheral release of beta- 
endorphin was dose-related with respect to both time and intensity while CSF levels of 
beta-endorphin increased during low but not high intensity exercise [Radosevich, et al., 
1989]. Consequently, it appears that the increase in CSF beta-endorphin was not 
dependent upon exercise intensity or plasma levels of beta-endorphin.
Beta-endorphin levels following exercise in the horse have been examined by few 
investigators. Evans et al [1985] demonstrated increased plasma beta-endorphin levels 
in the horse following a strenuous gallop with levels returning to baseline within a half 
hour. Li and Chen [1987] demonstrated incremental increases in beta-endorphin levels 
following a trot, slow gallop and fast gallop in Thoroughbred horses. Although Li and 
Chen [1987] reported approximate speed, none of these investigators reported heart rate, 
respiratory rate, lactate levels or any other parameters used in evaluating exercise 
intensity. Also, Evans, et al. [1985] used a human radioimmunoassay kit to measure 
equine plasma beta-endorphin levels without reporting any validation of this method. 
Despite the fact that Li and Chen [1987] developed a radioimmunoassay for equine beta- 
endorphin, their antibody was made using porcine beta-endorphin as the immunogen, 
which differs by two amino acids from equine beta-endorphin [Li, et al., 1981]. The 
antiserum cross-reacted 15% with beta-lipotropin, 100% with camel beta-endorphin and 
60% with porcine beta-endorphin. They did not report the cross-reactivity of equine beta-
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endorphin with their antiserum although it differs in amino acid sequence from all those 
tested. Therefore, although increases in beta-endorphin levels probably do occur 
following exercise in the horse, the intensity of exercise which stimulates a response and 
the exact magnitude of the response have yet to be addressed.
2. Exercise-Induced Changes in Pain Threshold
Changes in both central and peripheral levels of endogenous opioids following 
exercise have led many investigators to suggest that exertional stress is also capable of 
altering pain threshold through modulation of endogenous opioid function. Following a 
three minute swim, mice exhibited increased pain thresholds, while swim stress also 
reduced chronic pain in mice as measured by modification of behavioral responses to 
subcutaneous formalin injection [Christie, et al., 1981, Carmody and Cooper, 1987]. This 
effect was abolished by administration of naloxone which suggests an opioid mediated 
mechanism [Carmody and Cooper, 1987]. After an hour of running, rats trained to run 
spontaneously in running wheels displayed increased pain thresholds which were also 
reversed by naloxone [Shyu, et al., 1982].
Investigation into the effect of exercise on pain thresholds in humans has led to 
conflicting results. Droste, et al. [1988] were unable to detect any change in electrical 
pain thresholds after exercise in patients with silent and symptomatic myocardial 
ischaemia. These results may have been influenced by the ability of these patients to 
reach a sufficient level of intensity of exercise since exercise was terminated with angina 
pectoris. Janal, et al. [1984] reported that intense exercise (85% V O ^*) produced a
27
hypoalgesic effect that was reversed by naloxone. These investigators also reported 
elevated ratings of joy, euphoria, cooperation and conscientiousness after exercise. Of 
these, only the elevations in joy and euphoria were attenuated by naloxone, suggesting 
a role for beta-endorphin or some other endogenous opioid in what is popularly called the 
"runner’s high." Surbey, et al. [1984] also reported that naloxone decreased pain 
threshold in human athletes following a maximal exercise test although not significantly. 
Although these reports suggest that endogenous opioids are involved in increased pain 
threshold following exercise, there is no definitive reproducible data to support this claim.
3. Evaluation of Exercise Intensity
Exercise intensity is commonly assessed by measuring such variables as heart rate, 
respiratory rate, maximal oxygen consumption ( V O ^ ) ,  and blood lactate levels. Blood 
lactate levels are used as an index of anaerobic metabolism with high levels indicating 
lactate accumulation commonly noted after maximal exercise. The anaerobic threshold 
is defined as the "point where metabolic acidosis and associated changes in gas exchange 
in the lungs occur during graded exercise" [Astrand and Rodahl, 1986]. It has also been 
described as the "onset of blood lactate accumulation" and has been standardized in 
humans to occur when lactate blood levels reach 2.5 to 4.0 mmol/L [Astrand and Rodahl, 
1986]. In horses, lactate levels do not exceed 4 mmol/L after submaximal exercise but 
increase 20 to 25 fold over baseline after maximal exercise. Therefore, it has been 
concluded that submaximal work is below anaerobic threshold for skeletal muscle 
metabolism in Thoroughbred racehorses [Judson, et al., 1983]. As in humans, a blood
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lactate level of 4 mmol/L is considered to be the approximate level of exercise induced 
onset of blood lactate accumulation or anaerobic threshold in horses [Persson, 1983]. In 
exercising horses, the running speed at which lactate accumulation occurs has been 
measured as occurring at 10.25-11.75 m/sec [Wilson, et al., 1983].
Blood lactate levels have been shown to be exponentially related to both exercise 
heart rate and work load (expressed as velocity). The measurement of maximal heart rate 
provides very reproducible results which can be used to assess the degree of fitness of a 
horse. At a work load where the heart rate reaches 200 beats/min, blood lactate levels 
reach those corresponding to anaerobic threshold. Therefore a heart rate of 200 beats/min 
(HR200) is used to define maximal aerobic work power in the horse [Persson, 1983]. The 
heart rate recovery curve is also considered to be a good objective assessment of the 
degree of fatigue experienced by a horse during exercise [Rose, 1983].
Respiration in exercising horses differs from that of humans in that the horse's 
ability to increase cardiac output and oxygen uptake is greater than that of a human 
athlete, therefore making respiration a possible limiting factor in equine athletic 
performance. Also, in horses, breathing frequency is a function of stride frequency. 
Because of this, during a gallop respiratory frequency and stride frequency become 
synchronized on a one to one basis in the horse. Therefore, a galloping horse is forced 
to respire very frequently (up to 140 breaths/min) but with a low tidal volume. This is 
opposed to a human athlete in which locomotion has little affect on thoracic mechanisms 
so that in human athletes respiration is independent of step frequency. In a horse, 
respiration increases from resting values of approximately 35 breaths/min to 120-140
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breaths/min in a maximally exercising horse [Gillespie and Pascoe, 1983; Homicke, et al., 
1983].
Heart rate, lactate levels and respiratory rate can be used to evaluate exercise 
tolerance and fitness. In man, trained or fit athletes have lower muscle and blood lactate 
levels during submaximal exercise than do untrained individuals. The heart rate response 
to exercise is also lower in trained athletes [Persson, 1983]. In the horse, blood lactate 
levels in response to submaximal exercise at 8.5 m/sec decreased significantly throughout 
a training period [Thornton, et al., 1983]. Training also results in decreased heart rate 
during exercise as well as a shift in the slope of the post exercise recovery curve in the 
horse [Fregin and Thomas, 1983; Persson, 1983].
Release of beta-endorphin in humans has been associated with the degree of 
exercise intensity. Early studies did not accurately measure exercise intensity, thereby 
leading to conflicting and often confusing results. As interest and research in this area 
increased, the release of beta-endorphin has been linked with an exercise intensity of 75- 
80% [Sforzo, 1989]. Several investigators have suggested that there is a
connection between the onset of blood lactate accumulation and the release of beta- 
endorphin in humans. De Meirleir, et al. [1986] noted that after one hour of submaximal 
work below anaerobic threshold (4 mmol/1), beta-endorphin levels did not change. Beta- 
endorphin levels increased with high intensity exercise, with the rise in lactate levels 
above anaerobic threshold always preceding the rise in beta-endorphin. Mougin, et al. 
[1987] reported that the increase in beta-endorphin following exercise was significantly 
correlated with that of plasma lactate levels after a nordic ski race. They also noted that
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experienced trained skiers showed greater beta-endorphin and lactic acid levels than did 
the recreational skiers. Rahkila, et al. [1988] also reported that increases in beta- 
endorphin levels following exercise were always accompanied by corresponding increases 
in blood lactate levels.
In summary, intense exercise (75-80% V Q ^ )  stimulates the release of beta- 
endorphin into the peripheral circulation. Due to the different methods used to measure 
beta-endorphin levels, the exact magnitude of change measured varies greatly between 
studies. Current research suggests that exercise training results in augmented beta- 
endorphin release in response to exercise although not all studies support this theory. 
Despite the fact that most studies do detect changes in central opioid function following 
exercise, the lack of uniform results or experimental design has led to confusing and 
conflicting reports. Beta-endorphin levels also increase after exercise in the horse, 
although the intensity of exercise required to elicit a response and the magnitude of the 
response needs to be clarified. Intense exercise appears to alter pain perception through 
opioid mechanisms despite the conflicting reports from human experiments. The release 
of beta-endorphin appears to be correlated with the onset of blood lactate accumulation 
and exercise intensity above anaerobic threshold. Exercise intensity and fitness of the 
athlete may be evaluated by blood lactate levels, heart rate and respiratory rate. Lactate 
levels above 4 mmol/L indicate anaerobic threshold is surpassed in the horse and 
combined with a heart rate of approximately 200 beats/min can be used to indicate 
maximal work effort on the part of the animal. Fitness can be evaluated by decreased
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lactate levels, heart rate and respiratory rate and increased recovery to resting values.
C. BETA-ENDORPHIN AND IMMUNE FUNCTION
1. Opioid Receptors on Cells of the Immune System
A theory of interaction between the central nervous system and the immune 
system has emerged from current research. One finding which supports this theory is the 
existence of opioid receptors on cells of the immune system, particularly lymphocytes. 
Lymphocytes can be divided into two main subsets: T cells and B cells. T cells are 
derived from the thymus and regulate the proliferation and differentiation of B cells into 
antibody secreting plasma cells through secretion of interleukins and interferons. B cells 
are derived from the bone marrow and synthesize and secrete antibodies. The majority 
of circulating lymphocytes are T cells [Eisen, 1974]. T cells can be further subdivided 
into the subclasses of T helper cells, T suppressor cells and cytotoxic T lymphocytes 
(CTL’s). T helper cells facilitate immune function through the production of interleukins 
in response to antigen stimulation. Suppressor cells downregulate the activity of both 
cytotoxic T cells and T helper cells [Keast, et a l, 1988; Hodes, 1989].
The earliest reports of possible opioid receptors on lymphocytes came from 
Wybran and Govaerts [1977]. They reported that levamisole significantly increased the 
percentage of active and total T cells in the T cell rosette assay with sheep red blood cells 
(SRBC). Human T cells form rosettes with sheep red blood cells through interaction with 
an "E receptor" [Donahoe, et al., 1985]. The rosette formation requires activated rather 
than resting T cells and the assay can be used to purify T cells and assess cell number.
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This same group later reported that morphine reduced, while methionine-enkephalin (met- 
enkephalin) increased, the percentage of active T rosettes and that both of these effects 
were completely reversed by naloxone [Wybran, et al., 1979]. The fact that morphine and 
methionine-enkephalin exhibited opposite effects suggested that there existed multiple 
opioid receptor types on lymphocytes. These initial studies led to increased interest and 
research in this area.
The majority of the research which investigated opioid receptors on lymphocytes 
utilized receptor binding assays, but many neglected to perform the necessary components 
of classical receptor binding studies which are necessary for identification of a 
physiologically relevant receptor. In classical receptor studies, receptor saturability and 
specificity must be demonstrated. Saturability demonstrates a finite number of receptors, 
which would be expected in a biological preparation. Specificity of the receptor for the 
ligand can be demonstrated by competition-displacement assays using other ligands 
known to interact with the putative receptor. Saturation is commonly analyzed through 
linear transformations of the data (Scatchard plots) in order to determine binding 
parameters, such as the dissociation constant (IQ) and the total number of binding sites 
(BmJ  [Limbird, 1986].
Mehrishi and Mills [1983] reported that lymphocytes contained specific opioid 
receptors of the mu type as demonstrated by the binding of tritiated naloxone to freshly 
isolated human lymphocytes. Although this study demonstrated binding of naloxone to 
the lymphocytes, no saturability was demonstrated nor were competing ligands able to 
completely displace the bound naloxone. In contrast, Hazum et al. [1979] were unable
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to demonstrate classical opioid receptors on lymphocytes. In this study, high affinity 
binding was exhibited only in a transformed human lymphocyte cell line (RPMI 6237) 
which was apparently of non-opioid specificity since iodinated beta-endorphin binding 
was not displaced by any opiate agonists, antagonists or by enkephalin analogs. Although 
these investigators failed to perform a saturation isotherm, they did perform a Scatchard 
analysis of their competition data and reported an approximate dissociation constant of 
3 nM. Attempts by Mendelsohn, et al. [1985] to replicate these findings were 
unsuccessful as they were unable to demonstrate any specific binding of tritiated naloxone 
or tritiated 3H-D-Ala2-D-Leu5-enkephalin to freshly isolated human lymphocytes.
Several other studies have also reported binding of various opioids and opiates to 
human and rat lymphocytes. Ausiello and Roda [1984] reported that tritiated leucine- 
enkephalin (leu-enkephalin) exhibited specific saturable binding to cultured human T 
lymphocytes (Jurkat lymphoid T cell line), although they were unable to inhibit the 
binding of leu-enkephalin with either morphine or naloxone. Although these investigators 
performed a saturation isotherm and reported an approximate dissociation constant (Kd), 
they did not discuss how their nonspecific binding was determined, nor if unlabeled leu- 
enkephalin was capable of displacing tritiated leu-enkephalin from the receptor. Also, the 
Kd was reported as a value without any units, which made interpretation of these results 
difficult. Madden, et al. [1987] also reported a specific binding site for naloxone on 
human T lymphocytes. They demonstrated saturable specific binding using both a 
saturation isotherm and competition assays and reported a Kj of 50 nM, higher than that 
found in neuronal tissue (1-5 nM). In this study, the bound naloxone was partially
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displaced by morphine, beta-endorphin, and met- and leu-enkephalin. Another study also 
identified opioid binding sites on rat lymphocytes using tritiated naloxone and again 
reported a K,, of 10-20 nM. Binding was displaced by morphine and naloxone but not 
by any endogenous opioid peptides. These investigators found that spleen cells but not 
thymocytes exhibited specific binding to naloxone which suggested that the majority of 
binding seen in peripheral lymphocytes resides in the T cell population [Ovadia, et al., 
1989]. Another interesting fact presented by these researchers was that guanosine 5’-0- 
(3-thiotriphosphate) (GTP-gamma-S) inhibited the binding of naloxone. These results 
suggest that a GTP-binding regulatory protein that couples receptors to adenylate cyclase 
is involved in the binding of opiates to lymphocytes. Recently, Carr, et al. [1989] have 
reported evidence for the existence of both delta and kappa receptors on various cell lines 
using highly specific ligands. The existence of sigma receptors has also been reported 
on human peripheral blood leukocytes [Wolfe, et al., 1988].
A number of recent studies support the theory that beta-endorphin binding to 
lymphocytes involves a non-opioid site. Westphal and Li [1984] reported that binding 
of tritiated beta-endorphin to neuroblastoma x glioma hybrid NG108-15 cells had a 
component which was not displacable by the delta ligand, [D-Ser^-Leu-enkephalin-Thr6. 
The non-opioid binding site appeared to recognize only the carboxy terminal region of 
beta-endorphin. These investigators suggested that beta-endorphin recognizes two binding 
sites, one which is specific for the N-terminal sequence and one which is specific for the 
non-opioid carboxy terminal sequence. Schweigerer, et al. [1985b] also suggested that 
beta-endorphin binds to a non-opioid site on murine thymoma cells, since the binding was
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not inhibited by met- or leu-enkephalin. Although these investigators did not perform a 
saturation isotherm, a Scatchard analysis of the competition data revealed a curvilinear 
plot suggesting the existence of two classes of sites, one of high affinity possessing a Kd 
of 65 nM and one of low affinity with a Kd of 2200 nM. Later experiments performed 
by this group suggested that the receptor is internalized via a high affinity site (Mr 
72,000) [Schweigerer, et al., 1985a]. These data are also supported by the work of 
Borboni, et al. [1989] who demonstrated specific binding of iodinated beta-endorphin to 
freshly isolated human lymphocytes which was not displacable by N-terminal fragments 
of beta-endorphin or by naloxone, morphine, bremazocine or ethylketocyclazocine. Again 
no saturation isotherm was performed although a Scatchard analysis of the competition 
data revealed a curvilinear plot. A dissociation constant was not calculated.
A receptor site containing two chains with molecular weights of 46 and 31 kd on 
murine splenocytes has been identified using iodinated beta-endorphin [Carr, et al., 
1988b]. The binding of beta-endorphin to this receptor was reversed by naloxone, 
suggesting that an opioid site exists to which beta-endorphin binds. Binding of beta- 
endorphin to this site also resulted in reduced membrane potassium conductance 
presumably by decreasing potassium channel openings. Beta-endorphin thus appears to 
act on immunocytes (T cells) as it does on neurons in the central nervous system. An 
antibody has also been developed which recognizes opioid receptors on murine 
splenocytes and neuroblastoma x glioma hybrid cells (NG108-15 cells). This antibody 
competes with tritiated dihydromorphine as well as beta-endorphin, met-enkephalin and 
naloxone for the same binding site on the lymphocytes. Binding to this receptor resulted
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in suppression of cAMP production by lymphocytes by inhibiting adenylate cyclase. 
Inhibition of adenylate cyclase by opioid receptor interaction is also seen in neural tissue 
[Carr, et al., 1988a]. Confusion as to the type of opioid receptor existing on
lymphocytes has grown with increasing reports of conflicting data. A number of 
investigators report that beta-endorphin does not appear to bind to classical opiate 
receptors although naloxone appears to bind specifically to lymphocytes. These data 
suggest that there exist two types of sites on lymphocytes, "opioid" and "nonopioid". The 
lack of classical receptor binding studies which include saturation isotherms along with 
competition assays has perhaps contributed to the confusion in this area. Another factor 
which contributes to the confusion is the use of transformed cell lines. These cells are 
not representative of normal circulating lymphocytes since they differ genetically and 
therefore may not exhibit the same types of receptors.
2. Beta-endorphin Modulation of Immune Function
a. Proliferation Assays
The standard assay for assessing the ability of lymphocytes to respond to antigen 
stimulation is the lymphocyte blastogenesis assay. In this assay lymphocyte proliferation 
is determined by measuring tritiated thymidine uptake, as an indicator of DNA synthesis, 
in response to various mitogens. The mitogens most commonly used are Concanavalin 
A (ConA), a mitogen of both T and B cells, Phytohemagglutinin (PHA), a T cell mitogen, 
and Pokeweed mitogen, a B cell mitogen (although it requires the presence of T helper 
cells). Gilman, et al. [1982] reported that beta-endorphin enhanced the proliferative
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response of rat splenic lymphocytes to both ConA and PHA in a dose dependent manner. 
Alpha-endorphin and [D-Ala2, Met5]enkephalin did not affect the proliferative responses 
and naloxone was unable to reverse the enhancement produced by beta-endorphin. 
Kusnecov, et al. [1989] also reported that beta-endorphin enhanced ConA-stimulated rat 
splenocyte proliferation with no stimulation by alpha-endorphin or methionine-enkephalin, 
but they did not attempt to reverse the beta-endorphin enhancement with naloxone. Both 
of these investigators concluded that beta-endorphin acts through a non-opioid site to 
influence cell proliferation. Beta-endorphin also appeared to enhance murine lymphocyte 
proliferation in response to ConA with the carboxy terminal portion of the molecule 
required for activity. Again, it was concluded that beta-endorphin interacts with a non­
opioid receptor [Gilmore and Weiner, 1989].
Reports of beta-endorphin modulation of human lymphocyte proliferation generally 
indicate suppression of the mitogenic response. McCain, et al. [1982] showed that beta- 
endorphin suppressed PHA stimulated blastogenesis and this suppression was not blocked 
by naloxone. The results were supported by Puppo, et al. [1985] who also reported 
suppression of PHA-induced lymphocyte proliferation which was not reversed by 
naloxone. In contrast, Heijnen, et al. [1987] demonstrated that beta-endorphin was 
capable of either enhancing or inhibiting ConA induced proliferation. The ability of beta- 
endorphin to either enhance or suppress proliferation depended on both concentration and 
also donor. The activity seems to reside in the carboxy terminal sequence since removal 
of the N-terminal did not affect activity. This work was supported by McCain, et al. 
[1987] who demonstrated that the carboxy terminal dipeptide of beta-endorphin, glycyl-L-
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glutamine, enhanced the response of lymphocytes to PHA at low doses (10'IZ M) and 
suppressed blastogenesis at higher doses (10'7 M). These studies suggested that beta- 
endorphin is capable of both suppressing and enhancing lymphocyte blastogenesis, but 
that the effect may be dependent on the mitogen used, the dose, the individual and the 
species.
b. Natural Killer Cell Activity
Natural killer cells are a subpopulation of T lymphocytes that spontaneously 
recognize and lyse tumor and virally infected cells and are therefore thought to be critical 
in the immediate host defense to viral infections and the rejection of malignant cells. 
Opioid forms of stress (i.e. intermittent inescapable footshock stress) suppress the 
cytotoxic activity of natural killer (NK) cells as do daily injections of morphine in the rat 
[Shavit, et al., 1984]. Methionine- and leucine-enkephalin both enhanced NK cell activity 
in peripheral blood lymphocytes from cancer patients at a concentration range from 10'14 
to 10'6 mg/ml [Faith, et al., 1987]. In contrast, Oleson and Johnson [1988] reported that 
the enkephalins enhanced NK activity in low responder populations (basal activity of less 
than or equal to 50 lytic units) and suppressed in high responder populations (basal 
activity greater that 50 lytic units). In was concluded, therefore, that naloxone displayed 
both antagonist and agonist properties in this study.
Beta-endorphin has been reported to augment NK cytotoxicity by a number of 
investigators. Mathews, et al. [1983] and Kay, et al. [1984] both reported that beta- 
endorphin enhanced NK cell cytotoxic activity in a dose-dependent and naloxone-
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reversible manner. In another study, beta-endorphin also augmented NK cytolytic activity 
by 63% in a naloxone-reversible manner, whereas neither alpha- or gamma-endorphin 
were able to augment activity [Mandler, et al., 1986]. Kay, et al. [1987] demonstrated 
enhancement of NK cytotoxicity by non-opioid fragments of beta-endorphin, i.e. those 
lacking the N-terminal tyrosine. These fragments were more potent than beta-endorphin 
and the effect was reversed by naloxone. Consequently, two receptors sites may be 
present on NK cells: one activated by opioids, another by certain non-opioid fragments. 
Also, since naloxone could reduce the non-opioid activity, there may be some type of 
interaction between these two receptor sites. It has also been reported that beta-endorphin 
and methionine-enkephalin can enhance the generation of cytotoxic T cells and this 
enhancement can be partially blocked by naloxone. Simultaneous addition of beta- 
endorphin and met-enkephalin did not increase the enhancement of cytotoxic T 
lymphocytes over that of either peptide alone, therefore suggesting that they were acting 
at the same receptor [Carr and Klimpel, 1986].
Although the majority of the studies reported enhancement of NK cell function by 
beta-endorphin, one study did report that beta-endorphin suppressed NK cell activity by 
50% and that this effect was reversed by naloxone and was not due to changes in T cell 
subsets [Prete, et al., 1986]. These investigators used a different experimental design 
where beta-endorphin was incubated with the lymphocytes prior to the actual cytolytic 
assay rather than throughout the assay as was done in the previously mentioned studies. 
They concluded that beta-endorphin suppressed NK cell activity through interaction with 
classical opioid receptors and that lymphocytes may possess both opioid and non-opioid
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receptors which may explain the discrepancy between their work and others. McCain, 
et al. [1986] reported that beta-endorphin induced T cell suppressor activity and therefore 
may suppress immune function through activation of specific suppressor T cell 
populations. It seems therefore that beta-endorphin is capable of both enhancing and 
suppressing natural killer cell activity. This discrepancy may be explained by: 1) the 
existence of two populations of NK cells, i.e. low and high responders, 2) the possibility 
that NK cells possess both opioid and non-opioid receptors with which beta-endorphin is 
capable of interacting, or 3) that beta-endorphin may be enhancing T cell suppressor 
activity.
c. Macrophage and Granulocyte Activity
Beta-endorphin has been reported to modulate granulocyte and macrophage 
function in a number of ways. Opioid peptides have been reported to both enhance and 
inhibit granulocyte chemotaxis. Simpkins, et al. [1984] demonstrated a 20% increase in 
migration of granulocytes by beta-endorphin toward the attractant N-formyl methionyl 
leucyl phenylalanine (FMLP) in a soft agar medium, which was antagonized by naloxone. 
In contrast, Marcoli, et al. [1988] reported that both an enkephalin analog, dynorphin (1- 
9) and morphine inhibited casein-stimulated chemotaxis. In this assay, naloxone appeared 
to have an inhibitory action of its own. The enkephalin analog and dynorphin had no 
effect on spontaneous migration while morphine was able to increase spontaneous 
migration. Beta-endorphin has also been shown to enhance chemotaxis of human 
monocytes in a stereospecific manner, as (-)naloxone was capable of reversing this effect
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while (+)naloxone was not [Ruff, et al., 1985]. Beta-endorphin appeared to suppress 
production of the T lymphocyte chemotactic factor in a bimodal fashion with peaks of 
activity occurring at 10 " M and 10'6 M [Brown and Van Epps, 1985].
Human neutrophil adherence was increased by both beta-endorphin and met- 
enkephalin in a concentration dependent manner and this effect was partially reversed by 
naloxone [Van Epps and Kutvirt, 1987]. Again, the response appeared to be bimodal with 
the greatest peaks of activity occurring at 1013 to 10'12 M and 108 to 10‘9 M. Falke and 
Fischer [1985] demonstrated changes in polymorphonuclear leukocyte cell shape caused 
by beta-endorphin. Beta-endorphin induced both cell spreading and elongation in a 
manner equivalent to that of the chemotactic agent FMLP, and these changes could be 
antagonized by the opiate antagonist diprenorphine.
Beta-endorphin stimulates superoxide production in both neutrophils and 
macrophages. Superoxide production and the generation of other reactive oxygen species 
is linked to microbicidal activity and the regulation of natural killer cell activity by 
polymorphonuclear cells and monocytes. Beta-endorphin and dynorphin stimulate 
superoxide production in granulocytes and macrophages. The effect is rapid and sustained 
in granulocytes but brief in macrophages. Naloxone inhibits the response by 75% in both 
cell types [Sharp, et al., 1985]. This same group went on to demonstrate that the 
stimulation of superoxide production of neutrophils by beta-endorphin was stereoselective 
and apparently via an opioid receptor, since N-acetyl-beta-endorphin and (+)naloxone had 
no effect [Sharp, et al., 1987]. Although beta-endorphin appears to stimulate superoxide 
production in neutrophils, met-enkephalin and leu-enkephalin have been shown to inhibit
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superoxide release by neutrophils stimulated with FMLP [Simpkins, et al., 1986].
d. Antibody and Interferon Production
Beta-endorphin has been shown to influence in vitro antibody and interferon 
production. Alpha-endorphin, met-enkephalin, leu-enkephalin and beta-endorphin 
suppressed the in vitro antibody production of mouse spleen cells. Alpha-endorphin, 
which contains the first sixteen N-terminal amino acid residues of beta-endorphin, was 
a potent suppressor while beta-endorphin only minimally inhibited antibody production 
[Johnson, et al., 1982]. Heijnen, et al. [1986] also demonstrated suppression of antibody 
production by alpha-endorphin in human lymphocytes. The inhibition of antibody 
formation by alpha-endorphin occurred both at the T and B cell level. Removal of the 
N-terminal tyrosine resulted in loss of activity , therefore suggesting that alpha-endorphin 
inhibition of antibody production resulted from interaction with an opioid receptor. Most 
recently, Williamson, et al. [1988] demonstrated a biphasic effect of beta-endorphin on 
the production of specific anti-herpes viral antibodies in vitro. At concentrations of 10"14 
M and below, beta-endorphin enhanced antibody production, while at higher 
concentrations suppression of the antibody response occurred. It was noted that the 
effects of beta-endorphin on human natural killer cells are also biphasic but are a mirror 
image of the effects on antibody production, suggesting that the immunomodulatory 
effects of beta-endorphin may be mediated by effects on natural killer suppressor-inducer 
cells.
In addition to modulating antibody production, beta-endorphin enhanced
43
interleukin-2 production in mitogen stimulated murine lymphocytes. The enhancement 
was not naloxone reversible and was dependent on the presence of the carboxy-terminal 
amino acids although the N-terminal amino acids contributed to the potency [Gilmore and 
Weiner, 1988]. Beta-endorphin also modulated the production of gamma-interferon by 
peripheral blood mononuclear cells. Brown and Van Epps [1986] demonstrated enhanced 
interferon production in Con A-stimulated mononuclear cells by beta-endorphin which 
was not prevented by naloxone. Peterson, et al. [1987] reported conflicting results, in 
which beta-endorphin inhibited gamma-interferon production by Con A-stimulated 
mononuclear cells. In this study, the suppression was antagonized by naloxone and was 
specific for the N-terminal of beta-endorphin, suggesting that a classical opioid receptor 
was involved. Also, monocytes appeared to be the primary target cells and reactive 
oxygen intermediates (ROI) were important mediators in that scavengers of ROI 
eliminated the suppression.
3. Opioid Peptide Production by Cells of the Immune System
The hypothesis that the immune and neuroendocrine systems interact and modulate 
one another is supported by research that indicates that cells of the immune system 
synthesize opioid peptides which are biologically active. Immunoreactive pro-enkephalin 
A activity, as well as proenkephalin A-like RNA, has been identified in human leukocytes 
from patients with chronic lymphoblastic leukemia [Monstein, et al., 1986]. This work 
was confirmed by Zurawski, et al. [1986], who demonstrated preproenkephalin messenger 
RNA in a Con A-activated mouse T-helper cell line. Induced T-helper cell culture
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supernatants also demonstrated met-enkephalin immunoreactive material. Using T helper 
cell lines, Roth, et al. [1989] showed that posttranslational processing of the precursor, 
proenkephalin, is different in lymphocytes than in the brain or the adrenal gland. They 
found that activated T helper cells secreted significant concentrations of high molecular 
weight, opiate-inactive peptides which differed from those derived from the 
neuroendocrine system.
Beta-endorphin and related proopiomelanocortin derived-peptides have been 
identified in cells of the immune system. Mouse spleen macrophages have been shown 
to contain immunoreactive beta-endorphin and ACTH [Lolait, et al., 1984], Infection of 
human lymphocytes with Newcastle disease virus stimulated production of 
immunoreactive beta-endorphin that is identical to pituitary beta-endorphin, based on 
antigenicity, molecular size, association with ACTH and biologic activity [Smith, et al..
1985]. Bacterial lipopolysaccharide also induced de novo synthesis of immunoreactive 
ACTH and alpha- and gamma-endorphin [Harbour-McMenamin, et al.. 1985]. The 
production of ACTH and endorphins by leukocytes is induced by corticotropin releasing 
factor (CRF) and suppressed by dexamethasone in a manner similar to that of pituitary 
cells [Smith, et al., 1986]. The opioid gene for proopiomelanocortin (POMC) has been 
identified in Newcastle disease virus-infected murine splenocytes which offers more 
evidence that lymphoid cells can be activated to express POMC or its products [Westly, 
et al., 1986],
There appear to be two classes of stimulants for ACTH and endorphin production 
by leukocytes. The first is immunostimulants which include viruses, tumor cells and
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bacterial lipopolysaccharide. The other class is the hypothalamic-pituitary peptides, such 
as corticotropin releasing factor. Leukocytes therefore appear to be similar to pituitary 
cells in that the POMC gene is controlled by signals from the hypothalamus and feedback 
inhibition by corticosteroids. Although these similarities exist, leukocytes appear to differ 
somewhat from pituitary cells in posttranslational processing. Whereas Newcastle 
disease virus and CRF cause the production of ACTH and beta-endorphin, bacterial 
lipopolysaccharide elicits the production of immunoreactive ACTH and endorphins which 
correspond to the molecular weights of alpha- and gamma-endorphin [Blalock, 1985].
In summary, although the evidence suggests that leukocytes possess opioid 
receptors, the presence of these receptors on lymphoid cells remains poorly characterized. 
The lack of classical binding techniques has led to a number of confusing results of which 
some can not be interpreted. The evidence for these receptors led researchers to 
investigate a possible role for endogenous opioids in immune function. Beta-endorphin 
appears to modulate a number of immunological parameters although the exact nature of 
the effect often appears to depend on the cell type, species involved, the individual and 
the dose used. The role of beta-endorphin becomes more complicated when the opioid 
and non-opioid effects are considered. The presence of the POMC gene, immunoreactive 
ACTH and beta-endorphin in leukocytes lends further credence to the role of beta- 
endorphin as an immunomodulator and suggests that leukocyte-derived beta-endorphin 
may autoregulate and/or modulate immune function.
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D. EXERCISE AND IMMUNE FUNCTION
Evidence is accumulating which supports the theory that physical exercise, as a 
form of exertional stress, is capable of modifying immune function. Physical exercise 
over a wide range of exertion levels causes a marked increase in the number of 
circulating leukocytes in humans. The number increased within 5 minutes of beginning 
submaximal exercise and remained elevated for at least 15 minutes after cessation of 
exercise. The degree of leukocytosis may be inversely proportional to the amount of 
previous training [Keast, et al., 1988].
Physical exercise may also modify the proportions of lymphocyte subsets. 
Hedfors, et al. [1976] reported that short term exercise resulted in increased lymphocyte 
number in humans with decreased T lymphocytes, increased B lymphocytes, increased 
NK-cell cytotoxicity, and impaired response to the mitogens Con A, PHA and PWM. 
Later work by this group demonstrated decreased T lymphocytes after exercise which 
appeared to be due to a reduction of T helper cells. Results from this study also showed 
reduced antibody production and reduced lymphocyte DNA synthesis after stimulation by 
allogeneic cells [Hedfors, et al., 1983]. Exercise consisting of 5 minutes of running up 
and down stairs resulted in an increase in cytotoxic/suppressor lymphocytes and NK cells. 
The increase in NK cells was associated with significantly greater NK cell activity but 
there was no change in the proliferative response to the mitogen Con A [Edwards, et al., 
1984]. Acute exhaustive treadmill exercise also resulted in a decreased number of T 
helper cells and an increased number of T suppressor cells with no difference between 
athletes and non-athletes [Berk, et al., 1985]. Although the previously mentioned studies
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reported a decreased ratio of helper to suppressor cells, Bongers and Bertrams [1984] 
were unable to find any differences in T cell subsets following exercise.
In general, most levels of exercise stress produce a transient suppression of 
lymphocyte transformation in response to mitogens. As mentioned before, Hedfors, et al. 
[1976,1983] demonstrated decreased responsiveness to mitogens following exercise. 
Eskola, et al. [1978] also reported depressed responsiveness to the mitogens PHA and 
Con A after 2.5 hours of marathon running but were unable to detect any change in 
lymphocyte transformation following 35 minutes of running. In contrast, Edwards, et al. 
[1984] were unable to detect any change in T cell proliferation following exercise. The 
previous work was performed exclusively in humans. One study in horses demonstrated 
a significant suppression of the blastogenic response to the mitogens Con A and PHA, 30 
minutes after treadmill exercise to fatigue [Kurcz, et al., 1988].
The ability of exercise to modify the humoral immune response is not as clearcut. 
Hedfors, et al. [1983] reported suppressed antibody production following exercise while 
Eskola, et al. [1978] were unable to demonstrate any change in antibody production 
following a marathon. There are a number of other conflicting studies. Reductions of 
both serum and secretory immunoglobulins have been linked to increasing intensity of 
exercise in humans, while in mice and rats no difference could be detected in the response 
of antibody production to antigen inoculation in exercised animals [Keast, et al., 1988].
Several investigators have reported that exercise results in an increased number 
of NK cells and enhanced activity [Keast, et al., 1988]. One particularly interesting study 
demonstrated enhanced NK cell activity after a maximal bicycle ergometer exercise test
48
which was antagonized by naloxone administration prior to exercise. Significant 
stimulation of NK cell activity was observed with beta-endorphin in vitro before exercise 
but not after. When naloxone was given prior to exercise, exercise no longer blocked the 
in vitro stimulation of NK cells by beta-endorphin [Fiatarone, et al., 1988]. These results 
suggest that the opioid system plays a role in the modulation of NK cell function 
following exertional stress. Enhancement of NK cell activity following exercise is of 
interest in that there have been reports of decreased tumor growth in exercised animals 
[Keast, et al., 1988].
Exercise has also been reported to modulate the function and number of 
phagocytic cells. Exhaustive exercise has been found to decrease the binding efficiency 
of insulin to monocytes while moderate exercise increased the binding affinity. The 
number of insulin receptors on monocytes has been found to increase over a physical 
training period suggesting an increase in the phagocytic activity of the cells. Neutrophil 
function also decreased following exercise [Keast, et al., 1988].
Although most studies appear to indicate increased leukocyte number and 
temporary immune suppression following exercise, there are conflicting results due 
perhaps to the large variation in exercise protocols with respect to exercise duration and 
intensity. Although exercise appears to suppress lymphocyte proliferation and phagocyte 
function, exercise is reported to augment NK cell function and therefore perhaps suppress 
tumor growth. The enhancement of NK cell function is perhaps a result of changes in 
opioid peptide levels following exercise since administration of naloxone prior to exercise 
blocks the increase in natural killer cell activity. Several studies also suggest that
49
exercise results in changes in lymphocyte subsets, i.e. decreased T helper cells and 
increased T suppressor cells. The decreased helper/suppressor cell ratio following 
exercise may be responsible for the temporary immune suppression which follows certain 
types of exercise. These results suggest that overtraining may increase susceptibility to 
infection.
E. ANALYSIS OF RADIOLIGAND BINDING DATA
Radioligand binding assays allow direct identification of binding sites in target 
tissues by studying the binding of a radiolabeled drug or hormone to a receptor. In order 
to measure receptor binding, the assay requires a radioactively labeled drug or hormone, 
a tissue receptor preparation and a method for separating bound from free drug or 
hormone. The reaction of the drug or hormone with the receptor is said to follow the law 
of mass action if there is a single ligand reacting with a single population of homogenous 
binding sites by a fully reversible reaction. The law of mass action is described by the 
following equation:
ki
[D] + [R]jd*[DR]
k2
where [D] = hormone or drug 
[R] = receptor
[DR] = complex of the receptor with drug 
kj = association rate constant 
k2 = dissociation rate constant
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The choice of isotope for the radiolabeling of the ligand is a critical consideration 
in that full biological activity is necessary for accurate measurement of binding to the 
receptor. Tritium is popular because it has a long half-life but it is limited in its ability 
to detect receptors with limited availability because of its relatively low specific activity 
(29.4 Ci/mmol). In contrast, iodinated ligands, because they possess high specific activity 
(2200 Ci/mmol) and do not significantly alter biological activity, are frequently used when 
receptors are low in quantity and/or possess high affinity for the ligand. Optimum 
incubation conditions must be determined empirically for each tissue preparation used, 
such as intact cells, homogenates or isolated membrane fractions. The method used to 
separate bound from free ligand is also critical in that the separation process must not 
disturb equilibrium conditions [Limbird, 1986].
There are certain minimal criteria which must be met in order to establish binding 
to a physiologically relevant receptor. The binding of the ligand to the receptor should 
be saturable since a finite number of receptors are expected in a biological preparation. 
The binding should also be specific. This can be demonstrated by showing competition 
between the radioligand and other ligands known to interact with the putative receptor. 
The specificity of these ligands at the receptor should parallel the specificity of the 
ligands in vivo. Finally, the kinetics of the binding should be consistent with the time- 
course of the biological effect elicited by the ligand.
The saturability of the receptor is usually assessed by performing a saturation 
isotherm, in which the characteristics of binding as a function of increasing concentrations 
of the radioligand are determined. When the bound radioactivity [‘DR] represents
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saturable binding to a receptor possessing a single affinity, Kd, for the radioligand [*D], 
the plot of [*DR] versus [*D] will yield a rectangular hyperbola (Figure 3A). It is 
important to note that Kj (the dissociation constant), a measure of the affinity of the 
receptor for the ligand, is the concentration of the ligand that half-maximally occupies the 
receptor. Also, when a saturation isotherm is plotted as [*DR] versus [*D] resulting in a 
rectangular hyperbola, the horizontal asymptote is Bmax or the total receptor concentration 
or density. Therefore Bmax will be attained only at infinite concentrations of the 
radiolabeled ligand. Not all of the radioligand binding is necessarily so-called "specific" 
binding. Some radioactivity which is measured as bound ligand is actually "bound" or 
trapped to other sites, such as in the pellet or nonspecific binding to the membrane. 
Consequently, a valid determination of nonspecific binding is very important in setting 
up a reliable assay. Nonspecific binding increases linearly as a function of increasing 
concentrations of [*D] and therefore would not be saturable. Nonspecific binding can be 
determined by binding which cannot be competed for by unlabeled ligand present at 100 
x Kj of the unlabeled ligand. Nonspecific binding can also be defined using computer- 
assisted mathematics. Specific binding is traditionally calculated by subtracting 
nonspecific binding from total binding [Limbird, 1986].
Saturation binding data can be plotted two different ways. It can be plotted on a 
linear scale of [‘DR] versus [*D] (Figure 3A) or it can plotted as [*DR] versus Log10 [*D] 
(Figure 3B). On a linear scale the specific binding appears to plateau, giving the 
impression that a rectangular hyperbola or saturation of the receptor has been obtained. 
Transformation of the data with a plot using a log scale on the x-axis reveals a truncation
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Figure 3. Linear and log saturation isotherms of radioligand binding data.
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of the isotherm which occurs when too narrow a range of radioligand concentrations are 
used. Unfortunately, cost considerations and a second steeper slope of nonspecific 
binding may preclude saturation isotherms which even approach actual saturation of the 
receptor population. Therefore, linear transformations of binding data have been 
developed which allow estimation of the affinity of the receptor-ligand interaction (Kd) 
and the receptor density (Bmax) [Limbird, 1986].
There are several linear transformations which can be used to analyze radioligand 
binding data. Linear transformations give the advantage of estimating various parameters 
from the slope and the x- and y-intercept, all of which can be easily determined. 
However, linear transformations tend to distort the data, especially if extrapolated from 
data obtained over an insufficient range of concentrations of radioligand, and therefore 
may not disclose the true complexities of the receptor-ligand interaction. The most 
commonly used transformation is the Scatchard plot in which receptor affinity can be 
estimated from the slope of the plot and receptor density from the x-intercept. Another 
linear transformation is the Hill plot in which the Kd can be estimated from the x- 
intercept. The slope is referred to as the Hill coefficient, which can be used to determine 
the complexity of the ligand-receptor interaction. Least used is the double-reciprocal or 
Lineweaver-Burk plot. This plot, of all the linear transformations, results in the greatest 
distortion of the data and therefore results in limited or uncertain extrapolations [Limbird, 
1986].
As the Scatchard plot is the most frequently used linear transformation of 
radioligand binding data, a detailed discussion of its uses and limitations follows. The
Scatchard plot is a plot of fD R]/[‘D] on the ordinate versus [*DR] on the abscissa or B/F 
versus B (Figure 4A) where B or [*DR] is the concentration of radioligand present as a 
ligand-receptor complex at equilibrium and F or [*D] is the concentration of free 
radioligand present at equilibrium. From this plot, the data is transformed to a linear 
expression of y = mx + b or B/F = -l/K dB + Bmax/Kd, where m is equal to the slope or 
-1/Kj and b is equal to the x-intercept or Bmax. In a genuine Scatchard plot the 
concentration of the receptor species is known and therefore the x-intercept would give 
the number of binding sites per mole of receptor, not the total density of binding sites 
[Scatchard, 1949]. Consequently, a modification of the Scatchard plot, the Rosenthal plot, 
is used. The Rosenthal plot assumes that the concentration of receptors is unknown and 
therefore the x-intercept is a determination of the total receptor concentration ([R ]TOt) 
only when one population of binding sites exists; that is, when n = 1, n [R]XOT estimates 
[R]tot- Otherwise the x-intercept determines the total number of binding sites rather than 
total receptor concentration [Limbird, 1986; Rosenthal, 1967].
A number of assumptions are made in the algebraic derivations for the linear 
transformations which have been described. If the assumptions are not met when 
obtaining the raw data, then the interpretation of the Scatchard plot will be invalid. The 
first assumption is that the ligand-receptor interaction follows the law of mass action; that 
is, a single drug is interacting with a single receptor population in a fully reversible 
manner. If this requirement is not met, a single slope will not be obtained. The second 
assumption is that the binding must have attained equilibrium. Another assumption is that 
bound and free radioligand can be determined accurately. Therefore, an error in the
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SIMPLE BIMOLECULAR REACTION
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Figure 4. Sample Scatchard plots representing a simple bimolecular reaction (A), 
positive cooperativity (B), and negative cooperativity (C).
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determination of nonspecific binding will introduce artifactual error into the binding 
parameters obtained from a Scatchard analysis [Limbird, 1986].
A linear Scatchard plot allows for correct estimation of Kj and Bmax from the slope 
and x-intercept. However, frequently nonlinear or curvilinear Scatchard plots are 
observed which makes interpretation of the plot difficult and confusing as well as 
controversial. Nonlinear Scatchard plots can be concave downward or concave upward. 
A concave downward Scatchard plot (Figure 4B) may be interpreted to result from 
positive cooperativity of the receptor population. Positive cooperativity results when the 
affinity of the overall receptor population increases with increasing receptor occupancy. 
Positive cooperativity may result from receptor-receptor interactions within multisubunit 
receptor complexes or between physically separate receptors or from the binding of a 
ligand to a single receptor which possesses multiple binding sites and whose affinities are 
increased by sequential binding to the receptor. Downward concave Scatchard plots can 
also result from artifactual sources such as: determination of [*DR] before equilibrium is 
reached, inactivation of the ligand during incubation, inactivation of the receptor during 
incubation and stabilization of the receptor against degradation during occupancy by the 
ligand. A concave upward Scatchard plot (Figure 4C) may result from multiple orders 
of noninteracting binding sites, existence of multiple affinity states of the receptor or 
negative cooperativity. Technical problems which lead to artifactual upward concave 
Scatchard plots are: inappropriate definition of nonspecific binding, aggregation of the 
ligand at higher concentrations to a dimer or multimer which has lower affinity for the 
receptor and higher affinity of the radiolabeled ligand than the unlabeled ligand for the
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receptor [Limbird, 1986].
The popularization of the Scatchard graph has led to its use without a true 
understanding of its limitations. This trend has led to some controversy as to the 
legitimacy of its use in a number of situations. Klotz [1982] suggested that the 
extrapolation necessary to calculate the total number of receptors is generally not correct 
unless a plot of [B] versus log [F] is done in order to determine if the data has been 
obtained over a sufficiently broad concentration range of the radioligand. He concluded 
that the Scatchard plot is, in principle, correct only when extensive measurements are 
made and only the simplest ligand-receptor interaction is occurring. Munson and Rodbard 
[1983] also noted that the true value of Bmax can never be proven through a Scatchard 
analysis and one can only make an estimate of Bmax based on a particular model, such as 
one homogenous site or two or three classes of independent sites. They noted that small 
errors in data are magnified at either axis of a Scatchard plot but that similar 
magnification of error is also seen in the upper plateau when [B] is plotted against log 
[F]. These investigators suggest apparent Kd and Bmax values can be legitimately used 
under defined experimental conditions in order to determine changes as a result of a 
"treatment" as opposed to a "control".
The development of computerized least-squares curve fitting which is weighted 
to account for the statistical distributions of the errors may enable the investigator to 
avoid graphical methods altogether. An example is the computer program "LIGAND" 
which provides weighted least squares estimates of binding parameters such as affinity 
constants, binding capacities and nonspecific binding [Munson and Rodbard, 1980].
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However, the mathematical model upon which the computer program is based may not 
necessarily describe the molecular model which accounts for the ligand-receptor 
interaction and therefore may limit the validity of the computer-derived estimates of 
binding parameters [Limbird, 1986],
Competitive binding analysis is usually performed in order to determine the 
specificity of the radioligand binding. Due to technical and cost considerations, many 
investigators perform Scatchard analysis of competitive binding data rather than saturation 
isotherms to determine binding parameters. Data from competitive binding studies are 
usually plotted as the percent specific binding versus the Log10 [competitor]. Whether or 
not a competitor is interacting with the receptor by simple mass action law or with greater 
complexity, such as multiple affinity states, can be determined by the overall "shape" of 
the competition binding curve. If the ligand-receptor interaction is a simple bimolecular 
reaction, the competition curve for the competitor X will proceed from 10% to 90% 
competition over an 81-fold concentration range of X. Therefore curves which do not 
exhibit "normal steepness" are said to result from complex ligand-receptor interactions 
[Limbird, 1986]. Many investigators mistakenly report the ligand concentration at which 
50% of the bound radioligand is displaced as the dissociation constant of the ligand. 
However, the dissociation constant derived this way actually exceeds the actual 
dissociation constant, particularly if it is measured at high labeled ligand or binding site 
concentrations [Jacobs, et al., 1975]. The binding dissociation constant can be calculated 
from competitive displacement assays if a radiolabeled compound with a known Kd is 
used [Linden, 1982]. However, the calculation is a long, tedious process which does not
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lend itself to routine use. Therefore, many investigators perform Scatchard analyses of 
their competition binding data. The use of the Scatchard analysis for competitive 
displacement analysis of binding parameters is thought to be valid if the ligand-receptor 
interaction is simple competitive inhibition [Weiland and Molinoff, 1981]. However, 
artifactually nonlinear Scatchard plots result if the labeled and unlabeled ligands do not 
bind to the receptor with equal affinity. If the radiolabeled ligand binds to the receptor 
with lower affinity than the unlabeled ligand, a concave downward Scatchard plot will 
result. Conversely, if the radioligand binds with higher affinity to the receptor than the 
unlabeled ligand, then a concave upward Scatchard plot will be seen [Taylor, 1975].
In summary, radioligand binding assays provide a means for direct identification 
of biological receptors. In order to characterize a physiologically relevant receptor, it is 
necessary to show saturability, specificity and kinetics which parallel the time course of 
the biological effect. Scatchard analysis of radioligand binding data enables estimation 
of the dissociation constant (K^) and the total number of binding sites (Bmax). However, 
a good understanding of the limitations of the Scatchard plot are necessary for valid 
interpretation of radioligand binding data. Technical and cost limitations have resulted 
in the use of Scatchard analysis of competitive displacement studies. Although 
theoretically this is a valid use of this graphical interpretation of radioligand data, no 
comparisons have been made between Scatchard analysis of saturation binding data and 
competitive binding data using the same ligands. Therefore, Scatchard analysis of 
radioligand binding data requires proper knowledge of the assumptions upon which the
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algebraic derivations are made and accurate measurements in order to insure that 
interpretations are valid. It is also important to note that the parameters derived from this 
form of analysis are estimates only, as the values obtained result from extrapolations of 
the data and every investigators’ experimental conditions differ.
CHAPTER THREE 
DIURNAL VARIATION IN BETA-ENDORPHIN LEVELS AND 
NOCICEPTIVE THRESHOLDS IN THE HORSE
A. INTRODUCTION
Diurnal variation in both plasma and cerebrospinal fluid levels of beta-endorphin 
has been demonstrated in humans and monkeys with the highest levels occurring around 
0800 hours [Petraglia, et al., 1986; Farsang, et al., 1983; Barreca, et al., 1986; Naber, et 
al., 1981]. A diurnal rhythm of the precursor proopiomelanocortin messenger RNA has 
also been demonstrated in the intermediate pituitary of rats. The variation of the 
proopiomelanocortin (POMC) messenger RNA parallels that of beta-endorphin and these 
events are preceded by similar changes in POMC gene transcription [Millington, et al.,
1986].
Decreased pain sensitivity at night has been demonstrated in the rat and mouse 
[Wright, 1981; Frederickson, et al., 1977]. This diurnal rhythm in nociceptive thresholds 
coincides with the diurnal rhythm of endogenous opioids, since both the rat and mouse 
are nocturnal animals with higher opioid levels occurring at night [Tang, et al., 1984], 
Wesche and Frederickson [1979] have correlated diurnal variation of opioid peptide 
levels with nociceptive sensitivity in the mouse, although McGivern and Bernts jn [1980] 
suggested that the analgesic response may be due to patterns of food intake rather than 
circadian rhythm. Wesche and Frederickson [1979] also demonstrated higher levels of
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endogenous opioid peptides after a noxious stimulus in the afternoon as opposed to the 
morning in mice, suggesting that the endogenous opioid system exhibits tonic activity. 
In this study we present evidence of a diurnal rhythm in both pain sensitivity and plasma 
beta-endorphin levels in the horse.
B. MATERIALS AND METHODS
Eight mature Thoroughbred horses (seven mares; one gelding) were used. All 
subjects were acclimated to their stalls 24 hours before each experiment. Nociceptive 
thresholds, plasma beta-endorphin and cortisol levels and physiological parameters were 
measured at different times of the day: 0600, 0900, 1200, 1500, 1800, and 2400 hours. 
Experiments at each of the times were performed at least 4 days apart to avoid 
conditioning. Nociceptive thresholds were measured using the method of Kamerling, et 
al. [1985b]. A beam of intense light from a radiant-heat lamp1 was focused from a fixed 
distance on the withers, then the fetlock. The elapsed time from turning on the lamp to 
cutaneous musculature contraction was called the skin-twitch reflex latency (STRL); the 
elapsed time to limb withdrawal was called the hoof-withdrawal reflex latency (HWRL). 
The area of skin on both the withers and fetlock was shaved and blackened with india ink 
to provide a uniform surface for heat absorption. Lamp intensity was standardized by 
maintaining lamp voltage at 80 V to produce a reaction within 5 to 10 seconds. Voltage 
was calibrated at every use. A cut-off latency of 15 seconds was chosen to prevent tissue 
damage.
Custom design.
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Cardiac rate was measured from polygraph recordings2 of an electrocardiogram. 
Respiratory rate was determined from polygraph recordings3 using impedance 
pneumography. Vertical pupil diameter was obtained from photographs of the eye after 
standardizing the distance from camera4 to eye. Rectal temperature was recorded from 
a deep rectal probe5 and a digital thermometer6.
Blood samples for determination of beta-endorphin and cortisol levels were taken 
in the stall immediately prior to other measurements. Blood samples were obtained from 
the jugular vein into 7 ml evacuated siliconized glass tubes containing EDTA as an 
anticoagulant. The samples were immediately centrifuged, plasma removed and frozen 
at -20°C until the assays were performed. Plasma beta-endorphin levels were measured 
using a commercially available radioimmunoassay (RIA) kit7 for use in humans. This 
RIA kit consisted of two procedures. The first procedure involved the extraction of beta- 
endorphin from plasma using specific adsorption particles, i.e. affinity gel extraction. 
Extraction of beta-endorphin from plasma was necessary because iodinated beta-endorphin 
tends to nonspecifically bind to high molecular weight plasma components at an alkaline
2Grass Polygraph, Model 7, EKG Tachograph preamplifier, Model 7P4F, Grass 
Instruments, Quincy, Mass.
3Grass Polygraph, Model 7, Low-level DC pre-amplifier, Model 7P1FG, Grass 
Instruments, Quincy, Mass.
4Polaroid CU-5 close-up camera, Polaroid Corp., Cambridge, Mass.
5Rectal probe, Model RET-1, Sensortek, Clifton, N.J.
^Digital thermometer, Model TH-6D, Sensortek, Clifton, N.J.
7Plasma beta-endorphin RIA, INCSTAR Corporation, Stillwater, Minn.
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pH [Orf, et a l,  1979]. This binding interferes with the RIA and makes either extraction 
or column chromatography necessary. Neither silicic acid nor SP-Sephadex adequately 
separate beta-endorphin from the plasma components, therefore affinity gel extraction is 
used as an effective method of concentrating beta-endorphin. The second procedure is 
the RIA itself, which was a disequilibrium method based on an antibody with high 
sensitivity to beta-endorphin. The sample or standard was incubated with the rabbit anti- 
beta-endorphin serum for 16-24 hours at 2-8°C. Iodinated beta-endorphin was then added 
and a second incubation of 16-24 hours at 2-8°C followed. Separation of the beta- 
endorphin bound to the first antibody was achieved by addition of the goat anti-rabbit 
precipitating complex, a short incubation of 15-25 minutes at 2-8°C followed by 
centrifugation at 760 X g for 20 minutes. The supernatant was then decanted and the 
pellet was counted for two minutes using a gamma scintillation counter8. This kit was 
validated for use in horses by determining specificity, accuracy and precision in the 
measurement of equine beta-endorphin9.
Plasma cortisol levels were also measured by a commercially available RIA kit10. 
This procedure was a solid-phase RIA in which the antibody was attached to the wall of 
a polypropylene tube. The sample or standards were added to the tubes, iodinated cortisol 
was then added and the tubes were incubated for 45 minutes at 37°C. The tubes were 
then decanted and counted for one minute on a gamma scintillation counter. The kit was
8Searle Automatic Gamma System, Model 1185, Searle Analytic Inc., Des Plaines, II.
9Equine beta-endorphin, Dr. C.H. Li, Hormone Research Laboratory, University of 
California, San Francisco, Calif.
10Cortisol Coat-a-Count RIA, Diagnostic Products Corporation, Los Angeles, Calif.
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validated for use in horses by determining specificity, accuracy and precision in the 
measurement of equine cortisol.
Nociceptive thresholds and pupil photographs were obtained at 15 minute intervals 
during a 30 to 45 minute sampling period and were averaged from all horses at all times. 
Heart rate, respiratory rate, and rectal temperature were measured continuously. Plasma 
beta-endorphin and cortisol levels were obtained once immediately prior to the 30 to 45 
minute sampling period to avoid exciting the horses. Statistical differences between 
observations were determined using the Student’s paired t-test. Correlations were 
determined by Pearson’s correlation coefficient. Significance was assigned at the P<0.05 
level.
C. RESULTS
The results revealed a diurnal rhythm in most responses characterized by marked 
increases or decreases between 0800 and 0900 hours.
1. Nociceptive Thresholds
The STRL and HWRL were both significantly longest at 0900 hours (p<0.05) with 
smaller, secondary peaks at 1500 hours (Figures 5 and 6). These increases were preceded 
and followed by marked decreases. However, the secondary peaks did not differ 
significantly from the peaks at 0900 hours nor did they differ significantly from latencies 
at other times.
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Figure 5. Thermal evoked skin-twitch reflex latencies over 24 hours (Mean+SEM, 
n=8). (*) indicates statistical difference from the value at 0900 hours (P<0.05).
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Figure 6. Thermal evoked hoof-withdrawal reflex latencies over 24 hours 
(Mean+SEM, n=8). (*) indicates statistical difference from the value at 0900 hours 
(P<0.05).
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2. Physiologic Responses
Physiologic responses varied greatly. Cardiac rate was elevated at 0900 hours, 
followed by a significant decrease within three hours (Figure 7). Although the cardiac 
rate was significantly decreased at 1200 hours, there was another increase at 1800 and 
2400 hours which was not statistically different from values at 0900 hours. The 
respiratory rate was lowest at 0900 hours, preceded by a significantly higher value at 
0600 hours (Figure 8). The respiratory rate was also significantly highest at 1800 hours, 
demonstrating a general trend for higher values at later times of day. Rectal temperature 
was lowest at 0900 hours and significantly higher at 0600, 1800 and 2400 hours (Figure
9). Here again, there was a general trend for higher values in the evening suggesting that 
higher body temperatures may result in higher respiratory rates. Vertical pupil diameter 
was largest at 0900 hours, followed by a marked (6.3 mm) decrease at 1200 hours (Figure
10).
3. Hormonal Levels
Beta-endorphin concentrations were highest at 0900 hours, differing significantly 
from all other times except 1800 hours (Figure 11). Specificity of the beta-endorphin 
RIA kit was evaluated by demonstrating parallelism of serial dilutions of equine beta- 
endorphin and standard solutions. Dilutional parallelism was determined by measuring 
beta-endorphin levels of serially diluted samples as a determinant of accuracy. Accuracy 
was also demonstrated by the addition of equine beta-endorphin to equine plasma in 
concentrations of 5 to 40 pmoles/L (Table 4). The precision of the assay for equine beta- 
endorphin was comparable to that reported for human beta-endorphin by the manufacturer.
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Figure 7. Heart rate over 24 hours (Mean+SEM, n=8). (*) indicates statistical
difference from the value at 0900 hours (P<0.05).
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Figure 8. Respiratory rate over 24 hours (Mean+SEM, n=8). (*) indicates statistical
difference from the value at 0900 hours (P<0.05).
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Figure 9. Rectal temperature over 24 hours (Mean+SEM, n=8). (*) indicates
statistical difference from the value at 0900 hours (P<0.05).
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Figure 10. Vertical pupil diameter over 24 hours (Mean+SEM, n=8). (*) indicates
statistical difference from the value at 0900 hours (P<0.05).
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Figure 11. Plasma beta-endorphin concentrations over 24 hours (Mean+SEM), n=8).
(*) indicates statistical difference from the value at 0900 hours (P<0.05).
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TABLE 4. RIA PERFORMANCE DATA 
Dilutional Parallelism*
Undiluted 1:2 1:4
40 41 32
20 22 21
:uracy*
Background Beta-endorphin
Added
Expected
Value
Measured
Value
Recovery
Percent
6.3 5.0 11.33 11.55 102
6.3 10.0 16.33 17.75 109
6.3 20.0 26.33 28.75 109
6.3 40.0 46.33 42.00 91
‘Values = pmol/L
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The within assay or intra-assay variation yielded a coefficient of variation of 12.2%, 
which was in the range reported by the manufacturer (6.5-13.7%). The between assay or 
inter-assay variation yielded a coefficient of variation of 18.8%, which was also 
comparable to that reported by the manufacturer (18.1%).
Cortisol concentrations were highest at 0800 hours followed by a significant 
decrease following at 0900 hours (Figure 12). Specificity for equine cortisol was 
evaluated by demonstrating dilutional parallelism between standard solutions and serial 
dilutions of endogenous cortisol. Biological specificity was evaluated by demonstrating 
a two-fold increase in endogenous cortisol following the injection of 100IUIM  of ACTH 
(6.0 to 14.3 ug/dl). Accuracy was demonstrated by the addition of cortisol to equine 
plasma in concentrations of 1.05 to 50.0 ug/dl. Linear regression analysis of the recovery 
curve resulted in a correlation coefficient of 0.9999. The intra-assay precision at three 
concentrations (1.87,11.37,43.50 ug/dl) revealed coefficients of variation of 14.7%, 5.0% 
and 3.7%, respectively. The interassay coefficients of variation ranged from 4.2% to 
16.5%.
4. Correlations
There was a positive correlation between the HWRL and the STRL across all 
times (Table 5). There was also a strong positive correlation between beta-endorphin 
concentrations and the STRL. There was a positive correlation between the cortisol 
concentrations and both the STRL and HWRL. The heart rate and respiratory rate 
demonstrated a positive correlation across all times. The correlations between beta- 
endorphin and the STRL and between the STRL and HWRL were stronger than those
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Figure 12. Plasma cortisol concentrations over 24 hours (Mean+SEM, n=8). (*)
indicates statistical difference from the value at 0800 hours (P<0.05).
TABLE 5. Correlation Coefficients for Diurnal Physiologic 
and Nociceptive Parameters over 24 Hours
Comparison Libs Prob(r>[robs/H0:
P=0)*
STRL vs. HWRL 0.49488 0.0003
STRL vs. Beta-endorphin 0.51200 0.0002
Cortisol vs. STRL 0.34992 0.0148
Cortisol vs. HWRL 0.30104 0.0376
Heart rate vs. Respiratory rate 0.36702 0.0103
‘Probability estimate of acceptance of the null hypothesis.
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noted between cortisol and the pain threshold measurements or physiologic parameters. 
D. DISCUSSION
The increased skin-twitch and hoof-withdrawal reflex latencies at 0900 hours 
demonstrated a diurnal rhythm in nociceptive sensitivity. The smaller increases in 
nociceptive thresholds seen at 1500 and 2400 hours suggest an underlying episodic 
fluctuation in pain sensitivity throughout the day. The positive correlation between the 
hoof-withdrawal reflex and the skin-twitch reflex latencies emphasizes the consistent 
results obtained using two different techniques in the measurement of pain threshold. The 
significantly increased beta-endorphin concentrations at 0900 hours also demonstrated a 
diurnal rhythm in plasma beta-endorphin concentrations. The strong positive correlation 
between the beta-endorphin concentrations and the skin-twitch reflex latencies suggests 
that diurnal fluctuations in endogenous opioid levels may mediate the diurnal rhythm in 
nociceptive sensitivity. These results substantiate reports by other investigators which 
suggest that endogenous opioids may be involved in diurnal fluctuation of nociceptive 
responses [Wright, 1981; Frederickson, et al., 1977].
It is well known that adrenocorticotropin (ACTH) is released in a diurnal rhythm 
and beta-endorphin is coreleased with ACTH from the pituitary in response to the 
hypothalamic peptide, corticotropin-releasing factor [Rivier, et al., 1982|. 
Adrenocorticotropin is important in controlling the diurnal rhythm of cortisol and 
therefore has many physiologic effects. Although the cortisol concentrations peaked prior 
to that of beta-endorphin, cortisol concentrations varied diurnally in the horse in a manner
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which approximately paralleled that of beta-endorphin. The difference in the times at 
which beta-endorphin and cortisol peaked may be resolved by more frequent sampling 
times of both cortisol and beta-endorphin. Also, the measurement of ACTH rather than 
cortisol may provide a more sensitive indicator of hormonal fluctuations. However, 
cortisol concentrations were also positively correlated with both the skin-twitch reflex and 
the hoof-withdrawal reflex latencies. These results suggest that cortisol may also be 
involved in the modulation of pain through anti-inflammatory effects at the peripheral 
level. Corticotropin-releasing factor, which stimulates the release of beta-endorphin and 
ACTH, may also be involved in pain perception as the administration of CRF produces 
analgesia in humans and rats [Hargreaves, et al., 1987].
The results obtained from the validation procedures demonstrated accurate, precise 
measurements of equine beta-endorphin and cortisol using commercially available human 
RIA kits. Although equine beta-endorphin differs from human beta-endorphin by three 
amino acid residues [Li, et al., 1981], these residues are apparently not located in the 
antigenic determinant portion of the molecule. Therefore, the antibody used in this kit 
recognizes equine as well as human beta-endorphin. Validation of these kits will permit 
investigators to accurately measure equine beta-endorphin and cortisol with convenient 
commercially available RIA kits rather than with individually developed assays. Thus, 
the use of these kits could reduce the variability in results reported from different 
laboratories and help to clarify the quantitative levels of beta-endorphin release.
The diurnal rhythm of beta-endorphin in the bloodstream may indicate a role for 
this peptide in other physiologic systems besides that of pain. Beta-endorphin, by acting
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on opioid receptors, has many physiologic actions and therefore may control the diurnal 
rhythm of some physiologic parameters. Morphine is the prototypic mu-opiate receptor 
agonist and should produce similar responses to those of beta-endorphin which also binds 
to mu receptors. The changes observed in certain parameters resemble morphine effects 
in the horse. We observed analgesia, increased heart rate, and increased pupil diameter, 
all of which have been observed effects of morphine and other mu-agonists in the horse 
[Muir, et al., 1978; Muir, et al., 1980; Kamerling, et al., 1985a], Respiratory rate is also 
increased by morphine and other narcotic agents in the horse [Muir, et al., 1978]. 
However, this is contraiy to our results which showed decreased respiratory rate when 
analgesia and beta-endorphin levels were greatest. Rectal temperature was also decreased 
at this time and the decreased body temperature may have influenced respiratory rate. 
Perhaps the diurnal change of rectal temperature and respiratory rate is not controlled by 
change in opioid peptide levels. This would explain why the diurnal change in rectal 
temperature and respiratory rate do not mimic morphine effects in the horse.
The results of this study suggest that beta-endorphin, or other endogenous opioid 
peptides, may modulate pain threshold as well as other physiologic parameters. Further 
investigation into the role of opioid receptors in diurnal rhythms needs to be explored. 
Experiments using naloxone, an opiate receptor antagonist, would help to clarify the role 
of opioid receptors play in the diurnal rhythm of pain threshold and a number of 
physiologic parameters. Reversal or inhibition by naloxone of diurnal changes would 
indicate that there is opioid receptor and opioid peptide involvement. However, the use 
of naloxone would not necessarily clarify the role of endogenous opioid peptides that are
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unable to cross the blood brain barrier (i.e. beta-endorphin) in pain threshold changes.
In conclusion, a diurnal rhythm in both nociceptive thresholds and beta-endorphin 
levels has been demonstrated in the horse, with peaks at 0900 hours. These results 
suggest that beta-endorphin may modulate pain as well as other physiologic responses 
such as heart rate and pupil diameter.
CHAPTER FOUR
EXERCISE INDUCED CHANGES IN BETA-ENDORPHIN LEVELS
IN THE HORSE
A. INTRODUCTION
Intense physical exercise has been associated with increases in peripheral blood 
levels of beta-endorphin in humans [Colt, et al., 1981; Farrell, 1985]. Current studies 
suggest that beta-endorphin levels increase significantly after moderately high intensity 
exercise (i.e. 80% V 02max) or maximal exercise intensity (i.e. graded exercise test to 
exhaustion) [Gambert, e ta l ,  1981; Goldfarb, e ta l ,  1987]. Submaximal exercise intensity 
(i.e. 60% VO^a* or lower) does not consistently alter beta-endorphin levels [Rahkila, et 
al., 1987; Langenfeld, et al., 1987]. Recent research suggests that exercise training 
augments beta-endorphin release following high intensity exercise, although not all studies 
support this theory [Carr, et al., 1981; Mougin, et al., 1987; Howlett, et al., 1984]. The 
question arises as to whether the absolute exercise intensity alone which is attainable only 
by trained athletes is responsible for the increased levels of beta-endorphin noted in the 
majority of these studies. Considerable variation exists in the methods used to detect 
beta-endorphin or beta-endorphin-like immunoreactivity in plasma. The different methods 
used to measure beta-endorphin concentrations have led to reports of beta-endorphin 
concentrations varying from 10 pg/ml to 1.6 ng/ml [Farrell, 1985]. Therefore, while 
many of these studies may correctly indicate a change in beta-endorphin concentrations, 
the exact magnitude of change may not be accurate [Sforzo, 1989].
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Beta-endorphin concentrations following exercise in the horse have been examined 
by few investigators. Evans et al. [1985] reported increased plasma beta-endorphin 
concentrations in the horse following a strenuous gallop with levels returning to baseline 
within a half hour. Li and Chen [1987] demonstrated incremental increases in beta- 
endorphin concentrations following a trot, slow gallop and fast gallop in Thoroughbred 
horses. Although Li and Chen [1987] reported approximate speed, no other means of 
evaluating exercise intensity were reported by these investigators. Also, both groups of 
investigators used radioimmunoassay techniques to measure equine beta-endorphin 
without reporting adequate validation of these methods in the horse. Therefore, although 
increases in beta-endorphin concentrations occur following exercise in the horse, the 
intensity of exercise which stimulates a response and the exact magnitude of the response 
have yet to be addressed. Also, the role of training in the release of beta-endorphin has 
not been examined in the horse. Therefore this study was undertaken in order to 
determine the role of exercise intensity and physical conditioning in the release of beta- 
endorphin in the horse.
B. MATERIALS AND METHODS 
Horses
Ten healthy Thoroughbred horses, five males and five females, with a mean age 
of 4.5+0.5 (Mean+S.D.) years were used in this study. All horses had received previous 
exercise training but had not been raced or trained for nine months prior to this study. 
The horses were clinically normal as determined by a complete blood count, serum
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biochemistry profile and physical examination.
Exercise testing and conditioning regimen
Horses were subjected to 5 exercise tests of maximal intensity under varying 
conditions. The first two exercise tests were performed on horses in an unconditioned or 
unfit state which was followed by nine weeks of a conventional race conditioning 
program. Following the conditioning period, three more exercise tests were performed. 
Exercise tests were begun at approximately 0730 hours and completed by 1000 hours. 
The exercise tests were spaced at 10 day intervals to allow for recuperation. The 
experimental timetable and conditioning program is shown in Table 6.
Horses were fed their evening rations on the day before each exercise test and 
food was then withheld prior to testing. Blood samples were collected from the jugular 
vein at rest in their stalls before testing. The animals were then saddled, taken to the 
track, and ridden by the same experienced jockey. Each horse was then trotted for 1200 
meters and cantered for 800 meters in a clockwise direction (warm-up). The animals 
were then stopped, turned in the opposite direction and asked for a maximal effort run for 
400 or 1000 meters depending on the test. Exercise intensity and the degree of exertional 
stress were evaluated by heart rate, respiratory rate, lactate concentrations and pain 
threshold measurements. Naloxone pretreatment was used to evaluate opioid involvement 
in the horses’ response to the exertional stress. Naloxone hydrochloride1 was dissolved 
in a 0.9% sterile sodium chloride solution and injected intravenously immediately prior 
to exercise. In the 1000 meter exercise tests, either naloxone or an equal volume of
Naloxone hydrochloride, Sigma Chemical Company, St. Louis, MO.
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TABLE 6. Experimental Timetable
Week
1 Alternate daily 400m trot or 80m swim
2 Preconditioning exercise test - 400m
3 Preconditioning exercise test - 400m 
Naloxone pretreatment ( 0.75 mg/kg IV)
4-13 Horses conditioned 6 days/week:
1600m completed over 4-5 mins/day (5.3-6.7 m/sec) for 4 
days/week, adding 800m each week until 4000m/day 
was performed.
Speed increased over 9 weeks until 8.9m/sec was reached. 
Horses swum 2 days/week, increasing to 24 laps in 20 mins 
of an 11m pool by week 13.
14 Postconditioning exercise test - 400m
15 and 16 Postconditioning exercise tests - 1000m
Naloxone (0.75 mg/kg IV) or saline (0.9%, IV) pretreatment
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saline was injected prior to the exercise test in a double-blind crossover design. Blood 
samples for beta-endorphin, cortisol and lactate were taken before, immediately after and 
30 minutes after each exercise test. Measurements of pain sensitivity were obtained 
before and at 2, 10, 20 and 30 minutes after exercise using the method of Kamerling, et 
al. [1985] (Refer to Chapter 3 for detailed description of the procedure). Heart rate was 
measured using an on board heart rate monitor2. Respiratory rate was determined from 
polygraph recordings using impedance pneumography3. Heart rate and respiratory rate 
measurements were taken for 10 minutes prior to the exercise tests and continuously for 
thirty minutes following the exercise tests. Rectal temperature was recorded from a deep 
rectal probe and a digital thermometer before and immediately after each exercise test. 
Ambient temperature was recorded at the time of each exercise test using a digital 
thermometer.
Sample Analysis
Blood samples for plasma beta-endorphin and cortisol levels were collected into 
7 ml evacuated siliconized glass tubes containing EDTA as an anticoagulant. Blood 
samples for lactate concentrations were collected in 4 ml evacuated glass tubes containing 
sodium fluoride as a preservative. The samples were immediately centrifuged and the 
plasma or serum removed and frozen at -20°C until the assays could be performed. 
Plasma beta-endorphin levels were measured using a commercially available
2Equistat Model HR-7A, EQB Inc., Unionville, Penn.
3Grass polygraph Model 7, Low-level DC pre-amplifier Model 7P1FG, Grass Instruments
Co., Quincy, Mass.
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radioimmunoassay (RIA) kit. Cortisol concentrations were also determined using a 
commercially available RIA kit (For detailed procedures and validation of beta-endoiphin 
and cortisol RIA kits, refer to Chapter 3). Lactate concentrations were determined using 
a commercially available kit4. The lactate procedure was based on the measurement of 
the generation of the reduced form of nicotinamide adenine dinucleotide (NADH) 
spectrophotometrically at 340 nm. In the presence of excess nicotinamide adenine 
dinucleotide (NAD) and the enzyme lactate dehydrogenase, lactate was converted to 
pyruvate along with the generation of NADH, which caused increased absorbance at 340 
nm. A protein precipitant, 8% perchloric acid, was used initially on the sample and the 
supernatant was then used directly without further treatment. Lactates were measured on 
a narrow-bandwidth spectrophotometer5.
Statistical Analyses
Data were analyzed by multiple analysis of variance for repeated measures 
followed by Duncan’s multiple range test and Pearson’s correlation coefficients. 
Student’s paired t-test was also performed where applicable. Significance was assigned 
at the P<0.05 level.
C. RESULTS
Intense physical exercise resulted in significantly increased concentrations of beta- 
endorphin after all exercise tests when compared to levels obtained at rest (Figure 13).
4Sigma Diagnostics, Sigma Chemical Co., St. Louis, Mo.
5Gilford Spectrophotometer, Model 250, Gilford Instrument Laboratories, Oberlin, Ohio.
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Conditioned horses subjected to a 400m exercise test had significantly lower beta- 
endorphin levels at 30 minutes post exercise than did unfit horses (Figure 13, comparison
a) (P<0.05). These results indicate a more rapid return to baseline levels in the 
conditioned group. An increase in distance to 1000m resulted in increased beta-endorphin 
concentrations compared to levels following a 400m exercise test (Figure 13, comparison
b) (P<0.01). These results suggest that the increased distance resulted in an increase in 
exercise intensity and therefore suggest a correlation between exercise intensity and beta- 
endorphin concentrations following exercise. Naloxone pretreatment resulted in increased 
beta-endorphin concentrations in unfit horses 30 minutes following exercise as compared 
to unfit horses without naloxone pretreatment (Figure 13, comparison c) (P<0.05). This 
phenomenon was also noted in fit horses 30 minutes following a 1000m exercise test 
(saline vs. naloxone, P<0.05).
Cortisol concentrations were also elevated following exercise although conditioning 
did not significantly alter the response (Figure 14). Cortisol concentrations were 
significantly increased over baseline values after all times except immediately post 
exercise following a 400m exercise test in the unconditioned horses. The increase in 
distance from the 400m to 1000m exercise test resulted in higher levels 30 minutes post 
exercise (P<0.05) but not immediately post exercise (Figure 14, comparison a). These 
results again suggest a correlation between exercise intensity and hormonal concentrations. 
Significantly higher cortisol levels (P<0.01) were noted immediately following exercise 
in unconditioned, naloxone pretreated horses suggesting that naloxone pretreatment 
resulted in a faster rise in cortisol concentrations following exercise in unconditioned
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Figure 13. Change in plasma beta-endorphin concentrations from baseline following
exercise. Letters indicate statistical differences (P<0.05): (a) fit vs. unfit, 400m, 30
minutes post exercise, (b) fit, 400m vs. 1000m, (c) naloxone vs. saline.
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Figure 14. Change in plasma cortisol concentrations from baseline following
exercise. Letters indicate statistical difference (P<0.05): (a) fit, 400m vs. 1000m, (b)
unfit, 400m, no pretreatment vs. naloxone pretreatment.
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horses (Figure 14, comparison b). There was no difference in cortisol concentrations 
following naloxone pretreatment from saline pretreatment in conditioned horses.
The assessment of exercise intensity and the degree of exertional stress were 
analyzed by measuring pain threshold, heart rate, respiratory rate and blood lactate 
concentrations. Intense exercise resulted in significantly increased pain thresholds in the 
unconditioned horse at 2 minutes post exercise (PcO.Ol) (Figure 15). Naloxone 
pretreatment prior to the 400m exercise test in the unconditioned horses resulted in a 
significant decrease in pain threshold from baseline values at 10, 20 and 30 minutes post 
exercise. These results suggest that naloxone pretreatment in unconditioned horses results 
in hyperalgesia following intense exercise. The 400m exercise test in conditioned horses 
did not significantly elevate pain threshold although the increased distance of the 1000m 
exercise test did significantly increase pain threshold at 2 minutes post exercise (P<0.05). 
The increased pain threshold noted after 1000m in the fit horse was not as great as that 
seen after 400m in the unconditioned horse. Naloxone pretreatment reversed the analgesia 
noted following the 1000m exercise test in conditioned horses but did not result in 
hyperalgesia. Interestingly, the elevations in pain threshold occurred within two minutes 
post exercise and rapidly returned to baseline while the hyperalgesic effect of naloxone 
was not seen until 10 minutes post exercise and persisted for 30 minutes.
Heart rate was significantly increased following all exercise tests (P<0.001), with 
the highest peak values seen immediately following the 400m exercise test in the 
unconditioned horses (Figure 16, comparison a, Table 7). Conditioning significantly 
decreased the peak heart rate following the 400m exercise test (PcO.Ol) and decreased the
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Figure 15. Change in skin-twitch reflex latency from baseline over a 30 minute
period following exercise. (*) indicates statistical difference from baseline: *
P<0.05, ** P<0.01, ***P<0.001.
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Figure 16. Change in heart rate from baseline following exercise, averaged over 5 
minute intervals. Letters indicate statistical difference (P<0.05): (a) unfit vs. fit, 
400m, 1-5 min., (b) unfit vs. fit, 400m, 11-15 min.
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TABLE 7. Peak Heart Rates
Exercise Test Peak Heart Rates (Mean+SEM) 
(Beats/min)
Unfit, 400m 245.7+11.5
Unfit, 400m, Naloxone pretreatment 228.9+8.20
Fit, 400m 213.7+11.1
Fit, 1000m 182.6+5.80
Fit, 1000m, Naloxone pretreatment 162.1+2.50
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time for the heart rate to return to baseline or recovery time (P<0.05 at the 11-15 minute 
interval). Heart rate was also significantly elevated over all times following the 1000m 
exercise tests as compared to the 400m exercise tests in the conditioned horses (PcO.Ol). 
Naloxone pretreatment did not alter heart rate response to exercise in either the 
unconditioned or conditioned horse. An average peak heart rate of 201+8 beats/min was 
noted following all exercise tests.
Respiratory rate was also significantly increased following all exercise tests 
(P<0.001) (Figure 17) while respiratory rates following the 1000 m exercise tests were 
significantly higher than those following the 400 m exercise tests in unfit horses (P<0.05). 
Respiratory rates following the 400m exercise test in fit horses were also significantly 
higher when compared to the 400m test in unfit horses (P<0.05). Naloxone pretreatment 
had no significant effect on respiratory rate. Respiratory rates following the 1000m 
exercise test in naloxone pretreated horses appeared higher than saline pretreated horses 
but were not statistically significant. Lactate concentrations were significantly increased 
over baseline values (P<0.001) after all exercise tests, with post exercise values always 
exceeding 4 mmol/L or anaerobic threshold (Figure 18). There was no statistical 
difference between lactate concentrations following a 400m exercise test in unconditioned 
horses when compared to conditioned horses. The increased distance associated with the 
1000m exercise test resulted in significantly higher concentrations than seen both 
immediately and thirty minutes following the 400m test in conditioned horses (P<0.001) 
(Figure 18, comparison a). Naloxone pretreatment did not alter the lactate response to 
exercise in the unconditioned horse following the 400m exercise test but did decrease the
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Figure 17. Change in respiratory rate from baseline following exercise, averaged
over 5 minute intervals.
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Figure 18. Increase in lactate concentrations from baseline following exercise.
Letters indicate statistical difference (P<0.05): (a) fit, 400m vs. 1000m, (b) fit,
1000m, naloxone vs. saline.
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amount of lactate produced immediately following the 1000m exercise test in the 
conditioned horse (PcO.Ol) (Figure 18, comparison b).
Rectal temperature increased significantly from baseline values following all 
exercise tests except the 400m exercise test in conditioned or fit horses (PcO.Ol) (Figure 
19). Rectal temperatures following the 1000m exercise test were significantly higher than 
those noted after the 400m exercise test in fit horses (Pc0.02). Lower values following 
naloxone pretreatment were noted but were not statistically significant. Ambient 
temperature was significantly higher during the exercise tests following the conditioning 
or training period from the ambient temperature during the tests run prior to the nine 
week training period (PcO.001) (Figure 20).
In unconditioned horses pretreated with naloxone following a 400m exercise test, 
there was an inverse correlation between the skin twitch reflex latency and beta-endorphin 
concentrations across all times (Table 8). There was a strong positive correlation between 
beta-endorphin and lactate concentrations following all exercise tests. There was also a 
strong positive correlation between lactate concentrations and heart rate following all 
exercise tests. Lactate concentrations also showed a strong positive correlation with 
respiratory rates following all exercise tests. Beta-endorphin and cortisol concentrations 
were positively correlated following exercise tests with naloxone pretreatment.
D. DISCUSSION
Data from human research suggest that moderately high and high intensity exercise 
stimulate the release of beta-endorphin into the circulation [Sforzo, 1989]. Exercise
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Figure 19. Increased rectal temperature from baseline following exercise. (*)
indicates statistically different from baseline (P<0.01).
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TABLE 8. Pearson’s Correlation Coefficients for Exercise Test Param eters
Comparison f** obs Prob(r>[robs]/H0:
p=0)‘
Beta-endoiphin vs. Skin twitch Reflex Latency
Unfit, 400m, Naloxone pretreatment -0.60080 0.0009
Beta-endorphin vs. Lactate
Unfit, 400m 0.44542 0.0226
Unfit, 400m, Naloxone pretreatment 0.69779 0.0001
Fit, 400m 0.56732 0.0020
Fit, 1000m 0.68337 0.0001
Fit, 1000m, Naloxone pretreatment 0.86473 0.0001
Beta-endorphin vs. Cortisol
Unfit, 400m, Naloxone pretreatment 0.72269 0.0001
Fit, 1000m, Naloxone pretreatment 0.66854 0.0001
Lactate vs. Heart Rate
Unfit, 400m 0.55207 0.0035
Unfit, 400m, Naloxone pretreatment 0.73546 0.0001
Fit, 400m 0.78690 0.0001
Fit, 1000m 0.73986 0.0001
Fit, 1000m, Naloxone pretreatment 0.77263 0.0001
Lactate vs. Respiratory Rate
Unfit, 400m 0.65090 0.0003
Unfit, 400m, Naloxone pretreatment 0.80561 0.0001
Fit, 400m 0.46958 0.0135
Fit, 1000m 0.74852 0.0001
Fit, 1000m, Naloxone pretreatment 0.81020 0.0001
‘Probability estimate of acceptance of the null hypothesis.
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intensity was defined in this study by changes in heart rate, respiratory rate, and lactate 
levels following exercise as an approximation of V 02max. Based on peak heart rates and 
lactate concentrations, it can be concluded that the horses reached near maximal or 
maximal exercise intensity following all exercise tests. Peak heart rates averaged 201 
beats/min, while lactate concentrations exceeded 4 mmol/L or anaerobic threshold. These 
conclusions are substantiated by studies which have used heart rates of 200 beats/min in 
combination with lactate concentrations exceeding 4 mmol/L to define maximal aerobic 
work power in the horse [Persson, 1983], Increased peak heart rates, respiratory rates, 
and lactate concentrations following the 1000 m exercise test when compared to the 400 
m exercise test in conditioned or unconditioned horses suggested that the increase in 
exercise duration resulted in a corresponding increase in exercise intensity. Lactate 
concentrations were positively correlated with heart rate and respiratory rate in all 
exercise tests. The correlation of lactate concentrations with heart rate and respiratory 
rate suggests that increased exercise intensity results in increased lactate concentrations, 
heart rate and respiratory rate and supports the conclusion that an increase in exercise 
duration results in increased exercise intensity.
The degree of exertional stress experienced by individuals, following exercise of 
equal intensity, may vary with each individual. The level of fitness, state of health, and 
a number of psychological factors are capable of influencing the degree of exertional 
stress [Cummings and Wheeler, 1987]. Exertional stress in humans is commonly defined 
by mood alteration, perceived work effort and, in some cases, pain threshold 
measurements [Janal, et al., 1984; Scott and Gijsbers, 1981; Kemppainen, et al., 1985].
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These measurements are usually determined by questionnaires and therefore represent 
subjective assessments of exertional stress. In this study however, the degree of 
exertional stress was analyzed by heart rate, pain threshold measurements, hormonal 
levels and other relevant physiologic parameters, therefore providing more objective 
means of assessing exertional or exercise stress levels. Peak heart rates were the highest 
following the 400 m exercise test in the unconditioned horses. Conditioning resulted in 
a significant decrease in peak heart rates and a faster return to baseline although work 
load remained the same. Increased exercise duration, which suggested a corresponding 
increase in exercise intensity (1000 m exercise test), resulted in an increase in peak heart 
rate from that seen in conditioned horses following the 400 m exercise test. However, 
the peak heart rates following the 1000 m exercise tests in fit horses were lower that 
those following the 400 m test in unfit horses. These results suggest that the 
unconditioned horses experienced a greater degree of exertional stress than the 
conditioned horses, even when the conditioned horses were subjected to an exercise test 
requiring increased exercise intensity or work load.
The increased pain threshold following the 400 m exercise test in the 
unconditioned horses again suggests that the unfit horses experienced a greater degree of 
exertional stress. The increase in pain threshold or analgesia noted after the 400 m 
exercise test in unfit horses was not seen in the conditioned horses following the 400 m 
exercise test. However, increasing exercise duration and/or intensity to 1000 m again 
elevated pain threshold, although it was not as great as that seen in the unfit horse. These 
results confirm the conclusions drawn based on the heart rate measurements, that the unfit
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horse may experience a greater degree of exertional stress than does the conditioned or 
fit horse, even when the fit horse is subjected to an exercise test of greater exercise 
intensity.
Rectal temperature was not significantly increased following the 400 m exercise 
test in the fit horses, although it was elevated following all other exercise tests. This 
again supports the theory that the conditioned horses experienced less exertional stress 
than the unconditioned horses. Respiratory rate analysis did not support this conclusion, 
as the respiratory rates were higher in the fit horses than the unfit horses. This may be 
due to the increased ambient temperature during the time of the post-conditioning exercise 
tests.
Beta-endorphin concentrations increased significantly following all exercise tests. 
Beta-endorphin levels were lower in all 400 m exercise tests when compared to the 1000 
m exercise tests. The higher levels seen following the 1000 m exercise tests suggest that 
there is a correlation between exercise intensity and beta-endorphin release. However, 
actual oxygen consumption measurements, along with more rigorously standardized test 
conditions (i.e., graded treadmill exercise to exhaustion), would be necessary to clearly 
define a correlation between exercise duration, exercise intensity and beta-endorphin 
levels.
Beta-endorphin concentrations returned to baseline faster following a 400 m 
exercise test in fit horses when compared to unfit horses, suggesting a correlation also 
exists between beta-endorphin concentrations and the amount of exertional stress 
experienced by the horse. The greatly increased beta-endorphin concentrations noted
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following the 1000 m exercise test, when compared to the 400m exercise test, however, 
suggested that beta-endorphin release is linked more with the degree of exercise intensity 
than with the amount of exertional stress. If beta-endorphin release was linked primarily 
with the amount of exertional stress experienced by the horse, the highest beta-endorphin 
concentrations would have occurred following the 400 m exercise test in unfit horses, 
which was not the case.
Conditioning did not increase the release of beta-endorphin in response to the 
400 m exercise test. However, the increase in exercise intensity and/or duration (1000 
m exercise test) did result in a substantial elevation in beta-endorphin concentrations when 
compared to those following the 400 m exercise tests. Most studies in humans which 
evaluated the effects of training on beta-endorphin release increased the level of exercise 
intensity in the trained athletes when compared to exercise tests performed in sedentary 
individuals. The studies which did not increase exercise intensity did not demonstrate 
increase releasability, with one exception [Sforzo, 1989]. These studies support our 
conclusion that the fit horse is capable of attaining a higher degree of exercise intensity, 
and it is this level of exercise intensity which is responsible for the increased releasability 
of beta-endorphin that has been noted in trained human athletes.
Cortisol concentrations were significantly increased following all exercise tests, 
with higher levels noted thirty minutes following the 1000 m exercise tests when 
compared with the 400 m exercise tests. There was no difference in the cortisol response 
to exercise between fit and unfit horses following the 400 m exercise test. These results 
support the conclusion that hormonal release is linked to exercise intensity more than to
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the degree of exertional stress. However, increased sampling times may enable detection 
of a difference in the cortisol response to exercise between fit and unfit horses. Also, 
adrenocorticotropin concentrations may be a more sensitive indicator of the response to 
exercise than cortisol, and therefore may be a better alternative.
The correlation between beta-endorphin concentrations and lactate concentrations 
suggest that earlier reports linking beta-endorphin release with anaerobiosis may in fact 
be the case [DeMeirleir, et al., 1986; Mougin, et al., 1987]. The injection of lactic acid 
produces anxiety neurosis in humans [Pitts and McClure, 1972]. Increased lactate levels 
may therefore be associated with pain and anxiety, as well as exercise intensity, during 
exercise. Thus, increased beta-endorphin concentrations following exercise may result 
from increased anxiety or pain induced by elevated lactate levels. The mechanism by 
which exercise stimulated beta-endorphin release remains unclear. Although it has been 
suggested that anaerobiosis may be involved, other stimulatory stresses, such as 
hypoglycemia, or neural pathways may be involved [DeMeirler, et al., 1986]. The 
increased physical stress of a hot ambient temperature or dehydration has also been noted 
to increase opioid release [McMurray, et al., 1984], suggesting a relationship exists 
between exercise stress and the opioid response. Shyu, et al. [1982] have suggested that 
long lasting exercise may produce discharges in muscle afferents which influence central 
endorphin mechanisms. These investigators concluded that these mechanisms may result 
in exercise-induced analgesia. It may be through this stimulation of neural pathways that 
peripheral beta-endorphin release is also effected.
Naloxone is an opiate receptor antagonist which acts primarily at the mu receptor
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and is capable of antagonizing the analgesic effects of opiates or endogenous opioids. It 
is thought to be a pure antagonist with no physiologic actions of its own [Frederickson, 
1984]. Naloxone pretreatment resulted in higher beta-endorphin concentrations thirty 
minutes post exercise in both the fit and unfit horses. These higher levels suggest that 
naloxone may be blocking autoreceptors for beta-endorphin at the hypothalamic or 
pituitary level that are involved in regulating beta-endorphin release, thus prolonging the 
release of beta-endorphin following exercise. Naloxone pretreatment also resulted in 
higher cortisol concentrations immediately following exercise in the unconditioned but not 
the conditioned horse. This faster rise in cortisol concentrations following exercise in the 
unfit naloxone treated horse may again result from blockade of beta-endorphin or opioid 
receptors or from blockade of receptors at the hypothalamic level which control 
corticotropin releasing factor (CRF) release. As naloxone is capable of crossing the 
blood-brain barrier, its interaction with central opioid receptors that regulate pain 
transmission may increase the pain experienced by the animal. Naloxone has been shown 
to increase sensitivity to pain, or cause hyperalgesia, following intrathecal injections in 
rats suggesting that the hyperalgesic effects of naloxone are due to blockade of tonic 
inhibition by endogenous opioids in the spinal cord [Woolf, 1980]. This theory is 
confirmed by the significantly decreased pain threshold (or hyperalgesia) following 
exercise in the unfit naloxone pretreated horse. Therefore, since naloxone pretreatment 
did not significantly decrease the pain threshold in the fit horse after the 1000 m exercise 
test, but returned it to baseline, the fit horse did not have the benefit of the increase in 
pain threshold it normally would have experienced and therefore may have experienced
108
more pain and discomfort. The negative correlation between beta-endorphin levels and 
the skin twitch reflex latency noted in unfit naloxone pretreated horses after the 400 m 
exercise test suggests that increased pain perception may result in increased beta- 
endorphin and cortisol levels. This is confirmed by the positive correlation between beta- 
endorphin and cortisol concentrations following exercise tests in both fit and unfit 
naloxone pretreated horses.
The exercise induced increases in beta-endorphin levels along with increased pain 
threshold suggest that beta-endorphin may be involved in pain regulation. Beta-endorphin 
produces analgesia following intracerebroventricular injections and is found both centrally 
and peripherally [Frederickson and Geary, 1982]. Beta-endorphin that originates in the 
central nervous system is thought to be involved in pain control while peripherally 
occurring beta-endorphin may be involved in stress-induced analgesia [Akil, et al., 1984], 
Beta-endorphin is generally not thought to cross the blood-brain barrier, although some 
investigators suggest that opioid peptides have sufficient permeability to exert central 
effects [Rossier, et al., 1977; Rapoport, et al., 1980]. The role of corticotropin releasing 
factor (CRF) and glucocorticoids also cannot be eliminated. Corticotropin releasing factor 
administration produced analgesia in humans and rats [Hargreaves, et al., 1987]. 
Therefore, exercise produced analgesia may result from the anti-inflammatory effects of 
increased glucocorticoid levels, resulting from CRF release, or from a direct neural effect 
of CRF as immunoreactive CRF has been found in the dorsal horn of the spinal cord and 
the trigeminal nucleus, areas associated with nociception [Schipper, et al., 1983]. It has 
also been suggested that exercise-induced analgesia may result from muscle afferent
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discharges which influence central opioid mechanisms [Shyu, et a i,  1982]. Therefore, 
the analgesia seen following exercise may be due to beta-endorphin or other endogenous 
opioids originating in the central nervous system, perhaps through stimulation by muscle 
afferent fibers, or may result from increased CRF levels either at the central or peripheral 
level. However, a role for peripherally circulating beta-endorphin in exercise-induced 
analgesia cannot be eliminated.
The hyperalgesia noted after naloxone pretreatment in the unconditioned horse was 
not seen in the conditioned horse. The fact that hyperalgesia was demonstrated only in 
the unfit horse suggests that there is a change in opioid receptor number or affinity after 
conditioning. Up or down regulation of receptors is seen as a physiologic response to 
changing levels of hormones in the body [Hollenberg, 1985]. Decreased receptor number 
or decreased affinity of the receptor for beta-endorphin following conditioning would 
explain the lack of hyperalgesia following exercise in the naloxone pretreated fit horse. 
If the unfit horse had a higher number of receptors or a higher affinity of the receptors 
for the ligands, naloxone would either bind to more receptors or bind with greater affinity, 
and therefore would have a greater effect.
The significance of peripherally released opioid peptides has encouraged research 
into their role in exercise performance, exercise-induced affective responses such as 
analgesia, metabolic responses, cardiovascular responses and immune function [Cummings 
and Wheeler, 1987; Sforzo, 1989]. This study demonstrated the release of beta-endorphin 
in response to maximal exercise. The pattern of beta-endorphin release suggested that the 
release was more a function of exercise intensity than exertional stress and may be linked
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to anaerobiosis. Increased pain threshold following exercise in the unfit horse following 
a 400 m exercise test and in the fit horse following a 1000 m exercise test, along with 
increased heart rates, lactate levels and respiratory rates, demonstrate higher levels of 
exertional stress during these tests. Peripherally circulating beta-endorphin may be 
involved with modulating pain perception following exercise, although the role of 
endogenous opioids which originate in the central nervous system cannot be eliminated. 
Naloxone pretreatment reversed the analgesia seen following exercise, prolonged beta- 
endorphin release and accelerated cortisol release. These results suggest that indeed 
endogenous opioids play a role in modulating the physiologic homeostatic response to 
exercise. Although some studies suggest that endogenous opioids affect cardiovascular 
and respiratory responses to exercise [Sforzo, 1989; Grossman, et al., 1984], the results 
of this study do not support this theory. Naloxone did not significantly alter the 
cardiovascular or respiratory responses to exercise. However, naloxone is primarily a mu 
receptor antagonist, while delta and kappa receptors are associated with opioid 
cardiovascular regulation [Sforzo, 1989]. Also, naloxone appears to control ventilation 
only at high levels of power output in humans which may not have been reached in this 
study [Grossman, et al., 1984].
In order to determine whether or not central or peripherally originating endogenous 
opioid peptides are responsible for the analgesia seen after exercise will require 
experiments which measure central levels of endogenous opioids. Finally, physical 
conditioning appears to alter the response of the horse to exercise, thereby decreasing the 
level of exertional stress. The effects of physical conditioning on the response of the
I l l
horse to exercise may involve a number of complex interrelationships. Conditioning may 
involve adaptations of cardiac, vascular, hormonal, metabolic, neurologic and 
psychological functions. There may be increased work capacity of the heart, change in 
muscle fiber type, change in metabolic demands and change in the psychological response 
to exercise. It is possible that changes seen with conditioning in physiologic functions 
may be opioid regulated, in part, and therefore are due to changes in opioid receptor 
number or affinity.
In conclusion, this study demonstrated that beta-endorphin is released in response 
to exercise in the horse and the response is altered by physical conditioning. The use of 
naloxone also demonstrated that opioid receptors modulate the physiologic response to 
exercise, perhaps through interaction of the receptor with circulating beta-endorphin. 
However, further investigation into the significance of peripherally circulating beta- 
endorphin is necessary to clarify its role in exercise.
CHAPTER FIVE
CHARACTERIZATION OF BETA-ENDORPHIN RECEPTORS ON
EQUINE LYMPHOCYTES
A. INTRODUCTION
Data from current research support the theory of interaction between the central 
nervous system and the immune system. One finding which supports this theory is the 
existence of opioid receptors on cells of the immune system. Although a number of 
investigators have demonstrated binding of beta-endorphin and other opioids to 
lymphocytes, confusion exists as to the type of opioid receptor existing on lymphocytes. 
The presence of several types of classical opiate receptors have been reported. Mehrishi 
and Mills [1983] reported that lymphocytes contained specific opioid receptors of the mu 
type, as demonstrated by binding of tritiated naloxone to freshly isolated human 
lymphocytes. Madden, et al. [1987] also reported a specific binding site for naloxone on 
human T lymphocytes. In their study, the bound naloxone was partially displaced by 
morphine, beta-endorphin, and methionine-enkephalin (met-enkephalin). Recently, Carr 
et al. [1989] have found evidence for both delta and kappa receptors on various cell lines 
using highly specific ligands. This same group of investigators has also developed an 
antibody which recognizes opioid receptors on murine splenocytes and neuroblastoma x 
glioma hybrid cells. This antibody competes with tritiated dihydromorphine as well as 
beta-endorphin, met-enkephalin, and naloxone for the same binding site on lymphocytes,
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which suggests the presence of a classical opioid receptor of the mu or delta class [Carr, 
et al., 1988a].
The previous studies all suggest the presence of classical opioid receptors on 
lymphocytes. In contrast, a number of other investigators have been unable to confirm 
these results and therefore propose that a nonopioid receptor for beta-endorphin exists on 
lymphocytes. Hazum et al. [1979] were unable to demonstrate classical opioid receptors 
on lymphocytes. In this study, high affinity binding of iodinated beta-endorphin was 
exhibited only in a transformed human cell line and was of nonopioid specificity. 
Mendelsohn et al. [1985] were unable to demonstrate any specific binding of tritiated 
naloxone or leucine-enkephalin to freshly isolated human lymphocytes. Several other 
investigators have reported specific binding of endogenous opioids to lymphocytes, either 
freshly isolated cells or cell lines, that was not displaced by morphine or naloxone 
[Ausiello and Roda, 1984; Westphal and Li, 1984; Schweigerer, et al., 1985b; Borboni, 
et al., 1989]. In addition, Ovadia et al. [1989] reported binding of tritiated naloxone to 
rat lymphocytes which was not displaced by any endogenous opioids.
Due to the conflicting reports, confusion as to the type or class of receptor present 
on lymphocytes still persists. Many investigators report that beta-endorphin does not 
appear to bind to classical opioid receptors, although naloxone and other opiates have 
been shown to bind specifically to lymphocytes. These studies suggest that there may 
exist two types of sites on lymphocytes, "opioid" and "nonopioid", to which beta- 
endorphin binds. However, the lack of classical receptor binding studies and the use of 
cell lines which are not truly representative of circulating lymphocytes, has contributed
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to the confusion. Although beta-endorphin receptors on lymphocytes have been examined 
in humans, mice, and rats, they have not been identified in the horse. As beta-endorphin 
has been reported to modulate immune function, presumably through interaction with cell 
surface receptors [Sibinga and Goldstein, 1988], this study attempted to identify and 
characterize beta-endorphin receptors on equine lymphocytes.
B. MATERIALS AND METHODS 
Lymphocyte collection and preparation
Blood was collected from the jugular vein of healthy Thoroughbred horses into 
20 ml evacuated siliconized glass tubes containing preservative free heparin1 at a 
concentration of 10 U/ml as an anticoagulant. Lymphocytes were isolated using density 
gradient centrifugation. Whole blood was centrifuged for 10 minutes at 400 x g, the 
plasma was removed and discarded, and the buffy coat was removed and diluted 1:5 in 
Hanks’ Balanced Salt solution without calcium and magnesium (CMF Hanks)2 with 20 
mM Hepes3. Ten milliliters of the cell suspension were layered over 4 ml of Ficoll4 and 
centrifuged at 600 x g for 30 minutes. After centrifugation, the upper layer was removed, 
discarded, and the interface, which contained the mononuclear cells, removed and diluted
heparin , preservative free, sodium salt, Grade I: from porcine intestinal mucosa, Sigma 
Chemical Co., St. Louis, Mo.
2Hanks’ Balanced Salts without calcium chloride, magnesium sulfate and sodium 
bicarbonate, Sigma Chemical Co., St. Louis, Mo.
3Hepes, sodium salt, Sigma Chemical Co., St. Louis, Mo.
4Histopaque-1077, specific gravity 1.077+0.001, Sigma Diagnostics, St. Louis, Mo.
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1:4 in CMF Hanks. The cell suspension was washed three times in CMF Hanks and then 
resuspended in the assay buffer, Medium 1995 with Earle’s salts, L-glutamine and 25 mM 
Hepes supplemented with 0.1% bovine serum albumin (BSA)6, at a concentration of 7.5 
x 106 cells/ml. Cell viability was assessed by trypan blue dye7 exclusion. The binding 
assays were performed within 24 hours of cell collection as longer periods of storage 
resulted in decreased cell viability.
Determination of optimum time, temperature and pH
Optimum time and temperature were ascertained by incubating 0.1 ml of the cell 
suspension (3 x 106 cells/assay tube) with (3-[125I]iodotyrosyl27)beta-endorphin (human)8, 
specific activity 2075 Ci/mmol, at a final concentration of 9.9 x 10 "  M at 4°C, 25°C and 
37°C for 15, 30, 45, 60, 120, 180, and 240 minutes in 12 x 75 polypropylene tubes. The 
125I-labeled beta-endorphin used was prepared by iodination of synthetic human beta- 
endorphin using chloramine-T and sodium [125I]iodide and was purified by high 
performance liquid chromatography. It is a monoiodinated product, iodinated only at the 
carboxy-terminal tyrosine (tyrosine residue 27), and therefore is active in receptor binding 
studies as well as radioimmunoassay. Non-specific binding was determined by incubating 
the cells and iodinated beta-endorphin in the presence of excess unlabeled beta-
5Medium 199 with Earle’s salts, L-glutamine, 25 mM Hepes, without sodium bicarbonate, 
Sigma Chemical Co., St. Louis, Mo.
6Bovine Serum Albumin, Fraction V, Sigma Chemical Co., St. Louis, Mo.
7Direct Blue 15, Sigma Chemical Co., St. Louis, Mo.
8(3-[125I]iodotyrosyl27)beta-endorphin (human), Amersham Corp., Arlington Heights, II.
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endorphin9 at a final concentration of 3.6 x 10'6 M. All dilutions and incubations were 
performed in assay buffer, pH 7.4. Incubation was terminated at the appropriate time by 
removing duplicate 170 pi samples of well mixed cell suspension from each tube and 
adding to ice cold microfuge tubes10 containing 100 pi of dibutyl phthalate11 and 100 
pi of assay buffer. The microfuge tubes were then centrifuged in a microcentrifuge12 
for 2 minutes, the supernatants were aspirated and the tips of the microfuge tubes, which 
contained the cell pellet, were cut off and placed in 12 x 75 glass tubes. The tubes were 
then counted for 5 minutes in a gamma scintillation counter.
Optimum temperature and pH were assessed based on the optimum times 
determined in the previous experiment. Again, 3 x 106 cells/assay tube were incubated 
with 9.9 x 10 ” M iodinated beta-endorphin for 30 minutes at 37°C, 1 and 4 hours at 25°C 
and 1 hour at 4°C in assay buffer at pH’s of 7.0, 7.4, 7.6, 8.0 and 8.4. Nonspecific 
binding was again determined by incubating the cells and radiolabeled beta-endorphin in 
the presence of excess unlabeled beta-endorphin (3.6 x 10'6 M). The incubation was 
terminated and analyzed as described previously.
Determination of saturability
The saturability of the receptors was analyzed by setting up a saturation isotherm. 
This assay allows one to analyze the characteristics of the binding as a function of
9Beta-endorphin, human; beta-lipotropin (61-91), human; Bachem, Inc., Torrance, Ca.
10Eppendorf Micro test tubes, 400 ul, polypropylene, Brinkmann Instruments, Inc., 
Westburg, N.Y.
nDibutyl phthalate, Sigma Chemical Co., St. Louis, Mo.
12Abbott microcentrifuge, Model LN 9527-01, Abbott Laboratories, Irving, Texas.
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increasing concentrations of radioligand. In this assay, radiolabeled beta-endorphin 
(specific activity 1800 Ci/mmol) was added to 3 x 106 cells/assay tube to give final 
concentrations of 42.5, 81.7, 200.3, 432.0, 1017.7, 1142.9, 1430.2, 2648.6, 2827.8, and 
5117.4 pM. The cells and the radiolabeled beta-endorphin were incubated with and 
without excess unlabeled beta-endorphin (3.6 x 10'6 M) for 4 hours at 25°C in assay 
buffer, pH 8.0. The binding found in the presence of excess unlabeled beta-endorphin 
was determined to be nonspecific binding. The incubation was terminated by 
centrifugation in a microfuge and subsequent analysis by a gamma scintillation counter 
as described previously.
Determination of specificity
The specificity of the receptor for beta-endorphin was determined by analyzing the 
ability of various ligands to displace the radioligand from the receptor. Equine 
lymphocytes (3 x 106 cells/assay tube) were incubated with iodinated human beta- 
endorphin (specific activity 1800 Ci/mmol) at a final concentration of 3.2 x 10'10 M and 
different ligands at concentrations ranging from 1 pM to 42 (i.M for 4 hours at 25°C in 
assay buffer, pH 8.0. The ligands and concentrations used were: human beta-endorphin, 
equine beta-endorphin,13 naloxone,14 and [D-Ala2]-met-enkephalinamide15 at 
concentrations of .001, .01, .1, 1, 10, 100, and 1000 nM; fentanyl16 at concentrations of
13Beta-endorphin (horse), Peninsula Laboratories, Inc., Belmont, Calif.
14Naloxone hydrochloride, Sigma Chemical Co., St. Louis, Mo.
15[D-Ala2]-Met-Enkephalinamide, Peninsula Laboratories, Inc., Belmont, Calif.
16Fentanyl citrate, McNeil Pharmaceuticals, Inc., Spring House, Penn.
118
.001, .01, .1, 1, 10, 100, 1000 and 10000 nM; ethylketocyclazocine17 at concentrations 
of .0835, .835, 8.35, 83.5, 835, 8350, and 41800 nM; and U50,488H18 at concentrations 
of .068, .677, 6.771, 67.71, 677.05, 6770.5 and 33852 nM. The incubation was 
terminated by addition of duplicate 170 pi samples from each assay tube to ice-cold 400 
pi microfuge tubes containing 100 pi of assay buffer and 100 pi of dibutyl phthalate. 
The microfuge tubes were then centrifuged for 2 minutes in a microcentrifuge, the 
supernatants aspirated, and tips of the microfuge tubes cut and placed in 12 X 75 glass 
tubes. The tubes were counted for 5 minutes in a gamma scintillation counter. 
Nonspecific binding was determined as the amount of binding noted in the presence of 
1000 nM of equine beta-endorphin.
Radioligand degradation
To minimize radioligand degradation, the lyophilized iodinated peptide was 
reconstituted in distilled water at a concentration of 0.1 pCi/pl. In order to prevent 
damage by repeated freezing and thawing, the radioligand was then aliquoted in 50 pi 
aliquots, enough for one day’s experiments, in polypropylene vials and stored at -20°C. 
The radioligand was used by the expiration date given by the manufacturer which was 
within 28 days of receipt. According to stability trials carried out by the manufacturer, 
the decomposition of the reconstituted radioligand should not exceed 5% by the expiration 
date under these conditions.
"Ethylketocyclazocine methanesulfonate, Sterling-Winthrop Pharmaceutical Co., New
York, N.Y.
18U50,488H, Upjohn Co., Kalamazoo, Michigan.
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C. RESULTS
1. Effects of time, temperature and pH
The analysis of the effects of time and temperature on the binding of beta- 
endorphin to equine lymphocytes revealed optimum specific binding at 25°C (Figure 21). 
Cell viability was greater than 90% for all assays as determined by the trypan blue 
exclusion test. Specific binding was calculated by subtracting the counts per minute 
(cpm) of the nonspecific binding tubes from the cpm’s of the total binding tubes. 
Specific binding represents the actual binding of the radioligand to the receptor site as 
opposed to nonspecific binding sites, such as trapped radioactivity in the pellet or binding 
to the incubation tubes. Binding at 37°C reached equilibrium by 15 to 30 minutes. 
Binding at 25°C appeared to reach equilibrium between one and four hours, although there 
was considerable assay variability. Binding at 4°C reached equilibrium by one hour but 
binding began to deteriorate after 3 hours.
Based on these observations, the effects of time, temperature and pH were 
analyzed. Several time and temperature combinations were considered over a range of 
pH’s for optimum specific binding. Specific binding was greatest at 25°C, but assay 
variation made the determination of equilibrium difficult. Therefore, binding at 25°C was 
analyzed at both 1 and 4 hours of incubation over a range of pH values. Binding at 37°C 
plateaued by 15 minutes and remained stable for up to one hour. Therefore, an 
incubation time of 30 minutes was chosen for pH analysis. The specific binding at 4°C 
plateaued by one hour and therefore was analyzed for effect of pH at this incubation time. 
Incubation over a range of pH’s from 7.0 to 8.4 revealed that at 4°C and 37°C, optimum
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Figure 21. Rate of binding of [125I]beta-endorphin to equine lymphocytes at a pH 
of 7.4 at various temperatures.
specific binding was noted at a pH of 7.6 (Figure 22). At 25°C after one hour of 
incubation, the greatest binding was noted at pH 7.6. However, after four hours of 
incubation at a pH of 8.0, there was a dramatic increase in specific binding at 25°C. The 
effects of pH on binding were not dramatic at most time and temperature combinations, 
with the level of specific binding approximately the same for all with the one exception. 
This experiment was repeated and confirmed to ensure that the dramatic increase in 
binding at 25°C at pH 8.0 after 4 hours incubation was not an artifact, and was found to 
be reproducible. It is possible that this combination of pH, time and temperature 
somehow stabilizes the receptor, perhaps by preventing receptor internalization. 
Therefore, the incubation conditions for future experiments were chosen as 25°C for 4 
hours at a pH of 8.0.
2. Receptor saturability
The data from the saturation isotherm were analyzed in three ways. First, the data 
were plotted in the standard format of concentration of free radioligand versus bound 
radioligand (Figure 23). Analysis of the linear saturation isotherm reveals an apparent 
saturation of the receptor as demonstrated by the plateau achieved in the specific binding 
curve. Specific binding was calculated by subtracting the nonspecific binding from the 
total binding. Nonspecific binding increased in a linear manner (r=0.94490), which 
suggests that it was not saturable, as would be expected. Unfortunately, a linear 
saturation isotherm does not always truly demonstrate saturability, and therefore requires 
further analysis. A logarithmic transformation of the data, as seen in Figure 24, 
demonstrated that saturation of the receptors was achieved, although not at the
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Figure 22. Specific binding of [125I]beta-endorphin to equine lymphocytes over a 
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concentrations at which saturation seemed to occur in the linear plot. In the linear plot, 
saturation appeared to occur at radioligand concentrations of 1.5 nM, while in the 
logarithmic transformation, saturation did not occur until radioligand concentrations of 2.0 
nM or greater were reached.
3. Estimation of Binding Parameters
A Scatchard/Rosenthal linear transformation of the data was performed in order 
to obtain estimates of the binding parameters: the dissociation constant or K ,^ and the 
total number of binding sites or Bmax (Figure 25). In a Scatchard plot, linear regression 
analysis of the points yields a y-intercept and the slope, from which the binding 
parameters can be calculated. The dissociation constant (K J is calculated from the slope 
(Kj = -1/slope). Analysis of the data revealed a dissociation constant of 17.2 pM or 1.72 
x 10'u M for beta-endorphin receptors on equine lymphocytes. Using the y-intercept and 
the slope, the x-intercept can be calculated. The x-intercept is the total number of binding 
sites or Bmax. Based on these calculations, the x-intercept or BmiX was determined to be
0.538 fmoles/106 cells or 5.38 x 1016 moles/106 cells. The correlation coefficient for the 
linear regression was 0.68836 (P<0.01). Further analysis of the saturation binding data 
was performed using the LUNDON-1 computer program. This computer program utilized 
a nonlinear least squares curve regression analysis and employed progressive curve fitting 
with concurrent statistical analysis enabling analysis of goodness of fit between 
successively more complicated models [Lundeen and Gordon, 1986]. Analysis of the 
saturation binding data using the LUNDON-1 program revealed that a one-site model best 
fit the data. Therefore, a single slope was obtained from the linear transformation
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Figure 24. Saturation isotherm of equine lymphocyte beta-endorphin receptors 
plotted on a logarithmic scale.
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Figure 25. Scatchard/Rosenthal analysis of saturation binding data of beta-endorphin 
receptors on equine lymphocytes.
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suggesting that a single receptor population exists. If more than one receptor population 
existed or if the ligand-receptor interaction did not follow the law of mass action, a 
curvilinear plot with multiple slopes would result.
4. Receptor specificity
The specificity of the receptor for beta-endorphin was assessed by performing 
competition-inhibition curves of human iodinated beta-endorphin with various opioid 
ligands. The ability of these ligands to displace the radioligand from the receptor is 
shown in Figure 26. Highest potency at the receptor was observed with equine beta- 
endorphin and [D-Ala2]-met-enkephalinamide. Human beta-endorphin, naloxone and 
fentanyl were also able to displace the radioligand from the receptor although greater 
concentrations were required. Ethylketocyclazocine and U50,488H were unable to 
displace radiolabeled human beta-endorphin from the receptor at meaningful 
concentrations suggesting that they possess little or no activity at the receptor. From the 
overall "shape" of a competition curve, it can be determined whether or not a competitor 
is interacting with the receptor by simple mass action law or with greater complexity. 
If the ligand-receptor interaction is a simple bimolecular reaction, the competition curve 
for the competitor will proceed from 10% to 90% competition over an 81-fold 
concentration range of the competitor. Therefore curves which do not exhibit "normal 
steepness" are said to result from complex ligand-receptor interactions [Limbird, 1986]. 
All competitors in this study required approximately a 1000-fold concentration range to 
displace from 10% to 90% of the bound radioligand. Therefore, the ligand-receptor
%
 C
ON
TR
OL
 
SP
EC
IF
IC
 
BI
ND
IN
G
128
O  human beta 
endorphin 
equine b e ta -  
endorphin 
A  naloxone 
▲ [DAIa^lm et— 
enkepnalinamide 
□  fentanyl 
■  EKC 
V  U50.488H
B
.0001 .01 1.0 100 
LOG10 [COMPETITOR] (nM)
10000
Figure 26. Competition-inhibition curves for various ligands with beta-endorphin 
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interactions of the competitors could be described as complex.
In order to compare relative potencies of the ligands, the concentration of the 
ligand that inhibited the binding of the radioligand by 50% (IC50) was calculated from the 
competition-inhibition curves. The results are displayed in Table 9. Analysis of the 
competition-inhibition curves through calculation of IC50’s emphasizes the results which 
can be obtained visually from the graphs. Equine beta-endorphin has the highest potency, 
which suggests that this is the endogenous ligand for the receptor. Interestingly, the met- 
enkephalin analog, a delta opiate receptor ligand, had greater potency for the receptor than 
did human beta-endorphin and the mu opiate receptor ligands, naloxone and fentanyl. 
The kappa receptor ligands, ethylketacyclazocine and U50,488H, had little or no activity 
at this receptor.
D. DISCUSSION
This study demonstrated that equine lymphocytes possess opioid binding sites, as 
shown with iodinated human beta-endorphin. The binding takes place in a saturable and 
specific manner which is time, temperature and pH dependent. Optimum binding 
conditions were demonstrated with incubations at 25°C, pH 8.0 for 4 hours. The assay 
conditions which were found to be optimum for specific binding are not representative 
of the physiologic environment of lymphocytes, but may be necessary in order to 
accurately measure binding to receptors on functional whole cells as opposed to cell 
membrane fragments. Experiments by Schweigerer et al. f 1985a] suggest that the 
receptor-ligand complex is internalized via a high affinity binding site on murine
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TABLE 9. Relative Potencies Derived From 
Competition-inhibition Curves
ics„ RELATIVE
POTENCY
Equine beta-endorphin 35 pM 1.0
[D-Ala2] -met-enkephalinamide 40 pM 1.1
Human beta-endorphin 450 pM 12.8
Naloxone 600 pM 17.1
Fentanyl 10 nM 286.0
Ethylketocyclazocine >100 nM >3000.0
U50-488H >100 nM >3000.0
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thymoma cells. If internalization occurs in equine lymphocytes, detection of specific 
binding would be very difficult, as the radioactivity associated with the internalized beta- 
endorphin would appear to be nonspecific binding. Therefore, it may be that the 
combination of a relatively high pH at a lower temperature than seen physiologically may 
somehow stabilize the receptor so that internalization does not occur. This theory would 
explain the high nonspecific binding in relation to specific binding which was noted at 
lower pH’s and higher temperatures. The use of a monoiodinated radioligand also 
increased the ability to detect a receptor on equine lymphocytes. Earlier work on this 
project, with a less highly purified product, iodinated at one or both tyrosine residues, did 
not reveal any specific binding, only nonspecific binding to equine lymphocytes. This 
may have resulted from denaturation of the peptide resulting in loss of activity at the 
receptor, or from iodination at the N-terminal tyrosine, which was in the binding region 
of the molecule. The use of iodinated products which were iodinated on the N-terminal 
tyrosine may explain why some investigators failed to detect opioid binding sites on 
lymphocytes in other species.
There are certain criteria which must be met in order to establish that there is 
binding to a physiologically relevant receptor. The binding of the ligand should be 
saturable since a finite number of receptors are presumed to exist, and the specificity of 
various ligands at the receptor should parallel the specificity of the ligands in vivo. 
Finally, the kinetics of the binding should be consistent with the time-course of the 
biological effect elicited by the ligand. In the case of equine beta-endorphin receptors, 
the binding assay revealed association of the radioligand to the receptor in a time-
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dependent manner. Whether or not this mimics the time-course of the biological effect 
can not be determined as the biological effect has not been properly evaluated, and 
consequently there is not enough consistent data on which to base such an evaluation.
Analysis of the saturation isotherm data revealed a saturable site which was 
confirmed by a logarithmic transformation of the data. A Scatchard/Rosenthal linear 
transformation of the saturation binding data enabled estimation of the binding parameters. 
The Kd was 17.2 pM or 1.72 x 10 ” M and Bmax was 0.538 fmoles/106 cells. The 
dissociation constant is consistent with biological levels of beta-endorphin in the plasma 
in the horse. Earlier work [Chapter 4] has shown basal circulating levels of beta- 
endorphin in the horse to range from 2-40 pmoles/L. Other investigators have reported 
dissociation constants in the nanomolar range in humans which seems unlikely as plasma 
levels in humans are similar to those in horses [Sforzo, 1989; Madden, et al., 1987]. If 
the dissociation constant was in the nanomolar range, then plasma levels would have to 
reach 100 to 1000 times the basal circulating levels in order to elicit an effect. The fact 
that a linear Scatchard plot was obtained allows one to assume that a fairly accurate 
estimation of the true Kd has been made [Limbird, 1986]. Based on these observations, 
it seems reasonable to assume that beta-endorphin binds in a saturable manner to equine 
lymphocyte with a Kj of 17.2 pM. The Bmax values usually obtained from 
Scatchard/Rosenthal plots, represent the total number of binding sites. However, if n=l, 
i.e. one binding site, then Bmax represents the total receptor concentration. Since the 
Scatchard plot in this experiment was linear, it can be assumed that only one binding site 
exists, and the Bmax value of 0.538 fmoles/106 cells represents the total receptor
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concentration. Nevertheless, this number has little meaning in itself since the receptor has 
not been isolated. Without isolation of the receptor, and determination of its molecular 
weight, the actual number of receptors can not calculated. Therefore, the Bmax value 
obtained in this study represent an approximation of the number of moles of beta- 
endorphin which bind to the cells.
Competitive binding analysis revealed that the receptor on equine lymphocytes 
binds opioids which have affinity for the mu and delta classes of opioid receptors. Beta- 
endorphin binds with equal affinity to mu and delta receptors [Sforzo, 1989]. [DAla2]- 
met-enkaphalinamide is a met-enkephalin analog with increased resistance to enzymatic 
degradation, which binds preferentially to the delta opioid receptor [Pasternak and Wood, 
1986]. Naloxone and fentanyl both bind preferentially to the mu opioid receptor [Sforzo, 
1989; Jaffe and Martin, 1985]. Ethylketocyclazocine (EKC) and U50,488H are selective 
kappa opioid receptor agonists [VonVoigtlander, et al., 1983; Pert, et al., 1976]. Equine 
beta-endorphin and [D-Ala2]-met-enkephalinamide displaced the radioligand at the lowest 
doses, suggesting that they possess the greatest affinity for the receptor. Naloxone, 
human beta-endorphin and fentanyl were also able to displace the radioligand, but 
required higher concentrations. The kappa agonists, EKC and U50,488H were unable to 
displace the radioligand effectively, suggesting the lack of a specific kappa binding site 
on equine lymphocytes.
The results suggest that the receptor present on equine lymphocytes is of the mu 
or delta class. The high affinity of the enkephalin analog suggests that the receptor may 
be of the delta class. Reports of a common site with very high affinity for both
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enkephalins and mu receptor agonists such as morphine, termed the mu, site, also imply 
that this receptor may in fact be a mu, receptor site [Pasternak and Wood, 1986]. Most 
recently, evidence for a mu/delta opioid receptor complex with interacting mu and delta 
binding sites has been demonstrated in rat striatal membranes [Schoffelmeer, et al., 1990]. 
This theory perhaps best explains the data reported from the competition curves. The 
slope of the competition curves suggested that the competitors interacted with the receptor 
in a manner more complex than that described by the law of mass action. In other words, 
rather than a single ligand interacting with a single receptor population in a reversible 
manner, the ligands may be interacting with more than one receptor population, or 
interacting with a receptor with different affinity sites. An interacting mu/delta receptor 
complex would result in a more complex ligand-receptor interaction which would in turn 
result in competition curves which do not exhibit "normal steepness". The interacting 
mu/delta receptor complex would also explain the ability of both beta-endorphin and the 
enkephalin analog to bind to the site with such high affinity. If the receptor site was of 
the delta class or the mu, subtype, it would seem that the competition curves would have 
demonstrated "normal steepness". However, the Scatchard analysis of the saturation 
isotherm did not demonstrate a complex receptor-ligand interaction, but rather a simple 
interaction of a single ligand with a single population of receptors. Due to technical and 
cost constraints, the saturation isotherm was performed with only ten concentrations of 
radioligand. Many saturation isotherms are performed with twenty or more concentrations 
of radioligand [Limbird, 1986]. Therefore, increased number of radioligand 
concentrations in the saturation isotherm may have revealed a more complex interaction
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between the radioligand and the receptor, thus eliminating the discrepancy between the 
saturation and competition data.
In conclusion, an opioid receptor for beta-endorphin has been identified on equine 
lymphocytes which is both saturable and specific. It appears to be of the mu or delta 
class of opioid receptors, although results from the competition-inhibition curves suggest 
it may be a mu/delta receptor complex. The existence of such a receptor on equine 
lymphocytes coupled with reports of beta-endorphin modulation of lymphocyte function, 
suggest a role for beta-endorphin and other endogenous opioids in equine immune 
function.
CHAPTER SIX
CHANGES IN BETA-ENDORPHIN BINDING PARAMETERS OF EQUINE 
LYMPHOCYTES: EFFECTS OF EXERCISE AND PHYSICAL CONDITIONING
A. INTRODUCTION
Plasma beta-endorphin levels increase significantly in response to moderately high 
intensity exercise (i.e. 80% V O ^  or greater) or maximal exercise intensity (i.e. graded 
exercise test to exhaustion) in humans [Gambert, et al., 1981; Goldfarb, et al., 1987]. 
While some investigators report augmented beta-endorphin release following high 
intensity exercise in trained human athletes as opposed to untrained or sedentary 
individuals, other studies contradict these results [Carr, e ta l ., 1981; Howlett, etal., 1984]. 
These studies have raised the question as to whether the absolute exercise intensity which 
only trained athletes are able to attain is responsible for the increased beta-endorphin 
levels noted in most studies. Although increased beta-endorphin levels have been 
reported following exercise in the horse, the effects of training and exercise intensity have 
not been examined [Evans, et al., 1985; Li and Chen, 1987]. Recent work in our 
laboratory has demonstrated significantly increased levels of beta-endorphin following 
maximal intensity exercise [Hamra, et a l,  1987]. Training did not augment beta- 
endorphin release, although increased exercise intensity, which was attainable only by the 
trained horses, resulted in significantly higher beta-endorphin levels [Chapter 4).
Receptors for beta-endorphin and other opioid peptides have been identified on 
human and murine leukocytes. A number of in vitro studies have demonstrated the ability
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of opioid peptides to modulate immune function, such as lymphocyte proliferative 
responses and natural killer cell activity [Sibinga and Goldstein, 1988]. Therefore, it 
appears that endogenous opioids, which are released in response to stress, such as 
exercise, can interact with cells of the immune system and thereby modulate immune 
function. Although considerable work has been done in humans, mice, and rats, this issue 
has not been addressed in the horse. Previous work in our laboratory has demonstrated 
highly specific, saturable opioid receptors for beta-endorphin on equine lymphocytes 
[Chapter 5]. Therefore, we have established that beta-endorphin is released in response 
to exercise, that this response changes with physical conditioning and that equine 
lymphocytes possess a receptor for beta-endorphin. These results suggest a role for beta- 
endorphin in equine immune function.
Recently exercise, as a form of exertional stress, has been reported to modify 
immune function. Exercise has been shown to modify the proportions of lymphocyte 
subsets, enhance natural killer cell activity and suppress lymphocyte blastogenesis in 
response to mitogens in humans [Hedfors, et al., 1976; Keast, et al., 1988]. One study 
in horses demonstrated a significant suppression of the blastogenic response to the 
mitogens Concanavalin A and phytohemagglutinin 30 minutes after treadmill exercise to 
fatigue [Kurcz, et al., 1988]. These studies suggest that exercise modulates equine 
immune function, perhaps through interaction of beta-endorphin with receptors on equine 
lymphocytes. In this study, the effects of exercise and physical conditioning on beta- 
endorphin lymphocyte receptor binding parameters were evaluated in order to clarify the 
role of beta-endorphin and exercise in equine immune function.
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B. MATERIALS AND METHODS 
Horses
Fifteen healthy Thoroughbred horses, five males and 10 females with a mean age 
of 5.9+1.5 years, were used in evaluating the effect of exercise on binding parameters in 
trained horses. All horses had received previous racing and/or training experience but had 
not been raced or trained for at least six months prior to the study. The horses were 
subsequently trained on a high speed treadmill1 using interval training techniques 
[Harkins, et al., 1990].
Twelve healthy Thoroughbred horses, seven males and five females with a mean 
age of 6.7+1.7 years, were used in evaluating binding parameters in a population of 
sedentary horses. Four horses had not been raced or trained for at least six months, while 
eight horses had been detrained from the first study for 12 or more weeks.
Exercise testing and training regimen
Horses were conditioned using an interval training program for 20 weeks. The 
training regimen is detailed in Table 10. Horses received five days of training and 2 days 
off per week during the entire training period. Interval training (IT) was started during 
week 13 and continued through week 20. Interval training was performed twice a week 
with 3-4 days between training sessions and a more conventional exercise routine 
performed three days/week. The conventional exercise routine consisted of a walk at 1.5 
m/s for 1 min (90 m), a trot at 3.5 m/s for 2 min (420 m), a gallop at 9.0 m/s for 6 min
•Mustang 2200 High Speed Treadmill, Kagra International Inc., Fahrwangen, Switz.
TABLE 10. Training Schedule
WEEK TOTAL
DISTANCE
1-3 180m-2 min walk, followed by a trot 
increasing from 3.5-4.5 m/s in speed 
from weeks 1-3, followed by a 90m-1 
min walk
2370-3070m
4-12 90m-1 min walk, then 420m-2min trot, 
followed by a gallop increasing from 
7.6 m/s to 9.0 m/s over the 8 week 
period, followed by a 630m trot
3420-6340m
13-14 90m walk, 420m trot warmup, gallop at 
a 7% incline at speeds increasing from 
9.0m/s to 10.5 m/s over the 2 weeks, 
followed by a 700-800m trot at 3.5m/s 
as a rest period
5210m
15-18 90m walk, 420m trot warmup, gallop at 
7% incline at speeds increasing from 
11.0 m/s to 13.0 m/sec over the 4 
weeks, followed by a 600m trot at 3.5 
m/s as a rest period
4710m
19-20 90m walk, 420m trot warmup, gallop at 
7% incline at speeds increasing from 
13.0 m/s to 14.6 m/s over the 2 weeks, 
followed by a 600m trot at 3.5 m/s as a 
rest period
5310m
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(3200 m), and a warm-down at 3.5 m/s for 3 min (630 m) for a total distance of 4340 m 
at a 0% treadmill inclination.
Interval training consisted of progressively faster heats, performed at a 7% incline, 
separated by rest periods of a trot at 3.5 m/s at a 0% incline lasting 2-4 min depending 
on the time required for the heart rate to return to a threshold level of 110 beats/min. 
During weeks 13 and 14, two heats were run with speeds beginning at 9.0 m/s and 
progressively increasing to 10.5 m/s. The number of heats increased to 3 during weeks 
14-18 and then increased to 4 during weeks 19-20. As the number of heats increased, the 
distance was shortened, and the speed was progressively increased. By week 20, the 
speed had increased from 9.0 m/s to 14.6 m/s, and the distance was reduced from 1600 
m/heat to 600 m/heat.
The exercise tests consisted of one interval training session during weeks 18, 19, 
20. Six horses were tested during an interval training session in week 18, three during 
week 19 and six during week 20. Although the exercise protocols differed slightly 
depending on the week in which the horse was tested, all horses reached a near maximal 
exercise intensity. The protocol for the exercise tests is detailed in Table 11. All gallops 
in the exercise tests were performed on a 7% incline, with each heat separated by a rest 
period. During the rest periods, the horses were trotted at a 0% incline. Heart rates were 
measured by an on-board heart rate monitor2 which was supplied with the treadmill. The 
heart rate was transmitted by telemetry from two electrodes attached to a girth strap to 
two receivers mounted on the treadmill panel. The heart rate was automatically relayed
zHippocard, Bioengineering of Zurich, Kagra International, Inc., Fahrwangen, Switz.
TABLE 11. Exercise Test Protocols
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Week Heat Warm-up Gallop Warm-down Total
Distance
18 1 90m walk, 12.5 m/s, 800m 3.5 m/s, 600m 4710m
420m trot
2 12.8 m/s, 800m 3.5 m/s, 600m
3 13.0 m/s, 800m 3.5 m/s, 600m
19 1 90m walk, 13.0 m/s, 600m 3.5 m/s, 600m 5310m
420m trot
2 13.3 m/s, 600m 3.5 m/s, 600m
3 13.6 m/s, 600m 3.5 m/s, 600m
4 13.9 m/s, 600m 3.5 m/s, 600m
20 1 90m walk, 13.7 m/s, 600m 3.5 m/s, 600m 5310m
420m trot
2 14.0 m/s, 600m 3.5 m/s, 600m
3 14.3 m/s, 600m 3.5 m/s, 600m
4 14.6 m/s, 600m 3.5 m/s, 600m
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every 5 seconds to the display panel above the treadmill, and was recorded manually 
every 15 seconds Peak heart rate was reported as an average of the peak heart rates 
attained during each heat for each exercise test. Blood samples for beta-endorphin levels, 
lactate levels and radioligand binding assays were drawn from the jugular vein prior to 
exercise at rest in the stalls, in order to avoid excitement, and immediately upon 
completion of the exercise test.
Sample Analysis
Blood samples for plasma beta-endorphin concentrations were collected into 7 ml 
evacuated siliconized glass tubes containing EDTA as an anticoagulant. Blood samples 
for lactate concentrations were collected into 4 ml evacuated glass tubes containing 
sodium fluoride as a preservative. The samples were kept on ice until they could be 
centrifuged, no longer than 1.5 hours. The samples were then centrifuged and the plasma 
or serum removed and frozen at -20°C until the assays could be performed. Lactate 
concentrations were measured using a lactate analyzer3 which measures levels of L- 
lactate in serum, plasma or whole blood. Plasma beta-endorphin concentrations were 
measured using a commercially available radioimmunoassay kit (For detailed procedures 
and validation, refer to Chapter 3).
Radioligand Binding Assay
Binding parameters for beta-endorphin receptors on equine lymphocytes were 
analyzed by performing Scatchard analysis of competition-inhibition curves. Competition- 
inhibition curves were performed on each trained horse before (at rest) and after exercise,
3Lactate analyzer, Model 23L, YSI, Inc., Yellow Springs, Ohio.
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and on each sedentary horse at rest. Blood samples for the radioligand binding assays 
were collected into 20 ml evacuated siliconized glass tubes containing preservative free 
heparin at a concentration of 10 U/ml as an anticoagulant. Lymphocytes were isolated 
using density gradient centrifugation as described in Chapter 5. After the cells were 
isolated and washed, they were suspended in assay buffer, Medium 199 with Earle’s salts, 
L-glutamine and 25 mM Hepes supplemented with 0.1% bovine serum albumin, pH 8.0, 
at a concentration of 7.5 x 106 cells/ml. Cell viability was assessed by trypan dye 
exclusion. The binding assays were performed within 24 hours of cell collection as 
longer periods of storage resulted in decreased cell viability.
Optimal assay conditions were determined previously [Chapter 5]. Equine 
lymphocytes (3 x 106 cells/assay tube) were incubated with (3-[125I]iodotyrosyl27)beta- 
endorphin (human) at a final concentration of 3.2 x 10'10 M and equine beta-endorphin 
at concentrations of .001, .01, .1, 1, 10, 100, 1000, and 5000 nM in assay buffer for 4 
hours at 25°C in a total volume of 400 (J.1 in 12 x 75 polypropylene tubes. The incubation 
was terminated by addition of duplicate 170 |il samples from each assay tube to ice-cold 
400 |il microfuge tubes containing 100 (il assay buffer and 100 |il of dibutyl phthalate. 
The microfuge tubes were then centrifuged for 2 minutes in a microcentrifuge, the 
supernatants aspirated, and the tips, which contained the pellets, were cut and placed in 
12 x 75 glass tubes. The tubes were then counted for 5 minutes in a gamma scintillation 
counter. Nonspecific binding was determined by the amount of binding present at excess 
unlabeled concentrations of equine beta-endorphin; that is, binding at equine beta- 
endorphin levels of 5000 nM. Radioligand degradation is discussed in Chapter 5.
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Statistical Analyses
Data were analyzed by multiple analysis of variance and Pearson’s correlation 
coefficients. Student’s paired t-test was also performed where applicable. Significance 
was assigned at the P<0.05 level.
C. RESULTS
1. Physiologic Responses
The exercise tests, consisting of one interval training session, resulted in peak 
heart rates averaging 187.8+14.6 beats/min (n=15). The peak heart rates during exercise 
were statistically elevated as compared to baseline levels (P<0.001), and reached near 
maximal levels (Figure 27). Lactate concentrations were also significantly increased from 
resting levels (PcO.OOl), and greatly exceeded anaerobic threshold levels of 4 mmol/L 
(Figure 28). The combination of near maximal heart rates and lactate concentrations 
exceeding anaerobic threshold suggest that the horses reached near maximal exercise 
intensity. Maximal exercise intensity, i.e. 100% V O ^ ,  is usually associated with heart 
rates of 220 beats/min or greater and lactate concentrations exceeding 4 mmol/L or 
anaerobic threshold [Persson, 1983]. Therefore, the peak heart rates and lactate 
concentrations reached following the exercise tests are consistent with values obtained in 
other studies [Persson, 1983] and suggest that the horses reached exercise intensity levels 
of approximately 85% Beta-endorphin concentrations are reported to significantly
increase only after near-maximal or maximal exercise, i.e. 80% V O ^,, or greater 
[Gambert, et al., 1981; Goldfarb, et al., 1987]. Beta-endorphin concentrations were also
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Figure 27. Heart rates in conditioned horses at rest (baseline) and peak heart rates
during exercise. (*) indicates statistical difference from baseline (PcO.OOl).
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Figure 28. Lactate concentrations in conditioned horses immediately prior to
exercise and post-exercise. (*) indicates statistical difference from pre-exercise
values (PcO.OOl).
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significantly increased following the exercise tests (P<0.029), therefore confirming that 
the horses reached a level of exercise of at least 85% VO^a, (Figure 29).
2. Binding Parameter Evaluation
Figure 30 depicts the cumulative Scatchard plots of all horses in each group and 
illustrates the overall differences between the groups. Each curve was calculated from 
lymphocytes from each horse, under each condition, and contained 6-8 points with 3 
replicates each. Scatchard/Rosenthal plots of the binding data revealed that exercise 
resulted in an increased or steeper slope of the linear regression line in fit horses 
compared to values obtained prior to exercise. Sedentary horses at rest also had plots 
with steeper slopes than did fit horses at rest. The overall slopes and corresponding 
correlation coefficients are detailed in Table 12. An increase in or steeper slope results 
in a decrease in the dissociation constant, or Kd, and also results in a decrease in Bmax, or 
total number of binding sites.
The K,, and Bmax can be calculated from the y-intercept and the slope. Scatchard 
analysis of binding data from each horse was performed and the resultant binding 
parameters are detailed in Table 13. The dissociation constant for fit horses at rest ranged 
from 58 to 369 pM, while in sedentary horses the range was from 48 to 194 pM. The 
range in fit horses after exercise was from 38 to 162 pM. The average Kd values for each 
group are depicted graphically in Figure 31. The dissociation constant was significantly 
decreased by exercise in the fit horse, while sedentary horses had significantly lower Kd 
values than fit horses at rest (P<0.02). The results suggest that intense exercise acutely 
increases the affinity of the receptor for the ligand. It also suggests that the receptors in
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Figure 29. Beta-endorphin levels in conditioned horses immediately prior to and
post exercise. (*) indicates statistical difference from pre-exercise values (P<0.029).
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Figure 30. Scatchard analysis of beta-endorphin receptors on equine lymphocytes 
collected from fit horses at rest, fit horses after exercise and sedentary horses at rest.
150
TABLE 12. Cumulative Scatchard Plot Param eters
Group Y-intercept* Slope Correlation
Coefficient
Fit horses, at rest 3.7252 x 102 -7.1140 x 10'3 0.61474
Fit horses, post exercise 4.7780 x 102 -1.1046 x 10'2 0.50330
Sedentary horses, at rest 5.1583 x 10'2 -1.2320 x 10’2 0.67066
*Y-intercept values are calculated estimates.
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TABLE 13. Effects of Exercise and Training on 
Beta-endorphin Receptor Binding
Fit, at rest Fit, after 
exercise
Sedentary, at rest
Horse k ; R  * Kd ®max Horse Kd RD max
ID # ID #
106 189.76 0.8128 162.03 0.5441 74 67.47 0.3279
105 303.80 1.0405 149.50 0.9007 34 48.28 0.5083
135 162.90 0.5205 115.49 0.3053 93 65.26 0.5799
84 58.10 0.3238 106.90 0.5509 84 122.70 0.6166
107 160.78 0.5416 94.54 0.7473 107 100.14 0.5042
83 136.54 0.6819 37.97 0.0643 109 56.20 0.6183
104 112.49 0.5579 38.25 0.2271 95 89.38 0.3046
138 369.06 1.3050 125.80 0.4858 138 75.07 0.4808
56 60.60 0.3811 76.56 0.5708 136 72.82 0.5607
77 119.88 0.6442 52.51 0.2947 103 104.59 0.5914
57 236.89 1.0069 66.98 0.2238 57 194.45 1.5446
73 85.16 0.3569 70.65 0.2536 82 53.95 0.3215
82 106.95 1.0182 47.51 0.5166
115 88.02 0.6517 86.39 0.5031
108 113.90 0.4287 46.72 0.3928
Mean 153.65 0.6848 85.19 0.4394 87.53 0.5799
SEM 22.99 0.0757 10.28 0.0565 11.69 0.0938
*Kd values reported in units of pM, Bmax values reported in units of fmoles/106 cells.
DI
SS
OC
IA
TI
ON
 
CO
NS
TA
NT
 
(p
M
)
152
200 T
1 5 0 -
100 -
5 0 -
C Zlflt, at rest 
ESS fit, after exercise 
sedentary, a t rest
Figure 31. Dissociation constants (Kd) of beta-endorphin receptors on equine
lymphocytes derived from Scatchard analysis of binding data. (*) indicates statistical
difference from resting values in fit horses (P<0.02).
153
sedentary horses have higher affinity for the beta-endorphin than do receptors in fit 
horses. The total number of binding sites, i.e. Bmax, also changed in response to exercise. 
The Bm(ix values in fit horses at rest ranged from 0.32 to 1.30 fmoles/106 cells, while the 
values after exercise ranged from 0.06 to 0.90 fmoles/106 cells. The Bmax values in 
sedentary horses ranged from 0.3 to 1.5 fmoles/106 cells. The average Bmax values are 
depicted graphically in Figure 32. The total number of binding sites was significantly 
decreased after exercise (P<0.01) but did not change significantly with training. Although 
the mean Bmax value was lower in sedentary horses than in fit horses, it was not 
significantly different. The range of Bmax values showed no difference between fit and 
sedentary horses.
3. Correlations
Correlations were performed in order to determine if a relationship existed 
between physiologic indices of exercise and fitness, and binding parameters. In the fit 
horse, there was a positive correlation between beta-endorphin concentrations and lactate 
concentrations and heart rate (Table 14). There was also a strong positive correlation 
between heart rate and lactate concentrations in the fit horse. There was a negative 
correlation between heart rate and both Kd and Bmax in the fit horse. In the fit horse after 
exercise, there was a strong positive correlation between lactate concentrations and Kd. 
These correlations indicate that there are parallel fluctuations of beta-endorphin levels, 
heart rates and lactate concentrations over all times. However, increased heart rates 
corresponded to decreased binding parameters over all times, while increased lactate 
concentrations corresponded to higher K^s following exercise. In all horses, under all
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Figure 32. Total number of binding sites (Bmax) of beta-endorphin lymphocyte
receptors derived from Scatchard analysis of binding data. (*) indicates statistical
difference from resting values in fit horses (P<0.01).
TABLE 14. Pearson’s Correlation Coefficients for Exercise Test 
and Binding Data Parameters
Comparison fm obs Prob(r>[r0J /H 0:
P=0)*
Beta-endorphin vs. Lactate
Fit horses, pre and post exercise 0.40280 0.0273
Beta-endorphin vs. Heart rate
Fit horses, pre and post exercise 0.45520 0.0381
Lactate vs. Heart rate
Fit horses, pre and post exercise 0.86025 0.0001
Heart rate vs. Kd
Fit horses, pre and post exercise -0.55401 0.0092
Heart rate vs. Bmax
Fit horses, pre and post exercise -0.57330 0.0066
Kd vs. Lactate
Fit horses, post exercise 0.78984 0.0005
Kd vs. Bmax
Fit horses, at rest 
Fit horses, after exercise 
Sedentary horses, at rest
0.83293
0.63804
0.82940
0.0001
0.0105
0.0008
Probability estimate of acceptance of the null hypothesis.
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conditions, there was a strong positive correlation between Kj and Bmar 
D. DISCUSSION
The changes in lymphocyte beta-endorphin receptor binding parameters in response 
to exercise illustrate that beta-endorphin may be involved in modulating immune function 
following exercise. Enhanced affinity of the receptor following exercise suggests that 
beta-endorphin has increased ability to modulate immune function at this time. The 
dissociation constant was also lower in the sedentary population of horses as opposed to 
the fit horses. This again suggests that the higher affinity of the receptor for the ligand 
in the sedentary horses could result in increased ability of beta-endorphin to modulate 
immune function in these horses. Kurcz, et al. [1988] demonstrated suppression of the 
blastogenic response to mitogens in equine lymphocytes following exhaustive treadmill 
exercise. Increased beta-endorphin concentrations following exercise suggest that beta- 
endorphin may be involved in the suppression of immune function following exercise. 
Consequently, the question of the mechanism by which beta-endorphin alters immune 
function is raised. The existence of receptors on equine lymphocytes for beta-endorphin 
suggest that beta-endorphin modulates equine immune function through interaction with 
these receptors. If this is so, increased affinity for the receptor following exercise may 
result in augmented suppression of lymphocyte function. Beta-endorphin receptors in the 
sedentary horses had higher affinity than did receptors in the fit horses. This also 
suggests that stress, which would result in increased beta-endorphin levels in sedentary 
horses, could cause augmented suppression of lymphocyte function as compared to a fit
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horse. Based on these results, it would appear that a sedentary horse has decreased 
immune function in response to stress when compared with a fit horse and that maximal 
exercise results in a transient suppression in immune function in the horse.
The total number of binding sites also decreased significantly following exercise 
in the fit horses. These results suggest that there is an upregulation of the receptor to one 
of higher affinity and a decrease in the total number of receptors. There was a strong 
positive correlation between the Kd and Bmax values which confirms the relationship 
between the affinity of the receptor for the ligand and the number of receptors. As the 
affinity of the receptor increases, the number of receptors required to elicit the same 
response becomes smaller. Generally, low affinity receptors are more abundant than high 
affinity receptors. Therefore, a decrease in lower affinity receptors may explain the 
decrease in Bmax noted following exercise. However, there is also the possibility of 
receptor internalization. Receptor internalization occurs via a high affinity binding site 
in murine thymoma cells [Schweigerer, et ah, 1985a]. It is therefore possible that an 
increase in high affinity binding sites, along with increased plasma beta-endorphin levels 
following exercise, leads to increased receptor-ligand interactions and therefore increased 
receptor-ligand complex internalization, and thus a decrease in number of available 
binding sites on equine lymphocytes. The results following exercise differed from those 
noted in the horses at rest. The number of binding sites in sedentary horses did not differ 
significantly from the number of binding sites in fit horses at rest, although the average 
Bmax value was lower in sedentary horses. These results support the theory that the 
decreased number of binding sites following exercise result from receptor-ligand complex
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internalization. If the decreased Bm„  following exercise resulted from receptor 
internalization, it would then most likely be a transient response to increased beta- 
endorphin levels and therefore would not be seen in resting horses.
Near maximal exercise intensity was reached by the fit horses during the exercise 
tests. The positive correlations found between beta-endorphin and lactate concentrations 
and heart rate, as well as the positive correlation between heart rate and lactate 
concentrations confirm that these parameters are good indices of exercise intensity. 
Interestingly, both K,, and Bm„  were negatively correlated with heart rate in fit horses. 
These correlations suggest that as exercise intensity increases there is a corresponding 
decrease in Kd and Bmax, which results in an increase in receptor affinity and decrease in 
number of binding sites. Therefore, as exercise intensity increases or becomes more 
stressful, the affinity of the receptor for beta-endorphin increases, thereby augmenting the 
suppression of the immune response. Again, the corresponding decrease in binding sites 
may be due to a decrease in low affinity sites or an increase in high-affinity receptor- 
ligand complex internalization. However, changes in binding parameters following 
exercise may result from increases in body temperature or decreases in pH due to 
increased lactate levels.
In contrast, there was a positive correlation between Kj and lactate concentrations 
in fit horses after exercise. In other words, as lactate concentrations increased so did the 
Kd values. These results appear to conflict with the negative correlation between heart 
rate and Kd. It appears that the fit horses with the higher lactate concentrations after 
exercise also had lower affinity of the receptor for beta-endorphin following exercise. It
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has been suggested that trained human athletes produce greater amounts of lactic acid in 
response to maximal exercise than do untrained individuals [Mougin, et a\., 1987]. 
Therefore, the horses which were in better physical condition may have released greater 
amounts of lactic acid, had lower heart rates and also had a corresponding lower affinity 
of the receptor for the ligand. This would again suggest that the fitter animals’ response 
to exertional stress results in less immune suppression and therefore improved immune 
function.
The range of Kj values noted in this experiment were slightly higher than the Kd 
value reported in Chapter 5 (48-194 pM vs. 17 pM). The higher values reported in this 
study may be due to assay differences. The dissociation constant reported in Chapter 5 
was calculated from a Scatchard analysis of a saturation isotherm, while the Kd values 
reported in this study were calculated from Scatchard analysis of competition-inhibition 
curves. Scatchard analysis of competitive displacement binding studies, rather than 
saturation isotherms, are commonly used due to cost and technical considerations. It is 
considered to be a valid use if the ligand-receptor interaction is simple competitive 
inhibition [Weiland and Molinoff, 1981]. However, artifactually nonlinear Scatchard plots 
will result if the radioligand and the unlabeled ligand bind with unequal affinity [Taylor, 
1975]. Also, with all Scatchard plots, there is the problem of the inappropriate definition 
of nonspecific binding, which will also result in a nonlinear Scatchard plot [Limbird, 
1986]. In this study, the Scatchard plots of the competition binding data resulted in a 
nonlinear Scatchard plot (concave upward) if the X-axis was on a linear scale. This type 
of plot may result from multiple orders of noninteracting binding sites, the existence of
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multiple affinity states of the receptor, or negative cooperativity [Limbird, 1986]. The 
nonlinear Scatchard plots parallel the results obtained from the competition-inhibition 
curves performed in the previous study [Chapter 5]. In both cases, the shape of the 
curves suggest that there is a more complex ligand-receptor interaction occurring than 
when a single ligand interacts with a single population of receptors.
In order to obtain one overall Kd and Bmax value from Scatchard plots, the plot was 
linearized by performing a logarithmic transformation of the data. Many investigators 
subjectively split nonlinear concave upward plots into two sections, representing a high 
affinity and low affinity portion, upon which linear regression analysis is performed. 
However, this is a totally subjective procedure, which introduces a large amount of error, 
as it reduces the number of points used to calculate the binding parameters. Therefore, 
in an effort to reduce the error and increase the ability to detect a difference between 
treatment groups, the plot was linearized resulting in an "overall" K,, and Bmax values. 
The use of this technique may explain the difference in Kd values obtained in this study 
as compared with the previous study. Also, when performing Scatchard analysis of 
competitive displacement studies, the amount of free ligand reaches very high, 
nonphysiological levels, as compared the ligand levels in a saturation isotherm. This may 
result in an artifactually low affinity site which has no physiological function. Although 
the "overall" and Bmax values obtained in this study may not be quantitative, they can 
be accurately used to detect a difference between treatment groups. Scatchard plots, in 
general, give only estimates of the true dissociation constant due to inherent problems 
which lead to magnification of error. However, they can be legitimately used to evaluate
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changes as a result of a "treatment" as opposed to a "control" [Munson and Rodbard. 
1983].
In conclusion, exercise and physical conditioning alter the binding parameters of 
beta-endorphin receptors on equine lymphocytes. Intense exercise increases the affinity 
of the receptor for beta-endorphin while physical conditioning decreases the affinity of 
the receptor for beta-endorphin. If beta-endorphin suppresses lymphocyte function, as 
intense exhaustive exercise has been reported to do, then intense exercise or exertional 
stress may exacerbate immune function while physical conditioning may improve the 
immune response to stress through the interaction of beta-endorphin with its receptors on 
equine lymphocytes.
CHAPTER SEVEN 
MODULATION OF MITOGEN-INDUCED EQUINE LYMPHOCYTE 
PROLIFERATIVE RESPONSES BY BETA-ENDORPHIN
A. INTRODUCTION
The identification of opioid receptors on human and murine lymphocytes has 
generated considerable interest in evaluating the immunoregulatory actions of endogenous 
opioid peptides [Mehrishi and Mills, 1983; Carr, et al., 1989; Sibinga and Goldstein,
1988]. Beta-endorphin is coreleased from the pituitary with adrenocorticotropin in 
response to a variety of stressors, such as exercise, surgery and noxious or painful stimuli, 
and therefore represents a possible mediator of neural regulation of immune function 
[Cohen, et al., 1986; Guillemin, et al., 1977]. Current studies demonstrate modulation 
of a number of immune cell functions, such as lymphocyte proliferative responses and 
natural killer cell activity, by beta-endorphin [Sibinga and Goldstein, 1988]. Furthermore, 
the finding that beta-endorphin and related proopiomelanocortin derived peptides are 
produced by activated lymphocytes suggests that there exists a complete modulatory loop 
between the immune and neuroendocrine systems [Morley, et al., 1987].
The effect of endogenous opioid peptides on lymphocytes has commonly been 
assessed by testing the influence of these peptides on mitogen-induced lymphocyte 
proliferation in vitro [Murgo, et al., 1986]. The mitogens most commonly used are 
Concanavalin A (ConA), a T and B cell mitogen, phytohemagglutinin (PHA), a T cell 
mitogen, and Pokeweed mitogen (PWM), a B cell mitogen which requires the presence
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of T helper cells. Enhancement of ConA and PHA induced proliferation in rat 
splenocytes by beta-endorphin has been reported [Gilman, et al., 1982; Kusnecov, et al.,
1989]. Beta-endorphin also enhances murine ConA-induced lymphocyte proliferation 
[Gilmore and Weiner, 1989]. In these studies, the modulation of lymphocyte proliferative 
responses by beta-endorphin was not reversed by naloxone or methionine-enkephalin and 
appeared to require the carboxy terminal portion of the molecule for activity. Therefore, 
it was concluded that beta-endorphin influences lymphocyte proliferation through 
interaction with a nonopioid receptor.
Reports of beta-endorphin modulation of human lymphocyte proliferation generally 
indicate suppression of the mitogenic response [McCain, etal., 1982; Puppo, et al., 1985]. 
However, there are recent reports that beta-endorphin is capable of both enhancing and 
suppressing the proliferative response of human lymphocytes to the mitogens ConA and 
PHA [Heijnen, et al., 1987; McCain, etal., 1987]. These studies suggested that the effect 
was dependent upon both peptide concentration and donor, and that the activity of the 
peptide resided in the carboxy terminal sequence. These studies indicate that beta- 
endorphin is capable of modulating the proliferative response of lymphocytes, perhaps 
through interaction with a nonopioid receptor, and that the effect may be dependent on 
the mitogen used, dose, individual and species.
Recent work in our laboratory has demonstrated receptors for beta-endorphin on 
equine lymphocytes [Chapter 5]. These receptors appear to be opioid receptors of the mu 
or delta class and their affinity for the ligand, beta-endorphin, is altered by both exercise 
and physical conditioning [Chapter 6]. As yet, the ability of beta-endorphin to modulate
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equine lymphocyte function has not been studied. Therefore, in order to clarify the role 
beta-endorphin receptors play in equine immune function, equine lymphocyte proliferative 
responses to beta-endorphin were assessed using the mitogens Concanavalin A, 
phytohemagglutinin and pokeweed mitogen.
B. MATERIALS AND METHODS 
Lymphocyte collection and preparation
Blood was collected from the jugular vein of healthy, conditioned Thoroughbred 
horses into 20 ml evacuated siliconized glass tubes containing heparin at a concentration 
of 10 U/ml as an anticoagulant. Two experiments were performed, one using optimal 
mitogen concentrations and a later experiment using su'boptimal mitogen concentrations. 
In the first experiment eight Thoroughbred horses, 5 female and 3 male with a mean age 
of 5.9+1.7 years, were used. In the second experiment, six Thoroughbred horses, all 
female in order to control assay variability, with a mean age of 5.5+1.4 years were used. 
Heparinized tubes were prepared by injecting 100 U of preservative free heparin dissolved 
in Hanks’ Balanced Salt Solution into 20 ml evacuated tubes. The heparin solution was 
sterilized prior to use by filtering through 0.22 micron filters1 into sterile 50 ml 
centrifuge tubes2. Two 20 ml tubes were collected from each horse.
The whole blood was centrifuged at 400 x g for 10 minutes at room temperature.
'Acrodisc syringe filters, 0.2 micron, Gelman Sciences, Ann Arbor, Mich.
2Coming 50 ml polypropylene centrifuge tubes with cap, sterile, Coming Glass Works, 
Coming, N.Y.
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Using sterile techniques, the plasma was removed and discarded and the buffy coat 
transferred to a sterile 15 ml conical centrifuge tubes3. The buffy coat from each tube 
was diluted up to a total volume of 10 ml in calcium and magnesium free Hanks’ 
Balanced Salt solution (CMF Hanks). The cell suspension was mixed well and layered 
over 4 ml of room temperature Ficoll. The cell suspension was then centrifuged at 600 
x g for 30 minutes at room temperature. The upper supernatant layer was removed and 
discarded and the interface, which contained the mononuclear cells, was removed and 
placed in a sterile 15 ml conical centrifuge tube containing 8 ml of CMF Hanks. The cell 
suspension was mixed well and centrifuged at 400 x g for 10-15 minutes. The 
supernatant was then decanted, pellet disrupted, and 10 ml of fresh CMF Hanks’ was 
added. The cell suspension was centrifuged at 350 x g for 10 minutes and the supernatant 
was decanted. The cells were then resuspended in 5 ml of assay medium, RPMI 16404 
supplemented with 10% FBS5, 100 U/ml penicillin6, 100 |ig/ml streptomycin7 and 10'5M 
2-mercaptoethanol8. Lymphocyte concentration was determined by counting on a 
hemacytometer. Cell concentration was then adjusted to a final concentration of 1 X 106
3Coming 15 ml polypropylene centrifuge tube with cap, sterile, Coming Glass Works, 
Coming, N.Y.
4RPMI 1640 with L-glutamine, without sodium bicarbonate, Sigma Chemical Co., St. 
Louis, Mo.
5Fetal bovine serum, Gibco Laboratories, Grand Island, N.Y.
6Penicillin G potassium for injection, E.R. Squibb and Sons, Princeton, N.J.
7Streptomycin sulfate, Pfizer, Inc., Roerig Division, New York, N.Y.
82-mercaptoethanol, Aldrich Chemical Co., Milwaukee, Wi.
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cells/ml using the assay media. Cell viability was assessed by trypan blue dye exclusion 
and always exceeded 90% viable cells.
Lymphocyte proliferation assays
The lymphocyte proliferation assays were performed in 96 well round bottom 
multi-well microtiter plates.9 Cells were dispensed into the 96-well plates at a final 
concentration of 1 X 105 cells/well (100 (il of cell suspension at 1 X 106 cells/ml). 
Optimal mitogen concentrations were determined empirically. Equine lymphocytes (1 x 
10s cells/well) were incubated with increasing concentrations of each mitogen in a total 
volume of 200 (il. Mitogen concentrations were: PHA10 and PWM11 at 0.1, 0.2, 0.4, 
and 0.8 pg/well, and ConA12 at 0.25, 0.5, 1.0, and 2.0, [tgAvell. Cells were also 
incubated without mitogen for determination of basal activity. The cultures were set up 
in replicates of four and incubated at 39°C in a humidified atmosphere of air and 5% C 0 2. 
After 48 hours, each well was pulsed with 1 (i.Ci/5 (il of tritiated thymidine13 and 
incubated for an additional 16-18 hours. The lymphocytes were then harvested onto glass 
fiber filter paper14 using a cell harvester.15 The paper discs were put in scintillation
9Coming 96 well round bottom polystyrene cell wells, Coming Glass Works, Coming, 
N.Y.
10Phytohemagglutinin, M form, Gibco Laboratories, Grand Island, N.Y.
"Phytolacca Americana (Pokeweed), Sigma Chemical Co., St. Louis, Mo.
12Concanavalin A, Type IV-S, Sigma Chemical Co., St. Louis, Mo.
13Thymidine 5’ triphosphate, tetrasodium salt [Methyl 3H]-, Dupont Co., Wilmington, DE.
14Filter paper for Titertek cell harvester, Skatron, Inc., Lier, Norway.
15Automatic cell harvester, Model 7109, Skatron, Inc., Lier, Norway.
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vials16 and 1.5 ml of scintillation cocktail17 was added. The newly synthesized 3H- 
DNA, an indicator of blastogenesis, was quantified on a beta-scintillation counter.18 
Results were expressed as counts per minute (CPM).
In the first experiment, cells from each horse were incubated with optimal 
concentrations of mitogens: PHA and PWM at a final concentration of 2 pg/ml, and 
ConA at final concentration of 5 pg/ml. Cells were incubated with the mitogens alone 
and with mitogens and beta-endorphin at final concentrations of 10'11, 10'9, and 10'7 M. 
Lymphocytes were also incubated with beta-endorphin (10'7 M) and naloxone (10 5 M) 
with the mitogens. Cells from each horse were also incubated with beta-endorphin and 
beta-endorphin plus naloxone at all concentrations without the mitogens. Each well 
contained 1 x 10s lymphocytes and appropriate concentrations of mitogens, beta-endorphin 
or naloxone in a final volume of 200 pi and all dilutions were made in assay medium. 
The cultures were set up in triplicate and then incubated at 39°C in a humidified 
atmosphere of air and 5% C 02. After 48 hours, each well was pulsed with 1 pCi/5 pi 
of tritiated thymidine and incubated for an additional 16-18 hours. Cell were harvested 
and results analyzed as described previously.
The second experiment used the same procedure as the first with the exception of 
mitogen concentrations and the use of naloxone alone as well as in combination with 
beta-endorphin. In the second experiment, suboptimal mitogen concentrations were used:
16Packard Picopro 4 ml scintillation vials, Packard Instrument Co., Downer Grove, II.
17Ultima Gold liquid scintillation cocktail, Packard Instrument Co., Downer Grove, II.
18Beckman beta-scintillation counter, Model LS 5000 TD, Beckman Instruments, Palo 
Alto, Calif.
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PHA and PWM at final concentrations of 1 pg/ml and ConA at a final concentration of
2.5 |ig/ml. In addition, the effects of naloxone were analyzed. Lymphocytes from each 
horse were also incubated with naloxone alone, mitogen and naloxone, and mitogen, 
naloxone and beta-endorphin at 107 M. Naloxone was used at a concentration of 10'5 M. 
Statistical Analyses
Data were analyzed by Student’s paired t-test. Significance was assigned at the 
P<0.05 level.
C. RESULTS
1. Determination of optimal mitogen concentrations
Optimal mitogen concentrations were determined by the concentration of mitogen 
which produced the highest level of lymphocyte proliferation as indicated by uptake of 
tritiated thymidine as an indicator of newly synthesized DNA. The results are depicted 
in Table 15. The greatest response to the mitogen PHA was seen at 0.8 pg/well (4 
pg/ml). The highest level of proliferation in response to the mitogen PWM was noted 
at a concentration of 0.4 (ig/well (2 (ig/ml). ConA stimulated lymphocyte proliferation 
optimally at 1.0 (ig/well (5 pg/ml). Both ConA and PWM exhibited a "prozone" effect, 
that is, inhibition of proliferation at high concentrations of mitogen. Although this effect 
was not observed with PHA in the concentration range of 0.1-0.8 pg/well, the next lower 
concentration of mitogen (2 pg/ml or 0.4 pg/well) from the optimal dose was chosen for 
the next experiment to ensure adequate cell stimulation.
TABLE 15. Lymphocyte Proliferative Responses to 
Increasing Mitogen Concentrations
Mitogen Mean CPM + SEM*
PHA
0.1 (ig/well 21586 ±  1234
0.2 pg/well 30237 ±  2141
0.4 (ig/well 43377 + 2183
0.8 (ig/well 54234 + 2351
ConA
0.25 (ig/well 10701 ±  1290
0.5 (ig/well 28048 + 1045
1.0 |ig/well 52234 + 359
2.0 |ig/well 25983 + 3071
PWM
0.1 (ig/well 32932 + 361
0.2 (ig/well 38326 ±  2001
0.4 (ig/well 42401 + 1143
0.8 (ig/well 38679 + 2698
Control 2197 + 266
‘Mean + SEM of 6 horses.
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2. Experiment 1: Optimal mitogen concentrations
In the first experiment, the effects of beta-endorphin on mitogen-induced 
lymphocyte proliferation were assessed using optimal concentrations of mitogen 
determined previously. Beta-endorphin at all concentrations, and a combination of beta- 
endorphin plus naloxone, had no effect on lymphocyte proliferation in the absence of 
mitogen (Figure 33). Beta-endorphin also had no significant effect on PHA induced 
lymphocyte proliferation at any concentration (Figure 34), however, it significantly 
enhanced both PWM and ConA stimulated lymphocyte proliferation at the lowest dose, 
10 "  M, when compared to mitogen alone (P<0.05) (Figure 34). Naloxone did not alter 
the response to the mitogen PHA in the presence of beta-endorphin (Figure 35). 
Naloxone also did not alter the response to the mitogen PWM in the presence of beta- 
endorphin (Figure 36). However, naloxone at 10'5 M in combination with beta-endorphin 
at 10'7 M significantly enhanced the proliferative response to ConA (P<0.05) even though 
beta-endorphin at this dose had no significant effect (Figure 37). The effect of beta- 
endorphin at 10'7 M did not significantly differ from the effect of beta-endorphin plus 
naloxone on the ConA induced proliferation. The enhancement of the lymphocyte 
proliferative response suggests that beta-endorphin is capable of modulating equine 
immune function. The ability of naloxone to also enhance ConA induced proliferative 
responses suggests that naloxone possesses agonist properties in contrast to the current 
theory that it is a strict antagonist.
Due to the large individual variability and the small amount of significant effect 
found in the first experiment, another experiment was performed using suboptimal
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Figure 33. Effect of beta-endorphin and naloxone on basal proliferative activity of
equine lymphocytes in experiment one (Mean+SEM of 8 horses).
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Figure 34. Effect of beta-endorphin on mitogen induced equine lymphocyte
proliferation at optimal mitogen concentrations (Mean+SEM of 8 horses). (*)
indicates statistical difference from mitogen control ([BE]=0) (P<0.05).
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Figure 35. Effect of naloxone on beta-endorphin modulation of PHA-induced
lymphocyte proliferation; PHA at 2 fig/ml (Mean+SEM of 8 horses).
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Figure 36. Effect of naloxone on beta-endorphin modulation of PWM-induced
lymphocyte proliferation; PWM at 2 pg/ml (Mean+SEM of 8 horses).
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Figure 37. Effect of naloxone on beta-endorphin modulation of ConA-induced 
lymphocyte proliferation; ConA at 5 pg/ml (Mean+SEM of 8 horses). (*) indicates 
statistical difference from stimulation with ConA alone (P<0.05).
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concentrations of mitogen. Optimal mitogen concentrations may have reduced the ability 
to detect an effect as the cells are maximally stimulated, thus suggesting that perhaps 
suboptimal mitogen concentrations would enhance detection of enhancement or 
suppression of the proliferative response. Horses of all one sex (female) were also used 
in the second experiment in order to reduce individual variability.
3. Experiment 2: Suboptimal mitogen concentrations
In the second experiment, beta-endorphin at all concentrations, naloxone, or beta- 
endorphin plus naloxone had no effect on lymphocyte proliferation in the absence of 
mitogens (Figure 38). Interestingly, beta-endorphin significantly suppressed the 
proliferative response to all the mitogens when used at suboptimal doses (Figure 39). 
Beta-endorphin suppressed the response to the mitogens PHA and PWM at all 
concentrations but suppressed ConA-induced lymphocyte proliferation only at the two 
higher doses. The addition of naloxone revealed interesting results. Naloxone also 
significantly suppressed PHA-induced proliferation as did the combination of beta- 
endorphin (10'7M) and naloxone (10‘5M) (PcO.Ol) (Figure 40). There was no significant 
difference between the effect of naloxone alone and beta-endorphin plus naloxone on 
PHA-induced proliferative responses. Naloxone also had the same effect on PWM- and 
ConA-induced lymphocyte proliferation (Figures 41 and 42). In contrast to the first 
experiment, these results suggest that beta-endorphin does not enhance but rather 
suppresses mitogen induced proliferative responses, and therefore may suppress immune 
function in the horse.
Due to the conflicting results obtained with the two experiments, the results of the
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Figure 38. Effects of beta-endorphin and naloxone on basal proliferative activity of
equine lymphocytes in experiment two (Mean+SEM of 6 horses).
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Figure 39. Beta-endorphin effects on mitogen induced lymphocyte proliferation at 
suboptimal mitogen concentrations (Mean+SEM, n=6). (*) indicates statistical 
difference from mitogen control ([BE]=0) (* P<0.05, ** PcO.Ol, *** PcO.OOl).
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Figure 40. Effect of naloxone on PHA-induced lymphocyte proliferation with and 
without beta-endorphin; PHA at 1 |ig/ml (Mean+SEM, n=6). (*) indicates statistical 
difference from mitogen control (*P<0.05, **P<0.01, ***P<0.001).
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Figure 41. Effect of naloxone on PWM-induced lymphocyte proliferation with and
without beta-endorphin; PWM at 1 pg/ml (Mean+SEM, n=6). (*) indicates statistical
difference from mitogen control (*P<0.05, **P<0.01).
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Figure 42. Effect of naloxone on ConA-induced lymphocyte proliferation with and
without beta-endoiphin; ConA at 2.5 pg/ml (Mean+SEM, n=6). (*) indicates
statistical difference from mitogen control (P<0.05).
182
first experiment were analyzed according to sex of the horses in order to rule out sex as 
a contributor to the conflicting results. There was no significant difference between the 
responses of the male and female horses. It must be noted that the first experiment had 
a large amount of variability between individuals which was not present in the second 
experiment. It may be that the slight enhancement of the proliferative response in the 
first experiment was actually an artifact since it was not seen in the second experiment 
at the same beta-endorphin concentrations.
D. DISCUSSION
Endogenous opioid peptides may play a role in mediating stress induced behavioral 
and humoral responses [Morley and Levine, 1980]. Beta-endorphin is released from the 
pituitary in response to variety of stressors and has been implicated as a possible 
immunomodulatory agent [Cohen, et al., 1986; Sibinga and Goldstein, 1988]. The results 
of this study clearly indicate that beta-endorphin suppresses equine lymphocyte 
proliferation in response to suboptimal mitogen concentrations. Although the modulatory 
action of beta-endorphin is negative at suboptimal mitogen concentrations, it appears to 
have a slight stimulatory effect at optimal mitogen doses. The stimulatory effects of beta- 
endorphin occurred only at the lowest doses (10'11 M), while the suppressive effects 
occurred primarily at the higher doses, suggesting that perhaps beta-endorphin exerts a 
biphasic response which is dependent upon the level of blastogenic response. This 
concept is supported by earlier work which demonstrated biphasic responses of human 
lymphocytes to glycyl-L-glutamine, the carboxy terminal dipeptide of beta-endorphin,
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beta-endorphin and ACTH [Heijnen, et al., 1987; McCain, et al., 1987]. Although there 
may be a biphasic response to beta-endorphin, it is also possible that beta-endorphin is 
not capable of suppressing a maximal or optimal blastogenic response. Also, optimal 
mitogen concentration may not be physiologically relevant. Stimulation of lymphocytes 
by antigens in vivo most likely occurs at suboptimal levels, and therefore suboptimal 
mitogen concentrations may be more indicative of true in vivo activity.
The response to beta-endorphin appeared to be stimulation-dependent in that there 
was no suppression or enhancement of proliferative responses in the absence of mitogens, 
i.e. during basal activity. At optimal mitogen concentrations, beta-endorphin did not have 
any effect on the proliferative response to PHA, but enhanced the response to PWM and 
ConA at the lowest dose. Phytohemagglutinin stimulates the blastogenic response in T 
cells, while ConA stimulates both T and B cells, and PWM stimulates B cells although 
it requires T helper cells. Therefore, at optimal mitogen concentrations, it appears as 
though beta-endorphin enhances B cell proliferation. However, at suboptimal mitogen 
concentrations, beta-endorphin suppressed the proliferative responses to all the mitogens, 
suggesting that it is capable of modulating both T and B cell activity. Alpha-endorphin 
suppresses antibody formation in human lymphocytes at both the T and B cell level, while 
beta-endorphin enhances anti-herpes antibodies in a biphasic manner [Heijnen, et al., 
1986; Williamson, et al., 1988]. Beta-endorphin has also been found to enhance natural 
killer celi activity in a biphasic manner which is a mirror image of the effects on antibody 
production, therefore suggesting that the immunomodulatory effects of beta-endorphin 
may be mediated by effects on natural killer suppressor-inducer cells [Williamson, et al.,
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1988]. Therefore, beta-endorphin may modulate equine lymphocyte proliferative response 
by activating natural killer suppressor-inducer cells in a biphasic manner. The subset of 
natural killer cells which are activated may depend on the concentration of beta-endorphin 
or the receptor population of the respective lymphocyte subsets.
All experiments were performed using lymphocytes from conditioned or trained 
horses. Previous studies demonstrated decreased affinity of the receptor for beta- 
endorphin in fit horses [Chapter 6]. The decreased affinity of the receptor in fit horses 
may have decreased the ability of beta-endorphin to modulate proliferation in maximally 
stimulated cells. Therefore, the actual response of the cells to beta-endorphin may have 
been masked. These experiments also revealed a great deal of individual variation which 
has also been noted by other investigators. Heijnen, et al. [1987] commented that the 
modulatory activity of beta-endorphin was dependent upon, not only concentration, but 
on the donor of the cells, and that repeated testing of individuals revealed identical 
response patterns. It has also been noted that modulation of natural killer cell activity 
may be dependent upon certain "low responder" and "high responder" populations [Oleson 
and Johnson, 1988]. Therefore, the variation noted in these assays may be due to inherent 
capacities of each donor, as well as the activity state of the individual cells. The 
modulatory ability of beta-endorphin may be dependent on the expression of the opioid 
receptor on the lymphocyte, which may be related to the activity state of the cell. As 
activation occurs, i.e. stimulation by a mitogen, opioid receptor expression may increase 
and therefore increase the ability of beta-endorphin to modulate lymphocyte function. 
However, there may be a loss of sensitivity or masking effect in maximally stimulated
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cells.
The effect of naloxone on the proliferative response of equine lymphocytes to 
various mitogens yielded interesting results. Naloxone is thought to be a pure opiate 
antagonist with no activity of its own at opioid receptors [Martin, 1984]. However, 
naloxone also has apparent agonist actions similar to those seen with morphine in a 
variety of in vivo and in vitro studies [Sawynok, et al., 1979]. In the present experiments, 
naloxone both suppressed and enhanced lymphocyte proliferation responses significantly. 
At optimal ConA concentrations, naloxone plus beta-endorphin enhanced the response, 
although it did not differ significantly from the response to beta-endorphin alone. At 
suboptimal doses of all the mitogens, naloxone suppressed the proliferative response 
significantly. There was no difference between the response of naloxone and beta- 
endorphin and the addition of beta-endorphin and naloxone together did not enhance the 
response of either. Therefore, it is conceivable that beta-endorphin and naloxone were 
acting at the same receptor since the response did not change, or become additive, when 
the two were added together. Earlier studies which suggested that naloxone possessed 
agonist actions generally demonstrated agonist activity at high doses and antagonist 
activity at low doses [Sawynok, et al., 1979]. The results reported in this study are 
consistent with this report as the naloxone dose used in this study was very high (10'5M). 
Therefore, it would be interesting to see if lower naloxone doses would exhibit antagonist 
actions in this study. However, the effects of naloxone on equine lymphocyte 
proliferation could also result from a nonspecific physiologic blockade of nonopioid 
receptors responsible for mitogen activity. These results, when analyzed in conjunction
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with the results of the binding studies [Chapters 5 and 6], suggest that beta-endorphin is 
acting at an opioid receptor when modulating lymphocyte activity and that naloxone may 
also possess similar activity at this receptor.
In conclusion, beta-endorphin modulates equine lymphocyte mitogen induced 
proliferative responses through interaction with an opioid receptor. The conflicting results 
obtained at optimal and suboptimal doses of the mitogens may be due to individual 
responses to beta-endorphin, perhaps a result of the activity state or opioid receptor 
expression of the lymphocyte population of the individual, or may be indicative of a 
biphasic response to beta-endorphin. Naloxone also modulated the proliferative responses 
of equine lymphocytes, which suggests that naloxone possesses agonist activity at the 
opioid receptor. However, nonspecific effects of naloxone when used at high doses can 
not be eliminated. These results suggest a biological role for circulating beta-endorphin 
in the horse and support the theory of an immune system — central nervous system 
regulatory circuit.
CHAPTER EIGHT 
SUMMARY AND CONCLUSIONS
Beta-endorphin is released into the peripheral circulation in response to maximal 
exercise. Questions as to the significance of peripherally released beta-endorphin during 
exercise have led to research into its role in mood enhancement, analgesia, food intake 
suppression and reproductive dysfunction [Sforzo, 1989]. However, identification of 
opioid receptors on human and murine leukocytes, along with modulation of immune cell 
function by endogenous opioids, suggests that endogenous opioids may be potential 
mediators of stress-induced immunomodulation [Sibinga and Goldstein, 1988]. Although 
elevated beta-endorphin levels following exercise have been demonstrated in the horse [Li 
and Chen, 1987], the role of peripherally circulating beta-endorphin in the horse has not 
been examined. In addition, the effects of exercise and physical conditioning on immune 
function have not been examined, nor has the role of beta-endorphin in conditioning 
effects been assessed.
Beta-endorphin was found to vary diumally in the horse in a manner similar to 
that seen in humans, with peak levels at 0900 hours. Increased pain threshold, increased 
heart rate and increased pupil diameter were also observed at the time beta-endorphin 
concentrations were highest. These findings correlate well with the effects of morphine 
in the horse [Muir, et al., 1980], and suggest that beta-endorphin may modulate a number 
of physiologic responses. Based on earlier studies which suggested that endogenous 
opioid systems exhibit tonic activity, it was concluded that optimal experimental times
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would be when basal beta-endorphin levels were the highest, i.e. 0900 hours. Therefore, 
all further experiments were conducted between 0800 and 1000 hours.
During a 24 hour period, heart rate was the highest at 0900 hours, as was beta- 
endorphin, suggesting that beta-endorphin affects cardiovascular function. This is 
supported by earlier studies which suggest opioid peptides affect cardiovascular function 
[Sforzo, 1989]. However, administration of naloxone in the first exercise study did not 
alter the cardiovascular response to exercise, suggesting that beta-endorphin, or other 
endogenous opioids, does not mediate cardiovascular responses to exercise. Naloxone 
administration also does not alter the cardiovascular response to exercise in humans, 
which supports the theory that endogenous opioids are not involved in the cardiovascular 
response to exercise. Nevertheless, the use of naloxone as the sole method of determining 
opioid receptor involvement makes drawing appropriate inferences difficult. Naloxone 
exhibits a number of agonist activities as well as antagonist activity [Sawynok, et al., 
1979] and one investigator was able to demonstrate a significant, albeit minor, decrease 
in maximal heart rate in women with opiate blockade [Cummings and Wheeler, 1987]. 
Therefore, a role of beta-endorphin and other endogenous opioids in the cardiovascular 
response to exercise cannot be eliminated. In addition, although beta-endorphin may not 
be involved in acute cardiovascular responses to exercise, this does not rule out a role for 
endogenous opioids in cardiovascular adaptations to chronic exercise, i.e. physical 
conditioning, or in diurnal variation of heart rate.
Beta-endorphin release in response to maximal exercise in the horse appeared to 
be correlated with both exercise intensity and physical conditioning. Analgesia
measurements, combined with evaluation of heart rate and lactate measurements, were 
used to assess the degree of exertional stress. Analgesia was seen following exercise in 
the unfit horse, along with significantly higher heart rates. Although analgesia was noted 
after an increase in exercise duration in the fit horse, it was not as great as that seen in 
the unfit horse following a less strenuous exercise test. These results suggest that the 
unfit horse experienced a greater degree of exertional stress than did the fit horse, even 
when the fit horse was subjected to an exercise test of higher exercise intensity. The 
greater amount of exertional stress, however, did not result in higher beta-endorphin 
concentrations, as beta-endorphin concentrations were higher in the fit horse after a 1000 
m exercise test than in the unfit horse following a 400 m exercise test.. Therefore, it was 
concluded that beta-endorphin release was associated to a greater degree with exercise 
intensity rather than exertional stress. Nonetheless, beta-endorphin release in response to 
exercise can be enhanced by other physical stressors, such as hot ambient temperature and 
dehydration [Cummings and Wheeler, 1987], implying that many other factors contribute 
to the response of the opioid system to exercise.
A strong positive correlation between beta-endorphin concentrations and lactate 
concentrations following exercise support the theory that beta-endoiphin release is linked 
with onset of blood lactate accumulation. Several studies in humans have also noted a 
correlation between beta-endorphin and lactate concentrations [Sforzo, 1989] and 
speculation about a mechanistic link between beta-endorphin release and the onset of 
blood lactate accumulation can be found in the literature [DeMeirler, et al., 1986]. 
Although exercise intensity and the onset of blood lactate accumulation have been linked
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with the release of beta-endorphin, a number of factors may be involved. Other possible 
stimulatory stressors which have been suggested are hypoglycemia and stimulation of 
neural pathways [DeMeirler, et al., 1986].
Beta-endorphin concentrations were positively correlated with pain threshold 
measurements in the diurnal study. Analgesia was also noted following exercise, but did 
not correlate with beta-endorphin concentrations, as beta-endorphin concentrations were 
elevated when there was no analgesia. Also, beta-endorphin levels were higher in fit 
horses than in unfit horses although the unfit horses had a greater degree of analgesia. 
However, naloxone reversed the analgesia noted following exercise. These results suggest 
that endogenous opioids are involved with analgesia, but do not support the opinion that 
peripherally circulating beta-endorphin modulates pain perception. The fact that beta- 
endorphin concentrations correlated well with analgesia measurements in the diurnal study 
may be explained by diurnal fluctuation of endogenous opioids, which originate in the 
central nervous system. The lack of correlation between pain threshold measurements and 
beta-endorphin concentrations following exercise does not, however, eliminate a role for 
beta-endorphin in pain modulation. Pain modulation following exercise may result from 
interactions between a number of factors, such as beta-endorphin release, muscle afferent 
discharges, degree of exertional stress and perhaps, psychological factors. Therefore, 
beta-endorphin could be one factor which contributes to the modulation of pain 
perception.
The effects of physical conditioning on the opioid response to exercise has 
generated conflicting reports [Sforzo, 1989]. A nine week training period resulted in an
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attenuated beta-endorphin output following exercise in the horse, although the difference 
was noted at one time (thirty minutes following exercise). These results suggest that beta- 
endorphin concentrations return to baseline faster in the fit horse. However, increased 
exercise intensity resulted in significantly higher levels of beta-endorphin following 
exercise, suggesting that fit horses may accumulate beta-endorphin in a manner similar 
to the ability of trained individuals to accumulate great lactate concentrations [Sforzo,
1989]. Nonetheless, the greater beta-endorphin and lactate concentration accumulation 
noted in trained individuals may be a function of a degree of exercise intensity which is 
attainable only by trained athletes.
The effects of naloxone administration on the response to exercise in the horse 
generated some interesting results. While naloxone reversed the analgesia noted in the 
fit horse, it not only reversed but caused hyperalgesia in the unfit horse. Also, naloxone 
administration resulted in prolonged increases in beta-endorphin levels in both fit and 
unfit horses. The prolonged release of beta-endorphin following naloxone administration 
implies that opioid receptors are involved in modulating the response to exercise, perhaps 
through autoreceptors at the hypothalamic or pituitary level. The fact that the analgesic 
response to naloxone administration in the unfit horse differed from that in the fit horse 
indicates a change in opioid receptor function following athletic conditioning. The lack 
of hyperalgesia in the fit horse implies a down regulation of the receptor due to the 
effects of chronic exercise. A decrease in receptor number or affinity would explain the 
lack of sensitivity to the effects of naloxone.
A growing number of reports support the view that physical exercise can modulate
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immune function. Acute exercise causes a marked increase in the number of circulating 
lymphocytes, suppresses lymphocyte proliferative responses, reduces the ratio of T helper 
cells to T suppressor cell, and reduces antibody production [Keast, et al., 1988]. These 
reports imply that a temporary immune suppression occurs following acute exercise. 
However, the effects of chronic exercise on immune function have not been evaluated. 
These reports, coupled with reports of opioid receptors on leukocytes, suggest that beta- 
endorphin may be a mediator in the modulation of immune function following exercise.
Highly specific, saturable receptors for beta-endorphin were identified on equine 
lymphocytes. Binding to the receptors took place in a time, temperature and pH 
dependent manner. Scatchard/Rosenthal analysis of the saturation isotherm revealed a 
binding site with a Kj of 17 pM and Bmax of 0.538 fmoles/106 cells. Competition- 
inhibition curves revealed an opioid receptor, with mu and/or delta receptor specificity. 
The slopes of the competition curves revealed a complex ligand-receptor interaction 
which, coupled with the ability of both mu and delta agonists to displace radiolabeled 
beta-endorphin, suggests that the receptor may be a mu/delta opioid receptor complex 
with interacting mu and delta binding sites. However, the Scatchard analysis of the 
saturation binding data demonstrated a simple interaction between one ligand and a single 
population of receptors. On the other hand, the number of radioligand concentrations 
used in the saturation may not have been sufficient for detection of a more complex 
interaction. Therefore, this discrepancy may be resolved by increasing the number of 
radioligand concentrations used in the saturation isotherm.
While the identification of opioid receptors on equine lymphocytes suggests a role
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for beta-endorphin in the immune response to exercise, it is not conclusive. Therefore, 
binding parameters of beta-endorphin receptors on equine lymphocytes were analyzed 
following both acute and chronic exercise. Beta-endorphin receptors showed enhanced 
affinity for the ligand following acute near maximal exercise, coupled with decreased 
receptor number. The decrease in receptor number following exercise may indicate that 
receptor internalization was occurring in response to ligand-receptor interactions. These 
changes in receptor binding parameters provide further evidence that beta-endorphin may 
help to modulate the immune response to exercise. Beta-endorphin receptor binding also 
showed a decreased affinity for the ligand following a 20 week conditioning period, as 
compared to a population of sedentary horses. However, the total number of receptors 
did not change with chronic exercise. The number of receptors decreased following acute 
exercise, but did not change in resting populations of fit and unfit horses. This supports 
the theory that the decrease in receptor number following acute exercise is due to receptor 
internalization, and is a transient response to increased beta-endorphin levels and therefore 
would not be seen in resting horses.
The decreased affinity of the receptor following chronic exercise suggests that 
there is a down regulation of the receptor in response to continual high levels of 
circulating beta-endorphin. These results support the conclusions drawn from the effects 
of naloxone administration on pain threshold. It was concluded that the hyperalgesia 
noted in the unfit horse, which was not seen in the fit horse following naloxone 
administration, was due to a down regulation of opioid receptors following chronic 
exercise. Since peripherally circulating beta-endorphin cannot be definitively linked with
194
pain perception, the role of central opioid receptors cannot be eliminated. Therefore, 
these results imply that a down regulation of opioid receptors occurs following chronic 
exercise, not only on leukocytes, but perhaps in the central nervous system. Therefore, 
the effects of chronic exercise may be mediated, in part, by endogenous opioids, both at 
the central and peripheral levels.
Acute exhaustive exercise appears to suppress immune function in humans [Keast, 
et al., 1988]. Beta-endorphin also has been reported to suppress lymphocyte proliferative 
responses in humans [Sibinga and Goldstein, 1988]. If beta-endorphin suppresses immune 
function in the horse, then beta-endorphin may modulate the suppression of immune 
function following acute exercise. The changes in receptor binding following acute and 
chronic exercise in the horse suggest that beta-endorphin may be involved in suppressing 
immune function following acute exercise in the horse while physical conditioning may 
attenuate this response.
To confirm the ability of beta-endorphin to modulate equine immune function, the 
effects of beta-endorphin on equine lymphocyte proliferative responses were evaluated. 
Beta-endorphin significantly suppressed the proliferative responses of equine lymphocytes 
to the mitogens ConA, PHA and PWM at suboptimal concentrations. Although beta- 
endorphin appeared to enhance proliferation at optimal mitogen concentrations, this was 
most likely an artifact resulting from large population variance. Naloxone is generally 
thought to be a pure antagonist, acting primarily at the mu opioid receptor [Martin, 1984]. 
However, naloxone also appears to have weak agonist activity at opioid receptors when 
used in high doses [Sawynok, et al., 1979]. In this study, naloxone suppressed the
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proliferative response to all three mitogens, and the addition of beta-endorphin and 
naloxone was not different from either beta-endorphin or naloxone added alone. 
Therefore, the effects of beta-endorphin and naloxone were not additive, which suggests 
that they were acting through the same receptor. These results also suggest that naloxone 
may produce agonist effects when used in high concentrations.
The ability of beta-endorphin to suppress equine lymphocyte proliferative 
responses to mitogens supports the view that beta-endorphin mediates exercise-induced 
alteration of immune function. Therefore, since beta-endorphin suppresses equine 
lymphocyte proliferative responses, it is reasonable to conclude that beta-endorphin 
released during exercise may be, in part, responsible for the temporary suppression of 
immune function seen following acute exercise. Beta-endorphin influences immune 
function in the horse through interaction with specific receptors on lymphocytes. The 
change in binding parameters supports the popular idea that a fit individual is a healthier 
individual. The downregulation or decreased sensitivity of the receptor in the fit horse 
implies that physical conditioning improves the immune response to stress, such as 
exertional stress. Nonetheless, beta-endorphin can not be considered as the sole mediator 
of the effects of exertional stress on immune function. Adrenocorticotropin is co-released 
from the pituitary with beta-endorphin and stimulates the production of cortisol 
[Guillemin, et al., 1977]. Cortisol levels are increased following exercise and cortisol has 
also been shown to suppress mitogen-induced proliferative responses [Keast, et al., 1988]. 
Catecholamine levels also increase during exercise and have been shown to modify the 
number and function of circulating lymphocytes [Keast, et al., 1988]. Therefore, while
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the results from this study confirm a role for beta-endorphin in exercise-induced 
immunosuppression, it cannot be considered the only possible mediator.
The ability of beta-endorphin to modulate equine lymphocyte proliferative 
response through interaction with a highly specific, saturable receptor implicates a role 
for beta-endorphin in equine immune responses to exercise. The changes which occur as 
a result of chronic exercise suggest that beta-endorphin is also involved in adaptations to 
chronic exercise and that these adaptations result in improved immune function. 
However, until the effects of acute and chronic exercise on equine immune function are 
evaluated, a role for beta-endorphin in equine immune responses to exercise cannot be 
confirmed. Beta-endorphin modulation of immune function through opioid receptors on 
equine lymphocytes also supports the hypothesis of a bidirectional communication system 
between the immune system and the central nervous system. Here again, evidence for 
production of endogenous opioids by cells of the immune system would be required to 
confirm this theory. In conclusion, these data support the hypothesis that beta-endorphin 
is a mediator of acute exercise-induced immune responses and is also involved in 
adaptations of the immune response to chronic exercise.
BIBLIOGRAPHY
Akil, H., Shiomi, H. and Matthews, J. (1985) Induction of the intermediate pituitary by 
stress: synthesis and release of a nonopioid form of beta-endorphin. Science, 227, 424- 
426.
Akil, H., Watson, S.J., Young, E., Lewis, M.E., Kachaturian, H. and Walker, M.J. (1984) 
Endogenous opioids: biology and function. Annual Review o f Neuroscience, 7, 223-255.
Amann, J.F., Smith, R.M., Ganjam, V.R., Pauli, W.K., McClure, R.C., Green, E.M. and 
Gamer, H.E. (1987) Distribution and implications of beta-endorphin and ACTH 
immunoreactive cells in the intermediate lobe of the hypophysis in healthy equids. 
American Journal o f Veterinary Research, 48, 323-327.
Astrand, P. and Rodahl, K. (eds.). (1986) Textbook of Work Physiology. McGraw-Hill, 
New York, pp. 320-332.
Ausiello, C.M. and Roda, L.G. (1984) Leu-enkephalin binding to cultured human T 
lymphocytes. Cell Biology International Reports, 8, 353-362.
Banks, W.A. and Kastin, A.J. (1987) Saturable transport of peptides across the blood- 
brain barrier. Life Sciences, 41, 1319-1338.
197
198
Barreca, T., Siani, C , Franceschini, R., Francaviglia, N., Messina, V., Parria, C. and 
Rolandi, E. (1986) Diurnal beta-endorphin changes in human cerebrospinal fluid. Life 
Sciences, 38, 2263-2267.
Berk, L.S., Tan, S.A., Nieman, D.C. and Eby, W.C. (1985) The suppressive effect of 
stress from acute exhaustive exercise on T lymphocyte helper/suppressor cell ratio in 
athletes and non-athletes. Medicine and Science in Sports and Exercise, 17, 706.
Blake, M.J., Stein, E.A. and Vomachka, A.J. (1984) Effects of exercise training on brain 
opioid peptides and serum LH in female rats. Peptides, 5, 953-958.
Blalock, J.E. (1985) Proopiomelanocortin-derived peptides in the immune system. 
Clinical Endocrinology, 22, 823-827.
Bongers, V. and Bertrams, J. (1984) The influence of common variables on T cell subset 
analysis by monoclonal antibodies. Journal o f Immunological Methods, 67, 243-253.
Borboni, P.D., Cola, G., Sesti, G., Marini, M.A., Porto, P.D., Saveria, M., Montani, G., 
Lauro, R. and DePirro, R. (1989) Beta-endorphin receptors on cultured and freshly 
isolated lymphocytes from normal subjects. Biochemical and Biophysical Research 
Communications, 163, 642-648.
199
Bowen, W.D., Gentleman, S., Herkenham, M. and Pert, C.B. (1981) Interconverting mu 
and delta forms of the opiate receptor in rat striatal patches. Proceedings o f the National 
Academy o f Sciences, USA, 78, 4818-4822.
Brown, S.L. and VanEpps, D.E. (1986) Opioid peptides modulate production of 
interferon-gamma by human mononuclear cells. Cellular Immunology, 103, 19-26.
Brown, S.L. and VanEpps, D.E. (1985) Suppression of T lymphocyte chemotactic factor 
production by the opioid peptides beta-endorphin and met-enkephalin. Journal o f 
Immunology, 134, 3384-3389.
Bullen, B.A., Skrinar, G.S., Beitins, I.Z., Carr, D.B., Reppert, S.M., Dotson, C.O., Fence, 
M., Gervino, E.V. and McArthur, J.W. (1984) Endurance training effects on plasma 
hormonal responsiveness and sex hormone excretion. Journal o f American Physiology, 
56, 1453-1463.
Carmody, J. and Cooper, K. (1987) Swim stress reduces chronic pain in mice through 
an opioid mechanism. Neuroscience Letters, 74, 358-363.
Carr, D.B., Bullen, B.A., Skrinar, G.S., Arnold, M.A., Rosenblatt, M., Beitins, I.Z., 
Martin, J.B. and McArthur, J.W. (1981) Physical conditioning facilitates the exercise- 
induced secretion of beta-endorphin and beta-lipotropin in women. New England Journal
200
o f Medicine, 305, 560-563.
Carr, DJ.J. and Blalock, J.E. (1989) From the neuroendocrinology of lymphocytes 
toward a molecular basis of the network theory. Hormone Research, 31, 76-80.
Carr, D.J.J., Bost, K.L. and Blalock, J.E. (1988a) The production of antibodies which 
recognize opiate receptors on murine leukocytes. Life Sciences, 42, 2615-2624.
Carr, D.J.J., Bubien, J.K!, Woods, W.T. and Blalock, J.E. (1988b) Opioid receptors on 
murine splenocytes. Annals o f the New York Academy o f Science, 540, 694-697.
Carr, D.J.J., DeCosta, B.R., Kim, C.H., Jacobson, A.E., Guarcella, B., Rice, K.C. and 
Blalock, J.E. (1989) Opioid receptors on cells of the immune system: evidence for 
delta- and kappa-classes. Journal o f Endocrinology, 122, 161-168.
Carr, DJ.J. and Klimpel, G.R. (1986) Enhancement of the generation of cytotoxic T cells 
by endogenous opiates. Journal o f Neuroimmunology, 12, 75-87.
Christie, M.J., Chesher, G.B. and Bird, K.D. (1981) The correlation between swim stress 
induced antinociception and [3H]Leu-enkephalin binding to brain homogenates in mice. 
Pharmacology, Biochemistry and Behavior, 15, 853-857.
201
Cohen, M.R., Pickar, D., Dubois, M. and Cohen, R.M. (1986) Studies of the endogenous 
opioid system in the human stress response. In: Enkephalins and Endorphins. Plotnikoff, 
N.P., Faith, R.E., Murgo, A.J. and Good, R.A. (eds.), Plenum Press, New York, pp. 35-46.
Colt, E.W.D., Wardlaw, S.L. and Frantz, A.G. (1981) The effect of running on plasma 
beta-endorphin. Life Sciences, 28, 1637-1640.
Cummings, D.C. and Wheeler, G.D. (1987) Opioids in exercise physiology. Seminars 
in Reproductive Endocrinology, 5, 171-179.
Deakin, J.F.W., Dostrovsky, J.O. and Smyth, D.G. (1980) Influence of N-terminal 
acetylation and C-Terminal proteolysis on the analgesic activity of beta-endorphin. 
Biochemistry Journal, 189, 501-506.
DeMeirler, K., Naaktgeboren, N., Steirteghem, A.V., Gorus, F., Olbrecht, J. and Block, 
P. (1986) Beta-endorphin and ACTH levels in peripheral blood during and after aerobic 
and anaerobic exercise. European Journal o f Applied Physiology, 55, 5-8.
Donahoe, R.M., Madden, J.J., Hollingsworth, F., Shafer, D., and Falek, A. (1985) 
Morphine depression of T cell E-rosetting: definition of the process. Federation
Proceedings, 44, 95-99.
202
Donevan, R.H. and Andrew, G.M. (1987) Plasma beta-endorphin immunoreactivity 
during graded cycle ergometry. Medicine and Science in Sports and Exercise, 19, 229- 
233.
Droste, C., Meyer-Blankenburg, H., Greenlee, M.W. and Roskamm, H. (1988) Effect of 
physical exercise on pain thresholds and plasma beta-endorphin in patients with silent and 
symptomatic myocardial ischaemia. European Heart Journal, 9(Suppl.), 25-33.
Edwards, A.J., Bacon, T.H., Elms, C.A., Verardi, R., Felder, M. and Knight, S.C. 1984) 
Changes in the populations of lymphoid cells in human peripheral blood following 
physical exercise. Clinical and Experimental Immunology, 58, 420-427.
Eisen, H.N. (1974) Immunology: An introduction to molecular and cellular principles 
of the immune responses. 2nd edition. New York: Harper and Row, pp. 450-509.
Eskola, J., Ruuskanen, O., Soppi, E., Viljanen, M.K., Jarvinen, M., Toivonen, H. and 
Kouvalainen, K. (1978) Effect of sport stress on lymphocyte transformation and antibody 
formation. Clinical and Experimental Immunology, 32, 339-345.
Evans, C.J., Erdelyi, E. and Barchas, J.D. (1986) Candidate opioid peptides for 
interaction with the immune system. In: Enkephalins and Endorphins. Plotnikoff, N.P., 
Faith, R.E., Murgo, A.J. and Good, R.A. (eds.), Plenum Press, New York, pp. 3-15.
203
Evans, J.A., McKenna, B. and Lambert, M.P.T. (1985) The effect of exercise on beta- 
endorphin levels in the horse. The Sixth International Conference o f Racing Analysts and 
Veterinarians, Hong Kong, pp. 33-35.
Faith, R.E., Liang, H.J., Plotnikoff, N.P., Murgo, A.J. and Nimeh, N.F. (1987) 
Neuroimmunomodulation with enkephalins: in vitro enhancement of natural killer cell 
activity in peripheral blood lymphocytes from cancer patients. Natural Immunity and Cell 
Growth Regulation, 6, 88-98.
Falke, N. and Fischer, E.G. (1985) Cell shape of polymorphonuclear leukocytes is 
influenced by opioids. Immunobiology, 169, 532-539.
Farrell, P.A. (1985) Exercise and endorphins - male responses. Medicine and Science 
in Sports and Exercise, 17, 89-93.
Farrell, P.A. and Gustafson, A. (1986) Exercise stress and endogenous opiates. In: 
Enkephalins and Endorphins. Plotnikoff, N.P., Faith, R.E., Murgo, A.J. and Good, R.A. 
(eds.), Plenum Press, New York, pp. 47-57.
Farrell, P.A., Kjaer, M., Back, F.W. and Galbo, H. (1987) Beta-endorphin and 
adrenocorticotropin response to supramaximal treadmill exercise in trained and untrained 
males. Acta Physiologic Scandinavica, 130, 619-625.
204
Farsang, C., Vajda, L., Kapocsi, J., Malisak, Z., Alfoldi, S., Varga, K., Juhasz, I. and 
Kunos, G. (1983) Diurnal rhythm of beta-endorphin in normotensive and hypertensive 
patients: the effects of clonidine. Journal o f Clinical Endocrinology and Metabolism, 
56, 865-867.
Fiatarone, M.A., Morley, J.E., Bloom, E.T., Benton, D., Makinodan, T. and Solomon,
G.F. (1988) Endogenous opioids and the exercise induced augmentation of natural killer 
cell activity. Journal o f Laboratory Clinical Medicine, 112, 544-552.
Frederickson, R.C.A. (1984) Endogenous opioids and related derivatives. In: 
Analgesics: Neurochemical, Behavioral and Clinical Perspectives. Kuhar, M. and 
Pasternak, G. (eds.), Raven Press, New York, pp. 9-68.
Frederickson, R.C.A., Burgis, V. and Edwards, J.D. (1977) Hyperalgesia induced by 
naloxone follows diurnal rhythm in responsitivity to painful stimuli. Science, 198, 756- 
758.
Frederickson, R.C.A. and Geary, L.E. (1982) Endogenous opioid peptides: review of 
physiological, pharmacological and clinical aspects. Progress in Neurobiology, 19,19-69.
Fregin, G.F. and Thomas, D.P. (1983) Cardiovascular response to exercise in the horse: 
a review. In: Equine Exercise Physiology. Snow, D.H., Persson, S.G.B. and Rose, R.J.
205
(eds.), Burlington Press, Cambridge, pp. 76-90.
Gambert, S.R., Garthwaite, T.L. Pontzer, C.H., Cook, E.E., Tristani, F.E., Duthie, E.H., 
Martinson, D.R., Hayen, T.C. and McCarty, D.J. (1981) Running elevates plasma beta- 
endorphin immunoreactivity and ACTH in untrained human subjects. Proceedings o f the 
Society for Experimental Biology and Medicine, 168, 1-4.
Gero, A. (1986) Considerations on the nature of mu, kappa and sigma receptors. NIDA 
Research Monograph Series, 75, 37-40.
Gil-Ad, I., Dickerman, Z., Amdursky, S. and Laron, Z. (1986) Diurnal rhythm of plasma 
beta-endorphin, cortisol and growth hormone in schizophrenics as compared to control 
subjects. Psychopharmacology, 88, 496-499.
Gillespie, J.R. and Pascoe, J.R. (1983) Respiratory function in the exercising horse: a 
review. In: Equine Exercise Physiology. Snow, D.H., Persson, S.G.B. and Rose, R J. 
(eds.), Burlington Press, Cambridge, pp. 1-6.
Gilman, S.C., Schwartz, J.M., Milner, R.J., Bloom, F.E. and Feldman, J.D. (1982) Beta- 
endorphin enhances lymphocyte proliferative responses. Proceedings o f the National 
Academy o f Science, USA, 79, 4226-4230.
206
Gilmore, W. and Weiner, L.P. (1988) Beta-endorphin enhances interleukin-2 (IL-2) 
production in murine lymphocytes. Journal o f Neuroimmunology, 18, 125-138.
Gilmore, W. and Weiner, L.P. (1989) The opioid specificity of beta-endorphin 
enhancement of murine lymphocyte proliferation. Immunopharmacology, 17, 19-30.
Goldfarb, A.H., Hatfield, B.D., Sforzo, G.A. and Flyn, M.G. (1987) Serum beta- 
endorphin levels during a graded exercise test to exhaustion. Medicine and Science in 
Sports and Exercise, 19, 78-82.
Goodman, R.R. and Pasternak, G.W. (1984) Multiple opiate receptors. In: Analgesics: 
Neurochemir.al, Behavioral and Clinical Perspectives. Kuhar, M. and Pasternak, G. 
(eds.), Raven Press, New York, pp. 69-96.
Grossman, A., Bouloux, P., Price, P., Drury, P.L., Lam, K.S., Turner, T., Thomas, J., 
Besser, G.M. and Sutton, J. (1984) The role of opioid peptides in the hormonal responses 
to acute exercise in man. Clinical Science, 67, 483-491.
Guillemin, R., Vargo, T., Rossier, J., Minicek, S., Ling, N., Rivier, C , Vale, W. and 
Bloom, F. (1977) Beta-endorphin and adrenocorticotropin are secreted concomitantly by 
the pituitary gland. Science, 197, 1367-1369.
207
Hamra, J.G., Kamerling, S.G., Bagwell, C.A., and Freestone, J.F. (1987) Exercise and 
physical conditioning alter beta-endorphin release and nociceptive thresholds in 
performance horses. Society o f Neuroscience Abstracts, 13, 1304.
Harbour-McMenamin, D., Smith, E.M. and Blalock, J.E. (1985) Bacterial 
lipopolysaccharide induction of leukocyte-derived corticotropin and endorphins. Infection 
and Immunity, 48, 813-817.
Hargreaves, K.M., Mueller, G.P., Dubner, R., Goldstein, D. and Dionne, R.A. (1987) 
Corticotropin-releasing factor (CRF) produces analgesia in humans and rats. Brain 
Research, 422, 154-157.
Harkins, J.D. and Kamerling, S.G. (1990) A comparative study of interval and 
conventional training in Thoroughbred racehorses. Journal o f Equine Veterinary Sciences, 
10, 45-51.
Hazum, E., Chang, K. and Cuatrecasas, P. (1979) Specific nonopiate receptors for beta- 
endorphin. Science, 205, 1033-1035.
Hedfors, E., Holm, G., Ivansen, M. and Wahren, J. (1983) Biological variation of blood 
lymphocyte reactivity: T-cell subsets, immunoglobulin production and mixed-lymphocyte 
reactivity. Clinical Immunology and Immunopathology, 27, 9-14.
208
Hedfors, E., Holm, G. and Ohnell, B. (1976) Variations of blood lymphocytes during 
work studied by cell surface markers, DNA synthesis and cytotoxicity. Clinical 
Experimental Immunology, 24, 328-335.
Heijnen, C.J., Bevers, C., Kavelaars, A. and Ballieux, R.E. (1986) Effect of alpha- 
endorphin on the antigen-induced primary antibody response of human blood B cells in 
vitro. Journal o f Immunology, 136, 213-216.
Heijnen, C.J., Zijlstra, J., Kavelaars, A., Croiset, G. and Ballieux, R.E. (1987) 
Modulation of the immune response by POMC-derived peptides. Brain, Behavior and 
Immunity, 1, 284-291.
Henry, J.L. (1981) Diurnal variation in excitation of dorsal horn units by naloxone in the 
spinal cat suggests a circulating opioid factor. Neuroscience, 6, 1935-1942.
Hodes, R.J. (1989) T cell mediated regulation: help and suppression. In: Fundamental 
Immunology, Paul, W.E. (ed.), Raven Press, New York, pp. 587-620.
Hollenberg, M.D. (1985) Receptor models and the action of neurotransmitters and 
hormones: some new perspectives. In: Neurotransmitter Receptor Binding. Yamamura,
H.I., Enna, S.J., and Kuhar, M.J. (eds.), Raven Press, New York, pp. 1-39.
209
Hollt, V., Przewlocki, R., Haarmann, I., Almeeda, O.F.X., Kley, N„ Millan, M.J. and 
Herz, A. (1986) Stress-induced alterations in the levels of messenger RNA coding for 
proopiomelanocortin and prolactin in rat pituitaiy. Neuroendocrinology, 43, 277-282.
Homicke, H., Meixner, R. and Pollman, U. (1983) Respiration in exercising horses. In: 
Equine Exercise Physiology. Snow, D.H., Persson, S.G.B. and Rose, R.J. (eds.), 
Burlington Press, Cambridge, pp. 7-16.
Houghten, R.A., Prati, S.M., Young, E.A., Brown, H. and Spann, D.R. (1986) Effect of 
chronic exercise on beta-endorphin receptor levels in rats. NJDA Research Monographs 
Series, 75, 505-508.
Howlett, T.A., Tomlin, S., Ngahfoong, L., Rees, L.H., Bullen, B.A., Skrinar, G.S. and 
McArthur, J.W. (1984) Release of beta-endorphin and met-enkephalin during exercise 
in normal woman: response to training. British Medical Journal, 288, 1950-1952.
Iwamoto, E.T. and Martin, W.R. (1981) Multiple opioid receptors. Medical Research 
Review, 1, 411-440.
Jacobs, S., Chang, K. and Cuatresasas, P. (1975) Estimation of hormone receptor affinity 
by competitive displacement of labeled ligand: effect of concentration of receptor and 
of labeled ligand. Biochemical and Biophysical Research Communications, 66, 687-692.
210
Jaffe, J.H. and Martin, W.R. (1985) Opioid analgesics and antagonists. In: The 
Pharmacological Basis o f Therapeutics. Gilman, A.G., Goodman, L.S., Rail, T.W. and 
Mural, F. (eds.), MacMillan, New York, pp. 491-531.
Janal, M.N., Colt, E.W.D., Clark, W.C. and Glusman, M. (1984) Pain sensitivity, mood 
and plasma endocrine levels in man following long-distance running: effects of naloxone. 
Pain, 19, 13-25.
Johnson, H.M., Smith, E.M., Torres, B.A. and Blalock, J.E. (1982) Regulation of the in 
vitro antibody response by neuroendocrine hormones. Proceedings o f the National 
Academy o f Science, USA, 79, 4171-4174.
Judson, G.J., Frauenfelder, H.C. and Mooney, G.J. (1983) Biochemical changes in 
thoroughbred racehorses following submaximal and maximal exercise. In: Equine 
Exercise Physiology. Snow, D.H., Persson, S.G.B. and Rose, R.J. (eds.), Burlington Press, 
Cambridge, pp. 408-415.
Kamerling, S.G., DeQuick, D.J., Weckman, T J. and Tobin, T. (1985a) Dose-related 
effects of fentanyl on autonomic and behavioral responses in performance horses. 
General Pharmacology, 16, 253-258.
211
Kamerling, S.G., Weckman, T.J., DeQuick, D.J. and Tobin, T. (1985b) A method for 
studying cutaneous pain perception and analgesia in horses. Journal o f Pharmacological 
Methods, 13, 267-274.
Kant, G.J., Mougey, E.H. and Meyerhoff, J.L. (1986) Diurnal variation in neuroendocrine 
response to stress in rats: plasma ACTH, beta-endorphin, beta-LPH, corticosterone, 
prolactin and pituitary cyclic AMP responses. Neuroendocrinology, 43, 383-390.
Kay, N., Allen, J. and Morley, I.E. (1984) Endorphins stimulate normal human peripheral 
blood lymphocyte natural killer activity. Life Sciences, 35, 53-59.
Kay, N., Morley, J.E. and vanRee, J.M. (1987) Enhancement of human lymphocyte 
natural killing function by non-opioid fragments of beta-endorphin. Life Sciences, 40, 
1083-1087.
Keast, D., Cameron, K. and Morton, A.R. (1988) Exercise and the immune response. 
Sports Medicine, 5, 248-267.
Kemppainen, P., Pertovaara, A., Huopaniem, T., Johansson, G. and Karonen, S. (1985) 
Modification of dental pain and cutaneous thermal sensitivity by physical exercise in man. 
Brain Research, 360, 33-40.
212
Klee, W.A. and Nirenberg, M. (1976) Mode of action of endogenous opiate peptides. 
Nature, 263, 609-612.
Klotz, I.M. (1982) Number of receptor sites from Scatchard graphs: facts and fantasies. 
Science, 217, 1247-1249.
Kurcz, E.V., Lawrence, L.M., Kelley, K.W. and Miller, P.A. (1988) The effect of intense 
exercise on the cell-mediated immune response of horses. Journal o f the Equine 
Veterinary Society, 8, 237.
Kusnecov, A.W., Husband, A.J., King, M.G. and Smith, R. (1989) Modulation of 
mitogen-induced spleen cell proliferation and antibody-forming cell response by beta- 
endorphin in vivo. Peptides, 10, 473-479.
Langenfeld, M.E., Hart, L.S. and Kao, P.C. (1987) Plasma beta-endorphin responses to 
one-hour bicycling and running at 60% VCX^. Medicine and Science in Sports and 
Exercise, 19, 83-86.
Lee, N.M. and Smith, N.P. (1980) A protein-lipid model of the opiate receptor. Life 
Sciences, 26, 1459-1464.
213
Li, C.H., Ng, T.B., Yamashiro, D., Chung, D., Hammonds, R.G. and Tseng, L. (1981) 
Beta-endorphin: isolation, amino acid sequence and synthesis of the hormone from horse 
pituitary glands. International Journal o f Peptide and Protein Research, 18, 242-248.
Li, W. and Chen, C. (1987) Running and shipping elevate plasma levels of beta- 
endorphin-like substance in thoroughbred horses. Life Sciences, 40, 1411-1421.
Limbird, L.E. (1986) Identification of receptors using direct radioligand binding 
techniques. In: Cell Surface Receptors: A Short Course o f Theory and Methods. 
Martinus-Nijhoff Publishing, Boston, pp. 51-96.
Linden, J. (1982) Calculating the dissociation constant of an unlabeled compound from 
the concentration required to displace radiolabel binding by 50%. Journal o f Cyclic 
Nucleotide Research, 8, 163-172.
Lolait, S.J., Lim, A.T.W., Toh, B.H. and Funder, J.W. (1984) Immunoreactive beta- 
endorphin in a subpopulation of mouse spleen macrophages. American Society o f Clinical 
Investigation, 73, 277-280.
Lundeen, J.E. and Gordon, J.H. (1986) Computer analysis of binding data. In: Receptor 
Binding in Drug Research. O ’Brien, R.A. (ed.), Marcel Dekker, Inc., New York, pp.31- 
49.
214
Madden, J.J., Donahoe, R.M., Zwemer-Collins, J., Shafer, D. and Falek, A. (1987) 
Binding of naloxone to human T lymphocytes. Biochemical Pharmacology, 36, 4103- 
4109.
Mandler, R.N., Biddison, W.E., Mandler, R. and Serrate, S.A. (1986) Beta-endorphin 
augments the cytolytic activity and interferon production of natural killer cells. Journal 
o f Immunology, 136, 934-939.
Maneckjee, R., Archer, S. and Zukin, R.S. (1988) Characterization of a polyclonal 
antibody to the mu opioid receptor. Journal o f Neuroimmunology, 17, 199-208.
Marcoli, M., Riceveiti, G., Mazzone, A., Bekkering, M., Lecchini, S. and Frigo, G.M. 
(1988) Opioid-induced modification of granulocyte function. International Journal o f 
Immunopharmacology, 10, 425-433.
Martin, W.R. (1984) Pharmacology of Opioids. Pharmacological Reviews, 35, 283-323.
Martin, W.R., Eades, C.G., Thompson, J.A., Huppler, R.E. and Gilbert, P.E. (1976) The 
effects of morphine and nalorphine-like drugs in the nondependent and morphine 
dependent chronic spinal dog. Journal o f Pharmacology and Experimental Therapeutics, 
197, 517-532.
215
Mathews, P.M., Froelich, C.J., Sibbett, W.L. and Bankhurst, A.D. (1983) Enhancement 
of natural cytotoxicity by beta-endorphin. Journal of Immunology, 130, 1658-1662.
McCain, H.W., Lamster, I.B. and Belotta, J. (1986) Modulation of human T-cell 
suppressor activity by beta-endorphin and glycyl-L-glutamine. International Journal o f 
Immunopharmacology, 8, 443-446.
McCain, H.W., Lamster, I.B., Bozzone, J.M. and Grbic, J.T. (1982) Beta-endoiphin 
modulates human immune activity via non-opiate receptor mechanisms. Life Sciences, 
31, 1619-1624.
McGivem, R.F. and Bemtson, G.G. (1980) Mediation of diurnal fluctuations in pain 
sensitivity in the rat by food intake patterns: reversal by naloxone. Science, 210, 210- 
211.
McMurray, R.G., Sheps, D.S. and Guinan, D.M. (1984) Effects of naloxone on maximal 
stress testing in females. Journal o f Applied Physiology, 56, 436-440.
Mehrishi, J.N. and Mills, I.H. (1983) Opiate receptors on lymphocytes and platelets in 
man. Clinical Immunology and Immunopathology, 27, 240-249.
216
Mendelsohn, L.G., Kerchenr, G.A., Culwell, M. and Ades, E.W. (1985) 
Immunoregulation by opioid peptides: I. Absence of classical opioid receptors on human 
mononuclear cells. Journal o f Clinical Laboratory Immunology, 16, 125-129.
Metzgar, J.M. and Stein, E.A. (1984) Beta-endorphin and sprint training. Life Sciences, 
34, 1541-1547.
Millington, W.R., Blum, M., Knight, R., Mueller, G.P., Roberts, J.L. and O’Donohue, 
T.L. (1986) A diurnal rhythm in proopiomelanocortin messenger ribonucleic acid that 
varies concomitantly with the content and secretion of beta-endorphin in the intermediate 
lobe of the rat pituitary. Endocrinology, 118, 829-834.
Monjan, A.A. and Collector, M.I. (1977) Stress induced modulation of the immune 
response. Science, 197, 307-308.
Monstein, H.J., Folkesson, R. and Terenius, L. (1986) Proenkephalin A-like mRNA in 
human leukemia leukocytes and CNS tissues. Life Sciences, 39, 2237-2241.
Morawetz, R.F., Parth, P. and Poppel, E. (1984) Influence of the pain measurement 
technique on the diurnal variation of pain perception. In: Pain Measurement in Man, 
Neurophysiological Correlates o f Pain. Bromm, B. (ed.), Elsevier, New York, pp. 409- 
415.
I l l
Morley, J.E., Kay, N.E., Solomon, G.F. and Plotnikoff, N.P. (1987) Neuropeptides: 
conductors of the immune orchestra. Life Sciences, 41, 527-544.
Morley, J.E. and Levine, A. (1980) Stress-induced eating is mediated through 
endogenous opiates. Science, 209, 1259-1261.
Morley, J.S. (1983) A common opiate receptor? Trends in Pharmacological Sciences, 
pp. 370-371, September.
Mougin, C., Baulay, A., Henriet, M.T., Haton, D., Jacquier, M.C., Tumell, D., Berthelay, 
S. and Gaillard, R.C. (1987) Assessment of plasma opioid peptides: beta-endorphin and 
met-enkephalin at the end of an international nordic ski race. European Journal o f 
Applied Physiology, 56, 281-286.
Muir, W.W., Sams, R.A. and Huffman, R. (1980) Cardiopulmonary, behavioral and 
pharmacokinetic effects of propoxyphene in horses. American Journal o f Veterinary 
Research, 41, 575-580.
Muir, W.W., Skarda, R.T. and Sheehan, W.C. (1978) Cardiopulmonary effects of narcotic 
agonists and a partial agonist in horses. American Journal o f Veterinary Research, 39, 
1632-1635.
218
Munson, P J. and Rodbard, D. (1980) LIGAND: a versatile computerized approach for 
characterization of ligand-binding systems. Analytical Biochemistry, 107, 220-239.
Munson, P.J. and Rodbard, D. (1983) Number of receptor sites from Scatchard and Klotz 
graphs: a constructive critique. Science, 220, 979-981.
Murgo, A.J., Faith, R.E., and Plotnikoff, N.P. (1986) Enkephalins: Mediators of stress- 
induced immunomodulation. In: Enkephalins and endorphins: Stress and the immune 
system. Plotnikoff, N.P., Faith, R.E., Murgo, A.J. and Good, R.A. (eds.), Plenum Press, 
New York, pp. 221-239.
Naber, D., Cohen, R.M., Pickar, D., Kalin, N.H., Davis, G„, Pert, C.B. and Bunney, W.E. 
(1981) Episodic secretion of opioid activity in human plasma and monkey CSF: evidence 
for a diurnal rhythm. Life Sciences, 28, 931-935.
Oleson, D.R. and Johnson, D.R. (1988) Regulation of human natural cytotoxicity by 
enkephalins and selective opiate agonists. Brain, Behavior and Immunity, 2, 171-186.
Orf, J.W., Ellis, J., Johanson, N., Vanderloise, F. and Lindall, A.W. (1979) Extraction 
of beta-endorphin from serum binding proteins. Clinical Research, 27, 680A.
219
Ovadia, H., Nitsan, P. and Abramsky, O. (1989) Characterization of opiate binding sites 
on membranes of rat lymphocytes. Journal o f Neuroimmunology, 21, 93-102.
Pasternak, G.W. and Wood, P.J. (1986) Minireview: Multiple mu opiate receptors. Life 
Sciences, 38, 1889-1898.
Persson, S.G.B. (1983) Evaluation of exercise tolerance and fitness in the performance 
horse. In: Equine Exercise Physiology. Snow, D.H., Persson, S.G.B. and Rose, R.J. 
(eds.), Burlington Press, Cambridge, pp. 441-457.
Pert, C.B., Snyder, S.H. and May, E.L. (1976) Opiate receptor interactions of 
benzomorphans in rat brain homogenates. Journal o f Pharmacology and Experimental 
Therapeutics, 196, 316-322.
Peterson, P.K., Sharp, B., Gekker, G., Brummitt, C. and Keane, W.F. (1987) Opioid- 
mediated suppression of interferon-gamma production by cultured peripheral blood 
mononuclear cells. Journal o f Clinical Investigation, 80, 824-831.
Petraglia, F., Celia, S.G., Radice, L., Genazzani, A.R. and Muller, E.E. (1986) Gamma- 
aminobutyric acid inhibits beta-endorphin secretion from the anterior pituitary but not the 
neurointermediate lobe in the rat. Endocrinology, 118, 360-366.
220
Petraglia, F., Facchinetti, F., Parrini, D., Micieli, G. DeLuca, S. and Genazzani, A.R. 
(1983) Simultaneous circadian variations of plasma ACTH, beta-lipotropin, beta-endorphin 
and cortisol. Hormone Research, 17, 147-152.
Pitts, F.N. and McClure, J.V. (1972) Lactate metabolism in anxiety neurosis. New 
England Journal o f Medicine, 277, 1329-1336.
Prete, P., Levin, E.R. and Pedram, A. (1986) The in vitro effects of endogenous opiates 
on natural killer cells, antigen-specific cytolytic T cells and T cell subsets. Experimental 
Neurology, 92, 349-359.
Puppo, F., Corsini, G., Mangini, P., Bottaro, L. and Barreca, T. (1985) Influence of beta- 
endorphin on phytohemagglutinin-induced lymphocyte proliferation and on the expression 
of mononuclear cell surface antigens in vitro. Immunopharmacology, 10, 119-125.
Radosevich, P.M., Nash, J.A., Lacy, D.B., O ’Donovan, C., Williams, P.E. and Abumrad, 
N.N. (1989) Effects of low- and high-intensity exercise on plasma and cerebrospinal fluid 
levels of ir-beta-endorphin, ACTH, cortisol, norepinephrine and glucose in the conscious 
dog. Brain Research, 498, 89-98.
Rahkila, P., Hakala, E., Alen, M., Salminen, K. and Laatikainen, T. (1988) Beta- 
endorphin and corticotropin release is dependent on a threshold intensity of running
exercise in male endurance athletes. Life Sciences, 43, 551-558.
221
Rahkila, P., Hakala, E., Salminen, K. and Laatikainen, T. (1987) Response of plasma 
endorphins to running exercises in male and female endurance athletes. Medicine and 
Science in Sports and Exercise, 19, 451-455.
Rapoport, S.F., Klee, W.A., Pettigrew, K.D. and Ohno, K. (1980) Entry of opioid 
peptides into the central nervous system. Science, 207, 84-86.
Riley, V. (1981) Psychoneuroendocrine influences on immunocompetence and neoplasia. 
Science, 212, 1100-1109.
Rivier, C., Brownstein, M., Spiess, J., Rivier, J. and Vale, W. (1982) In vivo 
corticotropin-releasing factor-induced secretion of adrenocorticotropin, beta-endorphin and 
corticosterone. Endocrinology, 110,272-278.
Rose, R.J. (1983) An evaluation of heart rate and respiratory rate recovery for assessment 
of fitness during endurance rides. In: Equine Exercise Physiology. Snow, D.H., Persson, 
S.G.B. and Rose, R.J. (eds.), Burlington Press, Cambridge, pp. 505-509.
Rosenthal, H.E. (1967) A graphic method for the determination and presentation of 
binding parameters in a complex system. Analytical Biochemistry, 20, 525-532.
222
Rossier, J., French, E.D., Rivier, C., Ling, N., Guillemin, R. and Bloom, F.E. (1977) 
Foot-shock induced stress increases beta-endorphin levels in blood but not brain. Nature, 
270, 618-620.
Roth, K.A., Lorenz, R.G., Unane, R.A. and Weaver, C.T. (1989) Nonopiate active 
proenkephalin-derived peptides are secreted by T helper cells. FASEB Journal, 3, 2401- 
2407.
Ruff, M.R., Wahl, S.M., Mergenhagen, S. and Pert, C.B. (1985) Opiate receptor-mediated 
chemotaxis of human monocytes. Neuropeptides, 5, 363-366.
Sandrini, G., Alfonsi, E., Bono, G., Facchinetti, F., Montalbetti, L. and Nappi, G. (1986) 
Circadian variations of human flexion reflex. Pain, 25, 403-410.
Sawynok, J., Pinsky, C. and LaBella, F.S. (1979) Minireview on the specificity of 
naloxone as a opiate antagonist. Life Sciences, 25, 1621-1632.
Scatchard, G. (1949) The attraction of proteins for small molecules and ions. Annals o f 
the New York Academy o f Science, 51, 660-672.
Schipper, J., Steinbusch, W., Vermes, I. and Tilders, F. (1983) Mapping of CRF- 
immunoreactive nerve fibers in the medulla oblongata and spinal cord of the rat. Brain
223
Research, 267, 145-150.
Schoffelmeer, A.N.M., Yao, Y., Gioannini, T.L., Miller, J.M., Ofri, D., Roques, B.P. and 
Simon, E.J. (1990) Cross-linking of human [125I]beta-endorphin to opioid receptors in rat 
striatal membranes: biochemical evidence for the existence of a mu/delta opioid receptor 
complex. Journal o f Pharmacology and Experimental Therapeutics, 253, 419-426.
Schweigerer, L., Schmidt, W., Teschemacher, H. and Gramsch, C. (1985a) Beta- 
endorphin: surface binding and internalization in thymoma cells. Proceedings o f the 
National Academy o f Sciences, USA, 82, 5751-5755.
Schweigerer, L., Schmidt, W., Teschemacher, H. and Wilhelm, S. (1985b) Beta- 
endorphin: interaction with specific nonopioid binding sites in EL4 thymoma cells. 
Neuropeptides, 6, 445-452.
Schwyzer, R. (1986) Molecular mechanism of opioid receptor selection. Biochemistry, 
25, 6335-6342.
Scott, V. and Gijsbers, K. (1981) Pain perception in competitive swimmers. British 
Medical Journal, 283, 91-93.
Sforzo, G.A. (1989) Opioids and exercise. Sports Medicine, 7, 109-124.
224
Sforzo, G.A., Seeger, T.F., Pert, C.B., Pert, A. and Dotson, C.O. (1986) In vivo opioid 
receptor occupation in the rat brain following exercise. Medicine and Science in Sports 
and Exercise, 18, 380-384.
Sharma, S.K., Klee, W.A. and Nirenberg, M. (1977) Opiate-dependent modulation of 
adenylate cyclase. Proceedings o f the National Academy o f Sciences, USA, 74, 3365- 
3369.
Sharp, B.M., Keane, W.F., Suh, H.J., Gekker, G., Tsukayama, D. and Peterson, P.K.
(1985) Opioid peptides rapidly stimulate superoxide production by human 
polymorphonuclear leukocytes. Endocrinology, 117, 793-795.
Sharp, B.M., Tsukayama, D.T., Gekker, G., Keane, W.F. and Peterson, P.K. (1987) Beta- 
endorphin stimulates human polymorphonuclear leukocyte superoxide production via a 
stereoselective opiate receptor. Journal o f Pharmacology and Experimental Therapeutics, 
242, 579-582.
Shavit, Y., Lewis, J.W., Terman, G.W., Gale, R.P. and Liebeskind, J.C. (1984) Opioid 
peptides mediate the suppressive effect of stress on natural killer cell cytotoxicity. 
Science, 223, 188-190.
225
Shiomi, H., Watson, S.J., Kelsey, J.E. and Akil, H. (1986) Pretranslational and 
posttranslational mechanisms for regulating beta-endorphin-adrenocorticotropin of the 
anterior pituitary lobe. Endocrinology, 119, 1793-1799.
Shyu, B.-C, Andersson, S.A. and Thoren, P. (1982) Endorphin mediated increase in 
pain-threshold induced by long-lasting exercise in rats. Life Sciences, 30, 833-840.
Sibinga, N.E.S. and Goldstein, A. (1988) Opioid peptides and opioid receptors in cells 
of the immune system. Annual Review o f Immunology, 6, 219-249.
Simpkins, C.O., Alailima, S.T., Tate, E.A. and Johnson, M. (1986) The effect of 
enkephalins and prostaglandins on 0 2' release by neutrophils. Journal o f Surgical 
Research, 41, 645-652.
Simpkins, C.O., Dickey, C.A. and Fink, M.P. (1984) Human neutrophil migration is 
enhanced by beta-endorphin. Life Sciences, 34, 2251-2255.
Smith, E.M., Harbour-McMenamin, D. and Blalock, J.E. (1985) Lymphocyte production 
of endorphins and endorphin-mediated immunoregulatory activity. Journal o f 
Immunology, 135, 779s-782s.
226
Smith, E.M., Morrill, A.C., Meyer, W J. and Blalock, J.E. (1986) Corticotropin releasing 
factor induction of leukocyte-derived immunoneactive ACTH and endorphins. Nature, 
321, 881-882.
Surbey, G.D., Andrew, G.M., Cervenko, F.W. and Hamilton, P.P. (1984) Effects of 
naloxone on exercise performance. Journal o f Applied Physiology, 57, 674-679.
Tang, F., Tang, J., Chou, J. and Costa, E. (1984) Age-related and diurnal changes in 
Met5-ENK-ARG6-PHE7 and Met^-enkephalin contents in pituitary and rat brain structures. 
Life Sciences, 35, 1005-1014.
Taylor, S.I. (1975) Binding of hormones to receptors - an alternative explanation of 
nonlinear Scatchard plots. Biochemistry, 14, 2357-2361.
Thomas, C.L., ed. (1985) Taber Cyclopedic Medical Dictionary, 15th edition. F.A. Davis 
Co., Philadelphia.
Thornton, J., Essen-Gustavsson, B., Lindholm, A., McMiken, D. and Persson, S. (1983) 
Effects of training and detraining on oxygen uptake, cardiac output, blood gas tensions, 
pH and lactate concentrations during and after exercise in the horse. In: Equine Exercise 
Physiology. Snow, D.H., Persson, S.G.B. and Rose, R.J. (eds.), Burlington Press, 
Cambridge, pp. 470-486.
227
VanEpps, D.E. and Kutvirt, S.L. (1987) Modulation of human neutrophil adherence by 
beta-endorphin and met-enkephalin. Journal o f Neuroimmunology, 15, 219-228.
VonVoigtlander, P.F., Lahti, R.A. and Ludens, J.H. (1983) U-50,488H: A selective and 
structurally novel non-mu (kappa) opioid agonist. Journal o f Pharmacology and 
Experimental Therapeutics, 224, 7-12.
Wagner, H.N. (1986) Quantitative imaging of dopamine, serotonin and opiate receptors 
in the living human brain. In: Quantitative receptor autoradiography. Boast, et. al. 
(eds.), Liss, Inc., Philadelphia, pp. 233-254.
Wardlaw, S.L. and Frantz, A.G. (1980) Effects of swimming stress on brain beta- 
endorphin and ACTH. Clinical Research, 28, 482A.
Weiland, G.A. and Molinoff, P.B. (1981) Quantitative analysis of drug-rcceptor 
interactions: I. Determination of kinetic and equilibrium properties. Life Sciences, 29, 
313-330.
Wesche, D.L. and Frederickson, R.C.A. (1979) Diurnal differences in opioid peptide 
levels correlated with nociceptive sensitivity. Life Sciences, 24, 1861-1868.
228
Westly, H.J., Kleiss, A.J., Kelley, K.W., Wong, P.K.Y. and Yuen, P. (1986) Newcastle 
disease virus-infected splenocytes express the proopiomelanocortin gene. Journal o f 
Experimental Medicine, 163, 1589-1594.
Westphal, M. and Li, C.H. (1984) Beta-endorphin: evidence for the existence of opioid 
and nonopioid binding components for the tritiated human hormone in NG108-15 cells. 
Biochemical and Biophysical Research Communications, 122, 428-433.
Williamson, S.A., Knight, R.A., Lightman, S.L. and Hobbs, J.R. (1988) Effects of beta- 
endorphin on specific immune responses in man. Immunology, 65, 47-51.
Wilson, R.G., Isler, R.B. and Thornton, J.R. (1983) Heart rate, lactic acid production and 
speed during a standardized exercise test in standardbred horses. In: Equine Exercise 
Physiology. Snow, D.H., Persson, S.G.B. and Rose, R.J. (eds.), Burlington Press, 
Cambridge, pp. 487-496.
Wolfe, S.A., Kulsakdinum, C., Battaglia, G., Jaffe, J.H. and DeSouza, E.B. (1988) Initial 
identification and characterization of sigma receptors on human peripheral blood 
leukocytes. Journal o f Pharmacology and Experimental Therapeutics, 247, 1114-1119.
Woolf, C.J. (1980) Analgesia and hyperalgesia produced in the rat by intrathecal 
naloxone. Brain Research, 189,593-597.
229
Wright, D.M. (1981) Diurnal rhythm in sensitivity of a nociceptive spinal reflex. 
European Journal o f Pharmacology, 69, 385-388.
Wybran, J., Appelboom, T., Famaey, J. and Govaerts, A. (1979) Suggestive evidence for 
receptors for morphine and methionine-enkephalin on normal human blood T 
lymphocytes. Journal o f Immunology, 123, 1068-1070.
Wybran, J. and Govaerts, A. (1977) Levamisole and human lymphocyte surface markers. 
Clinical and Experimental Immunology, 27, 319-321.
Young, E.A. and Akil, H. (1985a) Changes in releasibility of ACTH and beta-endorphin 
with chronic stress. Neuropeptides, 5, 545-548.
Young, E.A. and Akil, H. (1985b) Corticotropin-releasing factor stimulation of 
adrenocorticotropin and beta-endorphin release: effects of acute and chronic stress. 
Endocrinology, 117, 23-30.
Young, E.A., Lewis, J. and Akil, H. (1986) The preferential release of beta-endoiphin 
from the anterior pituitary lobe by corticotropin releasing factor (CRF). Peptides, 7,603- 
607.
230
Zukin, R.S. and Tempel, A. (1986) Neurochemical correlates of opiate receptor 
regulation. Biochemical Pharmacology, 35, 1623-1627.
Zurawski, G., Benedik, M., Kamb, B.J., Abrams, J.S., Zurawski, S.M. and Lee, F.D.
(1986) Activation of mouse T-helper cells induces abundant preproenkephalin mRNA 
synthesis. Science, 232, 772-775.
VITA
Jena Gosselink Hamra was bom November 5, 1957 in New Brunswick, New 
Jersey. She attended Baton Rouge High School in Baton Rouge, Louisiana and graduated 
in May, 1975. She enrolled in Louisiana State University, Baton Rouge and received a 
Bachelor of Science degree in Medical Technology in August, 1979. She was then 
employed by the Pathology Laboratory of Baton Rouge. In October, 1980 she was 
employed by Tulane Medical School as a Research Technician and was employed there 
until July, 1984. In August, 1984, she enrolled at Louisiana State University, Baton 
Rouge to work toward a Ph.D. degree in Pharmacology. These studies were guided by 
Dr. Steven G. Kamerling of the Department of Veterinary Physiology, Pharmacology and 
Toxicology.
231
DOCTORAL EXAMINATION AND DISSERTATION REPORT
Candidate: Jena Gosse l ink  Hamra
Major Field: V eter inary  Medical S c ie n c e s  (Pharmacology Option)
Title of Dissertation: Beta-endorphin Receptors on Equine Lymphocytes:  
R e la t io n s h ip  to Immune Function and E xerc ise
Approved:
M ajo r P ro fe sso r  and  C h a irm an
D ean  of th e  G ra d u a te  School
E X A M IN IN G  C O M M IT T E E :
Date of Examination:
Septem ber 1 9 , 1990
